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Astrocyte-derived L-lactate (LL) is thought to metabolically support neurones during 
periods of high activity. LL also has signalling roles in the brain and its release can 
affect sleep/wake cycle, learning and memory, and cardiorespiratory control. We have 
previously shown that astrocyte-derived LL induces noradrenaline release in the locus 
coeruleus in vitro, and that this action was abolished by the enantiomer D-lactate. 
Moreover, LL application in the brainstem or pons in vivo increased sympathetic nerve 
activity, or caused cortical desynchronization, respectively. A new route for LL release 
in the brain mediated by connexin hemichannels has been described, raising the 
possibility that these conduits actively participate in LL effects in the brain.  
During this project, I have developed a range of molecular tools to selectively limit 
astrocyte-derived LL release and actions in the brain, in order to better understand its 
roles. These vectors induce expression of bacteria-derived enzymes that either 
reduce the intracellular LL pool by metabolising LL (LL monooxygenase – LMO; LL 
oxidase – LOX), or interfere with LL -noradrenaline signalling by production of D-
lactate (D-lactate dehydrogenase – DLDH). Moreover, a tool to drive astrocyte-
selective knock-down of connexin-43 was created in order to investigate 
hemichannel-mediated LL release from astrocytes. 
Functional validation of the novel molecular tools in vitro showed that the enzymes of 
bacterial origin are active when expressed in mammalian cells. Constitutive and 
forced LL release were reduced in primary dissociated cultured astrocytes as well as 
in organotypic brainstem slices. Moreover, expression of the DLDH-based molecular 
tool induced production and release of D-lactate by astrocytes. Evaluation of the 
impact of the new constructs on noradrenaline release suggested that expression of 
LOX inhibits LL -induced noradrenaline release from locus coeruleus neurons.  
Therefore, these novel tools show promise for future studies into the roles of astrocytic 
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1.1 Glia-neuronal network 
Glial cells have been classically assigned a secondary role in information coding and 
cognitive processing. Whilst neuronal activity is widely acknowledged as being mainly 
responsible for information processing and transmission, astrocytic activity was 
assigned the role of providing structural, trophic, and metabolic support to surrounding 
neurones. Over the last decade, however, an increasing amount of evidence has 
challenged the subservient view of glia functions, showing that these cells are directly 
involved in synaptic activity and neurotransmitter release (Allen & Lyons, 2018; Perea, 
Sur, & Araque, 2014). In fact, findings have shown that astrocytes can detect and 
modulate the activity of noradrenergic neurones, which in turn are involved in the 
regulation of many brain functions (Bekar, He, & Nedergaard, 2008; Tang et al., 
2014). A particularly interesting expanding field is the relevance of brain energy 
metabolism in the information processing, and the consequent metabolic and 
signalling coupling between astrocytes and neurones. 
 
1.1.1 Astrocytes  
Understanding of the cell biology of astrocytes is in its infancy. Most of our knowledge 
about astrocytic function presumes that astrocytes are a homogenous group of cells, 
without considering the different properties of brain regions and circuits in which 
astrocytes are situated (Mederos, González-Arias, & Perea, 2018). In reality, a range 
of recent evidence has demonstrated that astrocytes are a strikingly heterogenous 
group, comprising of cells with different gene expression patterns and complexity of 
cellular architecture, displaying brain region-specific features and activity (Khakh & 
Deneen, 2019; Oberheim, Goldman, & Nedergaard, 2012; Zhang et al., 2016). 
Although the term astrocytes originated from initial observations in the end of 19th 
century of cells with star-like appearance, it is becoming increasingly evident that 
astrocytic morphology is much more diverse and complex. Morphology and location 
of astrocytes in the brain was initially used to categorize astrocytes into protoplasmic 
and fibrous (Miller & Raff, 1984). Protoplasmic astrocytes, i.e. astrocytes localized in 
the gray matter, generally exhibit a spongiform shape with approximately 4 to 10 major 






different synapses as well as the vascular endothelium, integrating the neurovascular 
unit (Chai et al., 2017; Khakh & Sofroniew, 2017). Surprisingly, a single astrocyte in 
the hippocampus stratum radiatum is estimated to contact over 100,000 synapses 
(Chai et al., 2017; Khakh & Deneen, 2019). On the other hand, fibrous astrocytes 
contain fewer branches, although they are still able to reach blood vessels, and they 
are situated in the white matter in contact with the nodes of Ranvier (Miller & Raff, 
1984; Souza, Almeida, Souza, & Zimmer, 2019). This simplistic classification of 
astrocytes is likely to be expanded in the near future in face of increasing number of 
studies unveiling the heterogeneity of these cells (Chai et al., 2017; Khakh & 
Sofroniew, 2017). Astrocytes can establish interconnections through gap junctions, 
allowing dynamic exchange of ions and metabolites along an astrocytic network 
(Savtchouk & Volterra, 2018). 
Differently from neurones, astrocytes are electrically silent cells. Absence of 
propagated electrical signal that can be used as readouts of different functions 
prevent assessment of astrocytic roles using electrophysiology (Khakh & Deneen, 
2019). On the other hand, astrocytes are consistently shown to respond to various 
stimuli by altering intracellular Ca2+ concentration ([Ca2+]i transients or waves), which 
has been considered a form of excitability by which astrocytes communicate in vitro 
and in vivo (Oberheim et al., 2009; Schummers, Yu, & Sur, 2008; Smith, 1992). 
Different molecular mechanisms were described to underlie astrocytic Ca2+ 
fluctuations, including IP3 type 2 receptor, TRPV4 channel-mediated Ca2+ entry, or 
transient opening of the mitochondrial permeability transition pore (Agarwal et al., 
2017; Haustein et al., 2014; Straub & Nelson, 2007). In fact, Ca2+ signalling in 
astrocytes is remarkably diversified. By using Ca2+ indicators, researchers have 
identified spontaneous – without any identifiable external stimulation – as well as 
neuronal-mediated Ca2+ signalling, which can take place in either localized 
microdomains in a single astrocyte or widespread throughout the astrocytic network 
(Di Castro et al., 2011; Haustein et al., 2014; Khakh & Deneen, 2019). The role of 
Ca2+ signalling in astrocytes is also very broad, which includes functions such as 
release of signalling molecules and trophic factors, modulation of neurotransmitters 
and K+ uptake, and regulation of gene expression (Khakh & Deneen, 2019; 
Verkhratsky & Nedergaard, 2018). Overall, astrocytes take part in all essential CNS 






1.1.2 Communication between astrocytes and neurones  
Astrocytes are key cells in the modulation of neuronal function, actively participating 
in neuronal processing and information coding. Expression of many receptors to 
neurotransmitters and neuromodulators have been described in astrocytes, such as 
glutamate, serotonin, dopamine, adenosine, GABA, and adrenergic receptors 
(Doengi, Deitmer, & Lohr, 2008; Khan, Koulen, Rubinstein, Grandy, & Goldman-
Rakic, 2001; Latour, Gee, Robitaille, & Lacaille, 2001; Sandén, Thorlin, Blomstrand, 
Persson, & Hansson, 2000; Shao & Sutin, 1991; Vélez-Fort, Audinat, & Angulo, 2012; 
Verkhratsky & Nedergaard, 2018). Neuronal activity mediated by various signalling 
molecules can, therefore, be perceived by astrocytes through activation of 
intracellular signalling cascades, which in turn are implicated in the control of 
intracellular Ca2+ levels. (Bazargani & Attwell, 2016). In fact, astrocytes have been 
suggested to be able to distinguish between the different synaptic inputs and display 
different Ca2+ signals in response (Perea & Araque, 2005; Perea et al., 2014). 
By processing the neuronal information, astrocytes  can actively modulate neuronal 
network function. One of the astrocytic mechanisms of response to synaptic activity 
is the uptake of neurotransmitters, as it occurs with astrocytes wrapping the vicinity of 
glutamatergic neurones (Poulain, Oliet, & Piet, 2001). In addition, astrocytes can 
control neuronal function through the release of neuroactive substances – the 
gliotransmitters – such as glutamate, GABA, D-serine, and ATP (Araque et al., 2014; 
Bezzi & Volterra, 2001). Neuronal activity-driven Ca2+ elevations in astrocytes has 
been associated with gliotransmitters release in many parts of the brain, resulting in 
regulatory effects in different neuronal circuits (Perea et al., 2014; Savtchouk & 
Volterra, 2018; Zorec et al., 2012). Among the wide range of gliotransmitters effects 
on neurones, glutamate-induced activation of NMDA receptors has been shown to 
modulate neuronal excitability and synchronize action potential (D’Ascenzo et al., 
2007; Parri, Gould, & Crunelli, 2001).  
Importantly, modulators of astrocytic [Ca2+] signals are not restricted to 
neurotransmitters. Changes in protons and mitochondrial depolarization  underlie the 
chemoception role of astrocytes, which actively detect alteration in oxygen, pH and 
CO2 levels (Angelova et al., 2015; Gourine et al., 2010). Oxygen sensing by astrocytes 






succession of signalling events, results in astrocytic Ca2+ signalling. Increased 
intracellular Ca2+ concentration triggers vesicular- or connexin hemichannel-mediated 
ATP release, which in turn acts by activating respiration-involved neuronal circuitry in 
the brainstem (Angelova et al., 2015; Gourine & Funk, 2017). Alterations in CO2/H+ 
also culminates in increased intracellular Ca2+ concentration in brainstem astrocytes 
in a process mediated by the activity of membrane transporters. This Ca2+ signalling 
induces release of ATP, which acts in the respiratory neuronal network to evoke 
adaptative increases in breathing (Gourine et al., 2010; Marina et al., 2018; Turovsky 
et al., 2016). 
Thus, in gliotransmission, astrocytes are able to detect neuronal activity and 
participate directly in its regulation through a neurone-astrocyte bidirectional 
communication scheme. Some aspects of gliotransmission are nonetheless under 
debate, which is mainly due to the temporal and spatial complexity of Ca2+ signalling 
in astrocytes and its underlying consequences for neuronal activity (Bazargani & 
Attwell, 2016; Fiacco & McCarthy, 2018; Savtchouk & Volterra, 2018). In fact, 
gliotransmission has been suggested to be a complex event, requiring sophisticated 
tools for better comprehension of this phenomenon (Savtchouk & Volterra, 2018).  
 
1.1.3 Noradrenergic neurones and the Locus Coeruleus  
Noradrenaline (NA) in the central nervous system (CNS) is involved in the modulation 
of many brain functions, including attention and vigilance, arousal, cognition, appetite, 
sleep-wake cycle, and autonomic outflows (Aston-Jones & Cohen, 2005; Aston-
Jones, Rajkowski, & Cohen, 1999; Berridge & Waterhouse, 2003). The vast majority 
of the NA released in the brain is provided by noradrenergic neurones whose cell 
bodies are concentrated in a small and bilateral nucleus in the brainstem, the locus 
coeruleus (LC). The LC is localized in the pons adjacent to the fourth ventricle and it 
is comprised of a well-delineated and densely packed cluster of approximately 1,600 
NA-producing cells in the rodent brain (Robertson, Plummer, De Marchena, & Jensen, 
2013; Schwarz & Luo, 2015). LC receives afferent projections from many brain 
regions, including hypothalamus, brainstem and prefrontal cortex circuits, integrating 
cognitive, homeostatic and environmental information (Berridge & Waterhouse, 2003; 






axonal projection system, extensively innervating the forebrain and providing the 
entire NA supply for the hippocampus (Berridge & Waterhouse, 2003). The extensive 
projections of LC neurones target different adrenoceptor types in distinguished brain 
regions, underlying the various regulatory functions attributed to NA (Schwarz & Luo, 
2015). Although LC is generally considered a homogenous structure, evidence has 
long demonstrated that LC neurones exhibit different cell morphology and molecular 
composition (Holets, 1988; Loughlin, Foote, & Grzanna, 1986; Schwarz & Luo, 2015). 
Moreover, optogenetic experiments showed that different firing rates displayed by LC 
noradrenergic neurones affect the specificities of the behaviour seen in mice (Carter 
et al., 2010; Lonergan et al., 2005; McCall et al., 2015).  
NA is mainly released via non-junctional varicosities (synaptic boutons) spread 
throughout the noradrenergic neurone (O’Donnell, Zeppenfeld, McConnell, Pena, & 
Nedergaard, 2012). Through diffusion in the extracellular and spinal fluid, NA can 
target multiple cells over a wide area, evoking coordinated responses from cells within 
the space of diffusion  (Fuxe, Agnati, Marcoli, & Borroto-Escuela, 2015; O’Donnell et 
al., 2012). Amperometric recordings using carbon fibre microelectrodes revealed that 
NA is released through exocytosis from axonal varicosities as well as from the soma-
dendritic compartments (Chiti & Teschemacher, 2007).  Soma-derived NA may act in 
an autocrine manner, whereas NA released from axonal varicosities have a wider 
effect throughout the neuraxis (Chiti & Teschemacher, 2007; Kasparov & 
Teschemacher, 2008). 
 
1.1.4 Interaction between astrocytes and noradrenergic neurones  
An increasing body of evidence indicates that astrocytes are the main cell type 
targeted by noradrenergic volume transmission (Fuxe et al., 2015; Hertz, Chen, 
Gibbs, Zang, & Peng, 2004; Pankratov & Lalo, 2015). Expression of β-, α1- and α2-
adrenoceptors in the astrocytic membrane in vitro and in vivo in many regions of the 
brain was described long ago, raising postulations that astrocytes are targets of the 
central  noradrenergic system (Aoki, 1992; Aoki & Pickel, 1992; Hertz et al., 2004; 
Milner, Lee, Aicher, & Rosin, 1998; Shao & Sutin, 1991; Stone & Ariano, 1989). 
Nonetheless, the extent and impact of the signalling between astrocytes and 






In vivo electric stimulation of noradrenergic neurones in the LC as well as indirect LC 
activation triggered by footshock evoked robust rise in intracellular Ca2+ concentration 
in cortical astrocytes (Bekar et al., 2008). Such responses were sensitive to α-
adrenoceptor antagonists as well as to a neuronal toxin (Bekar et al., 2008). NA 
effects on astrocytes can also be illustrated by a report from Juric and colleagues 
(2008), which showed that application of NA in cultured astrocytes induces α- and β-
adrenoceptors-mediated increase in the expression of brain-derived neurotrophic 
factor (BDNF), a key regulator of neuronal plasticity (Jurič, Lončar, & Čarman-Kržan, 
2008). Moreover, activation of astrocytic β1- or α2-adrenoceptors has been shown to 
trigger glycogenolysis in astrocytes (Hertz et al., 2015b; Subbarao & Hertz, 1990).  
Conversely, little is known about the effects of astrocytes in noradrenergic neuronal 
activity. In fact, our group was the first to describe a signalling pathway by which 
astrocytes actively control the central noradrenergic system (Tang et al., 2014). As 
further described in section 1.4.4, astrocyte-derived L-lactate (LL) binds to a putative 
Gs-coupled receptor in noradrenergic neurones in the LC, evoking depolarization and 
NA release (Tang et al., 2014).  
 
1.2 Brain energy metabolism 
The energy required for normal brain functioning is remarkably high, accounting for at 
least 20% of all glucose consumed by the body. Besides, brain energy metabolism is 
highly dynamic – it must respond to transient and regional energetic demands. It is 
well-established that glucose is the mandatory fuel of the brain and, therefore, fulfils 
many critical roles, such as reconstitution of ion gradients across membranes, 
neurotransmitter and neuromodulator biosynthesis and oxidative stress handling 
(Dienel, 2018). Moreover, metabolic products including LL also carry signalling 
functions, closely coupling metabolism with signalling. Nonetheless, the exact 
metabolic role of glucose and LL in sustaining neuronal activity at the local level is a 
controversial issue. In this section, the main metabolic pathways involved in brain 
energy metabolism will be described. The differences in neuronal and astrocytic 
energetic profile will be also discussed, as well as the controversies behind the cellular 






1.2.1 Glycolysis  
Glycolysis is the transformation of one molecule of glucose into 2 molecules of 
pyruvate with the concomitant net generation of two molecules of ATP (Berg, 
Tymoczko, & Stryer, 2002) (Figure 1.1). In the cytosol, a phosphoryl group is 
transferred from ATP to glucose by the irreversible activity of the enzyme hexokinase. 
This reaction results in the formation of glucose 6-phosphate (G-6P), a molecule that 
cannot diffuse through the membrane due to its negative charge. G-6P subsequently 
undergoes isomerization, which is the rearrangement of atoms in a molecule, which 
in this case is catalysed by phosphoglucose isomerase, forming fructose 6-phosphate 
(F-6P). A second phosphorylation reaction then takes place, in which ATP donates a 
phosphoryl group to F-6P, generating fructose 1,6-biphosphate (F-1,6-BP). This 
irreversible process is catalysed by phosphofructokinase (PFK), a central enzyme 
regulating glycolysis rate. The six-carbon molecule F-1,6-BP is subsequently cleaved 
by the enzyme aldolase into two isomers containing three-carbon units each - 
glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP). GAP 
is the only fragment that can proceed through the glycolysis pathway. However, since 
GAP and DHAP can be readily interconverted through activity of triose phosphate 
isomerase, DHAP is not wasted in the process of energy generation due to its 
conversion into GAP. The following steps of glycolysis take place twice to account for 
the two phosphorylated molecules of GAP formed. While two molecules of ATP have 
been invested at this point, the final stage of glycolysis is comprised of a sequence of 
reactions that harvest the energy contained in GAP. Firstly, GAP is oxidized into 1,3-
biphosphoglycerate (1,3-BPG) by the enzyme glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), which concomitantly reduces the coenzyme nicotinamide 
adenine dinucleotide (NAD+) into NADH. Then, phosphoglycerate kinase catalyses 
the transfer of a phosphoryl group from 1,3-BPG to ADP, forming ATP and 3-
phosphoglycerate. The two molecules of ATP formed in this process compensate the 
2 molecules of ATP consumed in the initial steps of glycolysis.  The enzyme 
phosphoglycerate mutase subsequently shifts the position of the phosphoryl group in 
the 3-phosphoglycerate, forming 2- phosphoglycerate, which in turn is dehydrated into 
phosphoenolpyruvate (PEP) by the enzyme enolase. Finally, PEP donates a 






forming additional ATP and pyruvate. The net reaction of glucose metabolism into 
pyruvate is: 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 2 𝑃𝑖 + 2 𝐴𝐷𝑃 + 2 𝑁𝐴𝐷







Figure 1.1. Glycolysis pathway. Sequence of reactions driving the metabolism of 
one molecule of glucose into two molecules of pyruvate with associated net 






1.2.2 Fates of Pyruvate 
Although synthesis of pyruvate leads to the net production of 2 molecules of ATP, it 
also generates a redox unbalance due to the reduction of NAD+ to NADH by 
dehydrogenation of glyceraldehyde 3-phosphate. Since NAD+ concentration is limited 
within the cells, this intermediate electron carrier must be regenerated to maintain the 
continued operation of glycolysis. Therefore, the final process in glycolysis culminates 
with the metabolism of pyruvate, which in higher organisms can be either converted 
into lactate or engaged in the tricarboxylic acid cycle (TCA) and electron-transport 
chain. 
 
1.2.2.1 TCA cycle and electron transport chain 
While only a fraction of the energy of glucose is extracted through glycolysis, much 
more energy can be released upon complete oxidation of glucose, by means of TCA 
cycle and electron transport chain. The TCA cycle, which will be briefly discussed 
here, takes place inside the mitochondria and involves a series of oxidation reactions 
that breaks carbon compounds into smaller fragments and CO2 with simultaneous 
collection of high energy electrons.  
The entry point of TCA cycle is the formation of Acetyl CoA, which occurs through 
irreversible oxidative decarboxylation of pyruvate by the pyruvate dehydrogenase 
(PDH) complex. Carboxyl groups are lost as CO2 and the electrons released in this 
reaction, which resembles many of the enzymatic reactions of the TCA cycle, are 
transferred to the intermediate electron carrier NAD+, which in turn, conserves the 
energy of the oxidation process in the form of reduced NADH (Figure 1.2). Acetyl CoA 
– a two-carbon acetyl unit – fuses with the four-carbon oxaloacetate, generating the 
six-carbon TCA (citrate). Citrate undergoes oxidative decarboxylation, yielding a five-
carbon compound (α-ketoglutarate) that is also oxidatively decarboxylated to form 
succinate, a four-carbon molecule. Finally, succinate is enzymatically regenerated 
into oxaloacetate, which can restart the cycle upon condensation with acetyl CoA. 
The sequential oxidation of carbon atoms to CO2 in the TCA cycle releases electrons 
that are transferred as hydride ions (:H-) to NAD+ and as hydrogen atoms to flavin 






respectively. At the end of each turn of TCA cycle, three molecules of NADH, one 
molecule of FADH2, as well as one GTP and two CO2 are released (Figure 1.2). 
Importantly, the role of TCA cycle is not restricted to the harvest of energy from carbon 
compounds. Four- and five-carbon intermediate products of the cycle also act as 
precursors for a range of biosynthesis pathways, such as the generation of glutamate 
and aspartate from α-ketoglutarate and oxaloacetate, respectively. 
Figure 1.2. Overview of the products generated by each turn of the TCA cycle. 
In the mitochondria, acetyl-CoA is formed mainly by oxidative decarboxylation of 
pyruvate formed during glycolysis. The cycle starts with formation of citrate by the 
inclusion of oxaloacetate to the acetyl group of acetyl-CoA. Through a series of 
oxidative decarboxylation reactions, carbon elements are fragmented into smaller 
compounds and CO2. Electrons released in these reactions are transferred to 
intermediate electron carriers, forming NADH and FADH2. Schematic adapted from 
Berg et al. (2002). 
 
The energy collected in the TCA cycle and stored in the intermediate electron carriers 
is used to generate ATP in the respiratory chain, which comprises of molecular 
complexes embedded in the inner mitochondrial membrane. Although this process – 
oxidative phosphorylation – is mechanistically complex (Berg et al., 2002), the 
concept underpinning is straightforward as briefly outlined here. NADH and FADH2 






either of these complexes to complex III by the lipid-soluble carrier ubiquinone (Figure 
1.3). Cytochrome c carries electrons from complex III to IV, where electrons reduce 
oxygen to water. Thus, oxygen in mitochondrial respiration is the electron acceptor 
required to regenerate NAD+ and FAD consumed during glycolysis and TCA cycle. 
The transfer of electrons through the complexes is based on coupled redox reactions, 
in which a carrier is reduced and subsequently oxidized by the next carrier in the 
chain. The electron transport chain acts, therefore, as an electrical wire passing down 
the electrons through the chain. This process is exergonic, and the energy released 
is used to pump protons to the intermembrane space, creating a proton gradient 
across the membrane, also referred as proton-motive force. Finally, in the ATP 
synthase enzymatic complex, protons flow down the concentration gradient into the 
mitochondrial matrix, passing the energy required for the formation of ATP from ADP 
and inorganic phosphate (Pi). 
Figure 1.3. Generation of ATP through the respiratory chain. Electrons harvested 
in the TCA cycle are transferred from NADH and FADH2 to Complex I and II, 
respectively. Through the loosely membrane-associated carriers Ubiquinone and 
Cytochrome c, electrons are passed down the respiratory chain (curvy grey line) to 
complex IV. The energy released in this process is used to drive protons to the 
intermembrane space, creating a proton gradient across the membrane (proton-
motive force). At complex IV, electrons react with oxygen and protons to form water. 
Finally, the protons held in the intermembrane space pass down through the ATP 
synthase to the mitochondrial matrix, and the energy release in this process is used 






1.2.2.2 L-lactate production 
Another fate of pyruvate is its reduction into LL. This reversible reaction is catalysed 
by the enzyme L-lactate dehydrogenase (LDH) (Figure 1.4) and requires the 
intermediate electron carrier NAD.  
Figure 1.4. Reaction catalysed by the enzyme LDH. Pyruvate is reduced to LL 
through the activity of the NADH-dependent LDH. 
 
LDH is a tetramer composed of A (also known as M, or 5) and B (also known as H, or 
1) subunits. Combination of these subunits in all possible arrangements of four yields 
five different isoenzymes (Fisenne et al., 1961). Expression of LDH isoenzymes 
containing B subunits (LDH-B) is enhanced in tissues characterised by intense 
oxidative metabolism, such as the heart. On the other hand, tissues that often undergo 
anaerobic metabolism express mainly LDH isoenzymes enriched with A subunits 
(LDH-A), which is the case of skeletal muscle and liver (Laughton et al., 2000; 
Markert, Shaklee, & Whitt, 1975). In the brain, the cellular distribution of LDH 
isoenzymes has been investigated at the gene and protein levels. Previous reports 
have described enriched or exclusive expression of LDH-B in neurones, while 
astrocytes express mainly the LDH-A subtype (Bittar, Charnay, Pellerin, Bouras, & 
Magistretti, 1996; Laughton et al., 2000; O’Brien, Kla, Hopkins, Malecki, & McKenna, 
2007). More recent data using single-cell transcriptome analysis indicated twofold 
increase in LDH-B in astrocytes as compared to neurones, which in turn showed 1.7-
fold enhanced LDH-A (Zhang et al., 2014). 
This different expression pattern of LDH isoenzymes has been suggested to reflect 
the metabolic requirements of the tissue or cell population. This is due to the fact that 






constant (Km), which express the substrate concentration at which the reaction 
reaches half of its maximum value, and the maximum rate of reaction (Vmax), which is 
the rate of the reaction when the enzyme is saturated with the substrate. Different 
values of Km and Vmax may favour the reaction towards either LL formation (LDH-A) 
or LL degradation (LDH-B) (Bittar et al., 1996; Swiderek & Paneth, 2011). These 
observations led to the proposition of a predominant glycolytic profile in astrocytes, 
which culminates in accentuated LDH-A-mediated production of LL, which in turn is 
transported to neurones to be converted via LDH-B into pyruvate (Bittar et al., 1996; 
Pellerin & Magistretti, 2012). Nonetheless, this assertion has been challenged under 
steady-state conditions (Quistorff & Grunnet, 2011). According to the authors, the fact 
that the equilibrium constant is still the same in the different isoenzymes, variations in 
the kinetics properties would not dictate the level of LL concentration in steady-state 
conditions. Moreover, although non-steady situations may influence the time-course 
of LL accumulation, the high activity of LDH causes the transitions in net flux of LL to 
be short-lived (Quistorff & Grunnet, 2011).  
 
1.2.2.3 Control of the cellular redox balance  
The variety of coenzymes specialized in electron transport such as NAD, FAD, 
nicotinamide adenine dinucleotide phosphate (NADP), and flavin mononucleotide 
(FMN) is very insignificant if compared to the multitude of reactions in a cell that are 
catalysed by these electron carriers (Nelson & Cox, 2017). NAD, in particular, is 
essential for metabolism of glucose and LL and the ratio between the reduced and 
oxidized forms of this coenzymes can dictate the metabolic dynamics within a cell.  
The major processes that regulate NADH/NAD+ ratio in astrocytes and neurones are 
glycolysis, LDH activity and the malate-aspartate shuttle (MAS) (Dıaz-Garcıa et al., 
2017). Activity of GAPDH enzyme during glycolysis generates NADH, which is 






Figure 1.5. Regeneration of NAD in the glycolytic pathway. The electron acceptor 
NAD+ is reduced to NADH during glycolysis, whereas LL production causes NADH 
oxidation to NAD+. Therefore, conversion of glucose into lactate maintains the redox 
balance as there is no net change in NAD+ and NADH. Schematic adapted from Berg, 
Tymoczko, and Stryer (2002). 
 
Another mechanism to restore the cellular redox balance is the MAS, which consists 
of a mitochondrial shuttle system composed of a series of enzymes and transporters 
that carry reducing equivalents from cytosolic NADH to the mitochondria, as NADH is 
an impermeable molecule to the mitochondrial membrane. Briefly, the cytosolic 
malate dehydrogenase (MDH) enzyme reduces oxaloacetate to malate, regenerating 
NAD+ (Figure 1.6). Malate is then transferred to the mitochondrial matrix via the 
malate–α-ketoglutarate carrier in exchange for α-ketoglutarate. The mitochondria 
MDH, which is part of the TCA cycle, oxidizes malate to oxaloacetate, forming NADH 
that will transfer its electron to oxygen in the respiratory chain. Oxaloacetate is then 
converted to aspartate by the activity of aspartate aminotransferase, which also 
converts glutamate to α-ketoglutarate. Aspartate exits the mitochondria by the 
aspartate-glutamate carrier, which concomitantly carries glutamate and H+ in opposite 
directions. In the cytosol, aspartate aminotransferase converts aspartate to 
oxaloacetate at the same time that it forms glutamate from α-ketoglutarate (McKenna, 






Figure 1.6. Malate-aspartate shuttle. Through a series of enzymatic reactions and 
transporters, reducing equivalents from NADH are transferred from the cytosol to the 
mitochondrial matrix. All the components of the shuttle are regenerated, except for 
the cytosolic proton transported with glutamate in exchange for aspartate. cAAT: 
cytosolic aspartate aminotransferase; cMDH: cytosolic malate dehydrogenase; 
mAAT: mitochondrial aspartate aminotransferase; mMDH: mitochondrial malate 
dehydrogenase. Schematic adapted from McKenna et al. (2006). 
 
Some reports suggest that MAS is the major process regenerating the cytosolic levels 
of NAD+ in neurones under resting conditions (Cheeseman & Clark, 1988; McKenna 
et al., 2006). Recent work investigating the NADH/NAD+ ratio in stimulated neurones 
in hippocampal slices indicated that MAS contribution to the cytosolic NADH 
transients is minor as compared to the activity of LDH (Díaz-García & Yellen, 2019). 
In astrocytes, MAS activity has been suggested to be remarkably reduced or nearly 
absent (Ramos et al., 2003). 
 
1.2.3 Glycogen metabolism  
Glycogen is comprised of branches of glucose residues assembled around a core 
protein, forming granules in the cells’ cytoplasm with sizes ranging from approximately 
10 to 60 nm (Calì et al., 2016). In the brain, glycogen concentration is approximately 






(Stryer, 1995). Glycogen granules in the CNS appear almost exclusively in astrocytes, 
except for a few studies which detected glycogen in neurones – either in moto-
neurones or under pathological conditions, ultimately leading to neurodegeneration 
(Sotelo & Palay, 1968; Vilchez et al., 2007). More recently, evidence using more 
sensitive assays has suggested that neurones are endowed with enzymes that 
synthesize and degrade glycogen and, although in small amounts, glycogen is in fact 
accumulated in these cells (Saez et al., 2014). Interestingly, this study has suggested 
that neuronal glycogen plays an important role in neuronal survival under hypoxic 
conditions since absence of glycogen shunt in neurones increased their vulnerability 
to oxygen deprivation (Saez et al., 2014). 
Glycogen is readily metabolised to provide energy substrates to the brain. Its 
degradation relies on the activity of the enzyme glycogen phosphorylase, which adds 
Pi to the substrate, yielding glucose 1-phosphate (G-1P) (Table 1.1). The phosphoryl 
group in the G-1P is then shifted by phosphoglucomutase to form G-6P, a molecule 
that can engage in the metabolic mainstream. Importantly, generation of G-6P from 
glycogen is an energetically advantageous process as compared to the glycolytic 
degradation of glucose since it does not require energy input to phosphorylate the 
substrate (Berg et al., 2002). Therefore, since incorporation of glycogen-derived G-
6P into the glycolysis skips the hexokinase reaction, it yields 3 molecules of ATP, 
while 2 molecules of ATP are released from glucose-derived G-6P. 
Synthesis of glycogen is not the reverse reaction of the degradative pathway (Table 
1.1). Addition of a glycosyl residue in the glycogen chain is catalysed by glycogen 
synthase, which uses as a substrate the uridine diphosphate (UDP)-glucose – the 
activated form of glucose. UDP-glucose, in turn, is formed from uridine triphosphate 







Table 1.1. Biochemical processes mediating glycogen synthesis and degradation 
Berg et al. (2002). 
 
Although glycogen synthesis and degradation are fairly simple biochemical 
processes, these reactions are tightly regulated by multiple allosteric effectors. 
Glycogen turnover in astrocytes is regulated by cells’ energetic requirements as well 
as by the concentration of Ca2+ and K+ in the intracellular and extracellular 
compartments, respectively  (Dienel, 2018; Dienel & Cruz, 2016; Hertz et al., 2015b). 
Moreover, glycogen degradation can be driven by interactions of astrocytic receptors 
with neurotransmitters, such as serotonin, adenosine, and NA (Hertz et al., 2015b). 
NA-induced glycogenolysis has been shown to be mediated mainly by β1-
adrenoceptor activation and, to a lesser extent, by α2-adrenoceptors (Hertz et al., 
2015; Subbarao & Hertz, 1990). Contrarily to the classical view of glycogen as an 
emergency fuel to the brain, evidence has indicated that glycogen metabolism can 
take place under adequate conditions of glucose availability and delivery (Swanson, 
Morton, Sagar, & Sharp, 1992). Indeed, glycogen metabolism has been shown to 
have an essential role in brain energetics and aerobic glycolysis, which can greatly 
influence many aspects of brain function (Dienel, 2018; Hertz et al., 2015). 
 
1.2.4 Neuronal and astrocytic energetic profiles 
Brain cells exhibit different metabolic profiles. Neuronal metabolism is considered to 
be highly oxidative, whereas astrocytes are suggested to favour the glycolytic 
pathway, preferentially converting glucose to LL (Magistretti & Allaman, 2015). These 
metabolic differences are neither due to a decreased number of mitochondria in 
astrocytes nor because of defective astrocytic respiration (Lovatt et al., 2007; 
Magistretti & Allaman, 2015). Instead, differential metabolic profiles are thought to be 





Synthesis Glycogen synthase 
𝐺𝑙𝑦𝑐𝑜𝑔𝑒𝑛𝑛 + 𝑈𝐷𝑃𝑔𝑙𝑢𝑐𝑜𝑠𝑒 










enzymes that regulate metabolic fluxes as well as differential organization of the 
respiratory chain in the mitochondria.  
Single-cell transcriptome analysis showed that the glycolytic enzyme 6-
phosphofructose-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) is upregulated in 
astrocytes (Zhang et al., 2014). This enzyme converts F-6P to fructose-2,6-
biphosphate, which in turn acts as allosteric activator of PFK-1, stimulating glycolysis 
(Zhang et al., 2014). Furthermore, subtypes of another key enzyme regulating 
glycolysis – pyruvate kinase, subtypes PKM1 and PKM2 – are differently expressed 
in neurones and astrocytes (Zhang et al., 2014). The latter cell type expresses PKM2, 
which can regulate the glycolytic flux according to the local energy demand. This 
feature is not present in PKM1 expressed by neurones, which may prevent 
upregulation of glycolysis in these cells (Zhang et al., 2014). Following glycolysis, the 
rate-limiting step for pyruvate entry in the TCA cycle is its decarboxylation, catalysed 
by PDH. In astrocytes, PDH has been shown to be remarkably phosphorylated, which 
decreases its activity, suggesting reduced flux of pyruvate to mitochondrial respiration 
as compared to neurones (Halim et al., 2010). At the mitochondrial level, evidence 
has suggested that complexes of the respiratory chain in neurones are organized into 
supercomplexes, resulting in more efficient oxidative phosphorylation and decreased 
production of reactive oxygen species (ROS) (Lopez-Fabuel et al., 2016). On the 
other hand, complex I in astrocytes is free, which is associated with poor mitochondrial 
respiration and higher generation of ROS (Lopez-Fabuel et al., 2016). Importantly, LL 
production is driven by the cell redox state, which has been investigated in mouse 
hippocampal brain slices using an intracellular redox biosensor (Mongeon, 
Venkatachalam, & Yellen, 2016). Results indicated that the NADH/NAD+ ratio in 
astrocytes in steady-state condition is higher than in neurones, which is consistent 
with increased astrocytic conversion of glucose to LL (Mongeon et al., 2016).  
Moreover, a recent in vivo study using biosensors for real-time measurement of 
metabolite dynamics in brain cells of anesthetised mice indicated that astrocytes 
maintain higher resting levels of LL (Mächler et al., 2016). Other factor previously 
discussed that may also contribute to the glycolytic profile of astrocytes include the 
control of glycogen shunt. 
Overall, at the cellular level, astrocytes are in fact more equipped to produce LL than 






recent observations using mutant mice lacking Complex IV of the electron transport 
chain in Bergmann glia cells of the cerebellum (Supplie et al., 2017). Surprisingly, 
respiration-deficient astrocytes were completely viable even 1 year following gene 
knockout, implying that these cells can rely on glycolysis for energy generation 
(Supplie et al., 2017). 
 
1.2.5 Aerobic Glycolysis  
The net energy provided from the conversion of glucose to pyruvate is 2 ATPs per 
molecule of glucose, while oxidative phosphorylation releases approximately 32 
ATPs. Although LL production seems a coherent pathway for energy generation 
under hypoxic conditions, cancer cells tend to favour the glycolytic pathway even 
under adequate oxygen levels. This phenomenon is called Walburg effect and its 
underlying regulatory mechanisms have only now been elucidated (Vander Heiden & 
DeBerardinis, 2017; Yellen, 2018). The preferential conversion of glucose to LL in 
these cells is likely to be driven by an increase in the NADH/NAD+ ratio, which is due 
to the intense nucleotide production that sustains cell growth (Vander Heiden & 
DeBerardinis, 2017). Importantly, mitochondrial respiration is not defective in cancer 
cells. On the contrary, the TCA cycle must take place in order to generate precursors 
for the synthesis of cell components for the proliferative counterparts (Vander Heiden 
& DeBerardinis, 2017). In the brain, glucose is thought to be nearly completely 
oxidized to CO2 under resting conditions (Dienel, 2012). However, transient neuronal 
stimulation evokes a Warburg-like effect, also known as aerobic glycolysis. 
Accordingly, during transient episodes of neuronal activity, there is a disproportionate 
upregulation of glucose consumption as compared to oxygen utilization, even though 
the oxygen levels and means of delivery are adequate (Fox, Raichle, Mintun, & 
Dence, 1988). The actual physiological function of aerobic glycolysis has intrigued 
many researchers in recent decades. Astrocytes are thought to play an important role 
in this phenomenon since these cells are key regulators of glycogen turnover and LL 
can diffuse through the astrocytic gap-junction network (Dienel & Cruz, 2016). 
Nonetheless, the precursor substrate sustaining neuronal activity and the cellular and 






lasting controversial topic (Bak & Walls, 2018; Barros & Weber, 2018; Dienel, 2018; 
Magistretti & Allaman, 2018), and will be further discussed below. 
 
1.2.6 Astrocyte-to-neurone L-lactate shuttle hypothesis 
The astrocyte-to-neurone LL shuttle (ANLS) hypothesis has been proposed over two 
decades ago and provides an explanation for the paradoxical aerobic glycolysis that 
follows neuronal excitation (Pellerin & Magistretti, 1994). It originated from 
observations that, in glutamatergic neurotransmission, glutamate released in the 
synaptic cleft is taken up by closely associated astrocytes through glutamate 
transporters, which work upon symport with Na+, in order to restore the basal 
extracellular levels of glutamate (Figure 1.7). Increased influx of Na+ into the astrocytic 
cytosol activates Na+/K+ ATPase, which restores Na+ and K+ homeostasis at the 
expense of ATP. Energy utilization triggers glycolysis in astrocytes, in which glucose 
is non-oxidatively converted into LL via LDH. LL is then shuttled to neurones via 
monocarboxylate transporters (MCTs), where it is converted to pyruvate by the activity 
of LDH. Pyruvate in neurones is further metabolized in the TCA cycle for oxidative 
generation of ATP in the mitochondrial respiratory chain. Concomitantly, glutamine 
synthetase in astrocytes catalyses the conversion of glutamate into glutamine, which 
is released to the extracellular space and taken up by neurones to be recycled back 






Figure 1.7. LL shuttle from astrocytes to activated neurone. ANLS predicts that 
glycolysis in astrocytes surrounding active neurones is triggered by the activity of the 
Na+/K+ ATPase, which is activated by the astrocytic uptake of glutamate (Glu) through 
excitatory amino acid transporters (EAATs). LL produced by glycolysis in astrocytes 
is then exported to neurones, where it is oxidised to pyruvate to be further used in the 
production of ATP. Glutamate in astrocytes is converted to glutamine (Gln), which is 
released and taken up by neurones to be converted to glutamate. GluR: glutamatergic 
receptors.  Schematic adapted from Bélanger, Allaman, and Magistretti (2011). 
 
The ANLS model, which predicts that stimulated neurones use astrocyte-derived LL 
as a primary energy source, has gained support over the years by reports from several 
laboratories (Magistretti & Allaman, 2015, 2018; Weber & Barros, 2015). ANLS has 
expanded beyond glutamatergic neurotransmission, such as in a study showing that 
K+ released by excited neurones stimulated astrocyte-derived LL release (Fernández-
moncada, Ruminot, Robles-maldonado, Alegría, & Deitmer, 2018; Sotelo-Hitschfeld 
et al., 2015). Moreover, genetic ablation of specific glycolytic enzymes in Drosophila 
melanogaster resulted in neurodegeneration, suggesting that ANLS is a phylogenetic 
conserved mechanism (Volkenhoff et al., 2015). Other glia cells – the 
oligodendrocytes – were also reported to release LL, which was essential for 
maintenance of adequate axonal function (Saab & Nave, 2017). LL shuttle from 
astrocytes to neurones has proven to be feasible by various experiments in culture 
(Magistretti & Allaman, 2018; Pellerin & Magistretti, 2012). In particular, the astrocytic 
store of glycogen in regions of intense synaptic activity as well as astrocytic control of 






NA, is in favour of neurone-astrocyte metabolic coupling as predicted by ANLS 
(Pellerin & Magistretti, 2012).  
LL transport from astrocytes to neurones, where LL is subsequently used as an 
energy source, has been shown to be pivotal for long-term memory formation in the 
hippocampus (Suzuki et al., 2011). Inhibition of glycogen-derived LL through 
intrahippocampal injection of the glycogen phosphorylase blocker 1,4-dideoxy-1,4-
imino-d-arabinitol (DAB) disrupted long-term potentiation and memory consolidation. 
On the other hand, memory formation has been rescued when DAB was co-applied 
with LL. LL also rescued the amnestic effect evoked by downregulation of MCT1 and 
MCT4 expression, which has been induced by injection of targeted antisense 
oligonucleotides (Suzuki et al., 2011). According to the study, decreased expression 
of these transporters culminated in reduction of LL export from astrocytes. 
Conversely, downregulation of MCT2 expression prevented the rescue effect of LL on 
memory formation due to impaired LL import to neurones (Suzuki et al., 2011). The 
specific molecular mechanisms mediating LL effects on long-term memory 
consolidation has not been elucidated yet. Nonetheless, further research suggested 
that activation of astrocytic β2-adrenergic receptors in the hippocampus has an 
essential role in triggering glycogenolysis and LL release that support neuronal 
molecular changes related to memory consolidation processes (Gao et al., 2016). 
 
1.2.6.1 Controversies and challenges to the hypothesis  
The evidence supporting the ANLS is mostly indirect, such as the observations of a 
preferential glycolytic metabolism of glucose in astrocytes, whereas neurones rely 
mainly on oxidative phosphorylation (previously discussed in section 1.2.4). One of 
the cornerstones of the ANLS model is the differential expression of LDH and MCT 
subtypes in astrocytes and neurones, which, due to differences in kinetics and 
affinities explained elsewhere in this chapter, would lead to unidirectional LL flux from 
astrocytes to neurones (Bittar et al., 1996; Pellerin & Magistretti, 2012; Pierre & 
Pellerin, 2005). However, the equilibrative feature of these enzymes and carriers as 
well as single-cell transcriptome databases challenge the role of MCTs and LDHs in 
substantiating the ANLS hypothesis (Bak & Walls, 2018; Dienel, 2012; Yellen, 2018; 






Although LL shuttle from astrocytes to neurones at rest is feasible due to increased 
intra-astrocytic basal levels of NADH and LL (Kasparov, 2016; Mächler et al., 2016; 
Mongeon et al., 2016), ANLS operation during neuronal activation is broadly 
controversial (Dienel, 2017; Yellen, 2018). Technical limitations in temporal and 
spatial resolution prevent proper identification of the cell type accountable for 
stimulation-induced aerobic glycolysis and hinder direct measurement of LL transfer 
and its metabolic contribution to neuronal energetics. 
Many of the arguments against the ANLS are based on theoretical grounds which, for 
example, question the lack of adequate stoichiometry between the rate of glucose 
utilization, which is converted to LL, and the rate of oxygen consumption, which is 
used for energy generation following LL oxidation in neurones (Dienel, 2017). 
Moreover, the rate of glycolysis induced by treatment with glutamate did not match 
the rate of LL that is released from astrocytic cultures (Dienel, 2017). Opponents of 
the ANLS model also point out that glutamate oxidation following its uptake by 
astrocytes generates energy at higher yield than glycolysis, contributing at least in 
part for the energetic cost of glutamate uptake (Dienel, 2017, 2018; McKenna, 2013).  
A recent study using intracellular biosensors for NADH/NAD+ in acute hippocampal 
slices of mice showed that stimulation evoked a prolonged rise in neuronal 
NADH/NAD+ ratio, which was accompanied by an increase in the intracellular 
concentration of LL  (Dıaz-Garcıa et al., 2017). Blockade of MCTs did not prevent 
stimulation-induced NADH and LL transients in neurones, which is inconsistent with 
LL import from astrocytes as predicted by ANLS. In fact, the authors reported that 
inhibition of either MCTs or LDH increased NADH/NAD+ ratio, which not only implies 
that neurones enhance their own glycolytic rate to meet the acute metabolic demands 
of stimulation, but also may export LL in order to alleviate NADH accumulation (Dıaz-
Garcıa et al., 2017).  
In fact, there is no compelling evidence that irrefutably reveals the role of aerobic 
glycolysis during neuronal stimulation. The expression of glycolytic enzymes close to 
neuronal synaptic vesicles may indicate that glycolysis plays a role in the acute 
replenishment of energy in locations where ATP is highly required (Hinckelmann et 
al., 2016). A speculative interpretation of this process takes into consideration that, in 






phosphorylation, the rate of ATP production is much faster (Crow, 1982). Therefore, 
similar to fast-twitch muscle fibres, neurones may use LL as a prompt additional 
energy source to the costly process of neuronal processing (Yellen, 2018).  
 
1.3 L-lactate transport across membranes 
Although much is currently discussed about the source and actions of LL in the brain, 
the mechanisms by which LL is released from astrocytes and what regulates its 
release are not well understood. Transmembrane MCTs have been assigned as the 
main carriers accountable for LL trafficking. As a result, extensive pharmacological 
and genetic manipulations of MCTs activity and expression have been employed in 
order to investigate LL metabolism and signalling in the brain. Nonetheless, recent 
evidence has indicated that LL exchange is not exclusively executed by MCTs. In 
addition, the main source of LL in the brain, the astrocytes, are endowed with 
connexins and pannexins able to transport LL across membranes (Karagiannis et al., 
2015). Yet, another potential mechanism by which LL can be released from astrocytes 
is described as an efficient ion-channel that responds to neuronal depolarisation and 
can be modulated by LL itself (Sotelo-Hitschfeld et al., 2015).  
 
1.3.1 Monocarboxylate transporters 
Monocarboxylates such as LL, pyruvate, ketone bodies, acetate, among others, are 
carried across plasma membranes through a family of proton-linked transporters, the 
MCTs. MCTs are a family of 14 members that mediate the facilitated diffusion of a 
monocarboxylate with a proton across the membrane following a concentration 
gradient. Of note, metabolic processes generate monocarboxylic acids (R-COOH, R 
referring to the rest), which are nearly completely dissociated to their monocarboxylic 
anion (RCOO−) at physiological pH ( Halestrap, 2011). However, in case of low pH 
and high undissociated monocarboxylate concentration, a direct diffusion of the 
monocarboxylic acids across phospholipid bilayers of biological membranes can take 
place (Poole & Halestrap, 1993). Indeed, free diffusion of undissociated 
monocarboxylic acids through membrane lipids was believed to be the sole transport 






carrier was only demonstrated when transport of LL and pyruvate in erythrocytes was 
blocked by the inhibitor α-cyano-4-hydroxycinnamate (CHC) (Halestrap, 1976; 
Halestrap & Denton, 1974; Halestrap, 2011). Since then, extensive research has been 
carried out in order to characterize MCTs activity, specificity and expression.  
MCTs share a common structure that is predicted to contain 12 transmembrane 
helices with a large cytosolic loop between two of the intermediate helices and the C- 
and N-termini in the cytoplasm (Poole, Sansom, & Halestrap, 1996). The net 
cotransport of a monocarboxylate with a proton through MCTs requires that a proton 
binds to the MCT in the first place, followed by the binding of a monocarboxylate anion 
(Halestrap, 2011). As a consequence, the carrier experiences a conformational 
change, translocating the proton and the monocarboxylate across the membrane, 
with subsequent release of the ligands in the cytosol (Halestrap, 2011) (Figure 1.8A). 
Since MCT kinetics are the same regardless of the side of the membrane, the 
direction of monocarboxylate transport (influx or efflux) depends exclusively on the 
concentration gradient, which is provided by either monocarboxylate or protons 
(Halestrap, 2011).  
Translocation of MCTs binding site across the membrane occurs at faster speed when 
the substrate is bound to the carrier (Halestrap, 2011). The step limiting the 
transportation rate is, therefore, the return of the unloaded carrier to the original 
conformation. Nonetheless, following substrate release from the carrier, another 
monocarboxylate can bind the newly empty binding side of the MCT, a process called 
monocarboxylate exchange or trans-acceleration of MCTs (Fishbein, Foellmer, Davis, 
Fishbein, & Armbrustmacher, 1988; Halestrap, 2011) (Figure 1.8B). Since in this 
situation the translocation of the carrier to both sides of the membrane occurs at the 
bound state, monocarboxylate exchange is considered to be notably faster than the 
net proton-linked cotransport (Halestrap, 2011). Therefore, transport of a 
monocarboxylate is accelerated by the presence of another monocarboxylate on the 
opposite side of the membrane (Garcia, Goldstein, Pathak, Anderson, & Brown, 
1994). This concept has been recurrently applied in this project as well as in other in 
vitro and in vivo studies in order to deplete the cells of LL (Mächler et al., 2016; San 
Martín et al., 2013). Efflux of LL from astrocytes was achieved by increasing the 






Figure 1.8. Proton-linked transport of monocarboxylates through MCTs. (A) 
Proton (H+) and LL bind to the MCT evoking a conformational change that 
translocates the carrier across the membrane. After release of H+ and LL, the 
conformational change that brings the unbound carrier to the original configuration 
(K2) is slower as compared to the translocation of the bound MCT across the 
membrane (K1). (B) In this example of monocarboxylate exchange, an inward 
gradient of pyruvate (PYR) drives MCT-mediated transport of pyruvate to the 
intracellular compartment. Following PYR release, the inward-facing empty binding 
sites of MCTs bind to LL, translocating it to the extracellular compartment. This 
process is called trans-acceleration of MCTs since the carrier is continually in the 
bound state, where translocation of MCTs is faster (Halestrap, 2011; Mächler et al., 
2016). 
 
1.3.1.1 MCTs isoforms and their cell-specific distribution  
Although sequence homology studies have so far identified 14 isoforms of MCTs in 
mammals, only 4 of them have been unequivocally shown to be involved with 
monocarboxylate transport in humans, i.e. MCT1, MCT2, MCT4, and MCT3 
(Halestrap, 2011). Among those, MCT1, MCT2 and MCT4 are expressed in brain 
cells, while MCT3 is primarily found in the retinal pigment epithelium (Halestrap & 
Price, 1999; Philp, Yoon, & Grollman, 1998; Pierre & Pellerin, 2005). Even though 
there is a consensus that distribution of distinct MCT isoforms in the CNS differ 
regionally and cellularly, employment of different techniques, antibodies and animal 
species led to controversial results in this regard (Pierre & Pellerin, 2005). The data 
here presented are mostly based on RNA sequencing studies of acutely isolated brain 






MCT1 is the best described isoform and has been reported to exhibit a wide specificity 
for short chain monocarboxylates. Km values are 3.5 mmol/L and 1.0 mmol/L for LL 
and pyruvate, respectively (Table 1.2) (Bröer et al., 1998; Carpenter & Halestrap, 
1994). The higher Km for D-lactate (DL) (27.5 mmol/L) indicates that MCT1 is 
stereoselective for lactate isomers (Carpenter & Halestrap, 1994; Poole, Cranmer, 
Halestrap, & Levi, 1990). In the brain, MCT1 is expressed at the highest levels in 
endothelial cells, underpinning their role in the transport of LL between the periphery 
and the CNS (Bergersen, 2015; Zhang et al., 2014). Astrocytic somata and processes 
also express MCT1 and, although immunoreactivity studies have mostly failed in 
confirming this, neurones can also express MCT1, but at lower level as compared to 
astrocytes (Pierre & Pellerin, 2005; Zhang et al., 2014).  
MCT2 is characterized by the higher affinity to monocarboxylates (Bröer et al., 1999; 
Lin, Vera, Chaganti, & Golde, 1998). Despite the fact that the substrate specificity of 
MCT2 is similar to MCT1, Km values of most of the ligands are lower for MCT2 as a 
result of the enhanced affinity (Table 1.2). MCT2 is predominantly expressed in 
neurones, which has been confirmed by studies using a variety of techniques (Pierre 
& Pellerin, 2005; Zhang et al., 2014). 
MCT4, on the other hand, exhibits very low affinity to monocarboxylates, which results 
in increased Km values for the majority of the substrates (5- to 100-fold higher than 
observed for MCT1 – Table 1.2) (Dimmer, Friedrich, Lang, Deitmer, & Bröer, 2000; 
Manning Fox, Meredith, & Halestrap, 2000). Data on cellular distribution of MCT4 are 
the most contradictory amongst the MCT isoforms in the brain. Immunoreactivity 
studies detected expression solely in astrocytes, culminating in many reports 
considering MCT4 to be specific for these cells (Magistretti & Allaman, 2015; Pierre & 
Pellerin, 2005; Rafiki, Boulland, Halestrap, Ottersen, & Bergersen, 2003). 
Nonetheless, analysis of a transcriptome database revealed that neurones also 
express this carrier and at higher levels as compared to astrocytes (Zhang et al., 
2014). 
Expression of MCT isoforms has been proposed to be under transcriptional or post-
transcriptional regulation in order to meet fluctuations in energetic demands of brain 
cells (Halestrap & Wilson, 2012). Exposure of cultured cortical neurones to NA, 






in these cells (Chenal & Pellerin, 2007; Chenal, Pierre, & Pellerin, 2007; Robinet & 
Pellerin, 2010). Such changes in MCT2 expression have been associated with 
increased synaptic transmission and neuronal plasticity, which demands an enhanced 
energy supply (Pellerin & Magistretti, 2012). Although changes in MCT1 expression 
have been widely demonstrated in skeletal muscles in response to physical activity, 
denervation and spinal injury, there is no report to the best of my knowledge 
describing alterations of MCT1 expression levels in brain cells.  
 
Table 1.2. Cell-specific expression of MCT isoforms in brain tissue and their 
affinity to monocarboxylates that are relevant to this project. Non-available data 
are expressed as n.a. 80mM acetate did not saturate MCT4. Km values were taken 
from  Halestrap (2011) and Rae et al. (2012).  
  Affinity – Km values (mmol/L) 





3.5 1.0 27.5 3.7 








The majority of the naturally occurring substrates of MCTs are products of metabolic 
processes and exhibit a range of physiological roles in the CNS. Likewise, the different 
kinetics and expression profiles of the MCT isoforms in the brain are expected to 
follow the physiological relevance of their ligands. One of the pillars of the ANLS 
hypothesis is the fact that expression of the low affinity MCT1 and MCT4 in astrocytes 
indicates efflux of LL, while expression of the high-affinity MCT2 in neurones suggests 
influx of LL even at lower concentrations of this compound (Pellerin & Magistretti, 
2012). MCTs are, therefore, suitable for shuttling LL from astrocytes to neurones, 
where it can be oxidized to be used as an energy source according to the ANLS model 
(Magistretti & Allaman, 2015; Pellerin & Magistretti, 2012). Hypothalamic 
microinjections of antisense oligodeoxynucleotides to evoke knock-down of MCT2 in 






memory consolidation in rats due to impairment of glycogen-derived LL transport from 
astrocytes to neurones (Suzuki et al., 2011). Localized application of LL successfully 
rescued memory formation when either MCT1 or MCT4 was knocked down, but failed 
to do so with reduced expression of the neuronal MCT2 (Suzuki et al., 2011). Critics 
of the ANLS hypothesis claim that the evoked reduction of MCTs expression - around 
50% for MCTs 1 and 4 and 30% for MCT2 - is unlikely to be sufficient to overcome 
the high transport capacity of these carriers; also, other LL release mechanisms have 
not been taken into consideration in the investigation (Dienel, 2017; Dienel & Cruz, 
2016).  
 
1.3.2 Connexin hemichannels and pannexins 
Whilst MCT activity has been established for a long time as a means for LL trafficking 
in the CNS, a more recent publication has shown that connexin hemichannels and/or 
pannexins actively participate in LL efflux from brain cells (Karagiannis et al., 2015). 
Using amperometric LL sensors to monitor extracellular LL levels in acute brain slices, 
the authors showed that application of compounds inhibiting pannexin/connexin 
hemichannels reduced tonic release of LL. On the other hand, application of 
substances that enhance the open probability of hemichannels led to an increase in 
LL release from the slices (Karagiannis et al., 2015). Likewise, hypoxia-triggered LL 
release was significantly reduced following block of connexins. Pannexin and 
connexin hemichannels have also been shown to play a crucial role in LL release in 
vivo, where blockade of connexin hemichannels reduced LL release triggered by 
stimulation of Schaffer collateral fibres in the hippocampus (Karagiannis et al., 2015). 
Further discussion of the role played by connexin hemichannels on LL release will be 
presented in Chapter 6. 
 
1.3.3 L-Lactate-permeable anion channels  
The first preposition of the existence of an astrocytic LL-permeable anion channel 
arose from the observation that increased extracellular K+ concentration triggered 
membrane depolarisation-mediated LL release from astrocytes despite the absence 






authors, in vitro application of 9-12 mM of K+ increased glycolytic rate of astrocytes as 
indicated by alterations in the intracellular concentration of metabolic compounds. 
However, in contrast to what it is expected at high glycolytic rate, cytosolic LL levels 
fell, suggesting K+-dependent release of LL (Sotelo-Hitschfeld et al., 2015). Moreover, 
extracellular application of high concentrations of LL enhanced cytosolic LL levels to 
a lesser extent when it was coapplied with high doses of K+, indicating that LL efflux 
from a putative anion channel may outpace influx through MCTs (Sotelo-Hitschfeld et 
al., 2015). The putative astrocytic LL-permeable anion channel was partially blocked 
by the nonspecific ion channel inhibitor Cd2+, while the K+-driven LL release was 
mimicked by Ba2+, an ion that does not occupy K+ transporters (Sotelo-Hitschfeld et 
al., 2015).  
The specific anion channel involved in LL release has yet to be identified. Several 
anion channels have been described so far in astroglia (Kimelberg, MacVicar, & 
Sontheimer, 2006), including large anion channels that mediate efflux of anionic 
species that are larger than LL, such as the volume-regulated anion channel (VRAC), 
which has been shown to play an important role in the efflux of taurine, aspartate and 
glutamate from astrocytes following cell swelling (Hyzinski-García, Rudkouskaya, & 
Mongin, 2014; Okada et al., 2019). Although other anions and amino acids may 
permeate through astrocytic anion channels, most of the research being carried out 
uses mainly chloride for the biophysical characterisation, preventing further progress 
in the comprehension of LL-permeable anion channels (Kimelberg et al., 2006).  
 
1.4 L-lactate as a signalling molecule  
LL has been increasingly described to carry energy-independent signalling roles that 
are critical for a range of vital brain functions, including neuronal excitability and 
plasticity, learning and memory, and angiogenesis. Some of the metabolic-
independent LL actions are mediated by changes in the intracellular cAMP levels 
following LL interaction with either Gs or Gi protein-coupled receptors. Additionally, 
some of LL effects may be mediated by changes in the intracellular redox state that 
is controlled by the NAD-dependent and reversible conversion of LL into pyruvate. 
The latter mechanism requires transport of LL into the cell, while the first relies on 






LL levels in the brain, which are mainly the result of LL release from astrocytes, 
respond dynamically to neuronal network activity. Nonetheless, in contrast to wired 
neurotransmission, LL release and signalling does not rely on vesicular exocytosis in 
restricted spatial domains. On the contrary, it is more likely that it operates in volume 
transmission mode and affects a wider area and at expanded timescales (Magistretti 
& Allaman, 2018). Therefore, sensitivity of the mechanisms involved in LL-mediated 
signalling should be adequate to detect LL at physiological ranges, rather than the 
supraphysiological LL levels related to some disease states (Mosienko, 
Teschemacher, & Kasparov, 2015).  
 
1.4.1 Signalling effects of intracellular L-lactate 
LL transported into the neuronal cytosol is oxidized to pyruvate by the activity of the 
LDH enzyme, leading to the production of NADH and ultimately ATP, which directly 
modulate the redox and energetic state of the cells, respectively. Intracellular LL, 
therefore, has been suggested to signal by interfering with cellular redox- and energy-
dependent processes (Magistretti & Allaman, 2018).   
Yang et al. (2014) have reported a LL-dependent enhancement in the expression of 
numerous plasticity-related genes in neurones through a mechanism that involves 
activation of NMDA receptors, which in turn are modulated by changes in the redox 
state of the cell. Application of 2.5 - 20 mM LL in primary culture of neurones evoked 
dose-dependent increased expression at both mRNA and protein levels of immediate 
early genes (IEG) such as Arc, c-Fos, and BDNF. LL also enhanced phosphorylation 
of the extracellular signal-regulated kinase (Erk1/2), which is involved in NMDA 
receptor signalling-mediated neuronal plasticity (Yang et al., 2014). Although the 
precise molecular mechanisms underpinning LL actions on NMDA receptors have not 
been elucidated, previous research has shown that NMDA-gated currents are 
amplified by reducing agents (Sullivan et al., 1994). As LL conversion into pyruvate 
increases NADH/NAD ratio, the authors hypothesized that changes in the neuronal 
redox state is mediating LL effects on NMDA receptor and IEG expression (Figure 
1.9) (Yang et al., 2014). Indeed, extracellular application of NADH mimicked LL-






response. Conversely, exposure of cultured cortical neurones to an oxidizing agent 
abolished LL-induced increases in IEG expression (Yang et al., 2014).  
Another signalling effect of intracellular LL refers to the closure of ATP-sensitive 
potassium (KATP) channels due to increased cytosolic ATP/ADP ratio derived from LL 
metabolism (Parsons & Hirasawa, 2010). Orexin neurones in the perifornical area, 
which are essential modulators of food intake, have been shown to lose their 
spontaneous firing activity upon glucose deprivation. These effects could be reversed 
by a KATP channel blocker as well as by extracellular addition of LL (Parsons & 
Hirasawa, 2010). On the other hand, LL application upon MCT blockade failed to 
prevent the loss of neuronal firing activity under glucose withdrawal. The depolarising 
effect of LL on orexin neurones has been suggested to be mediated by KATP channels, 
which close under enhancement of energy supply (Figure 1.9) (Parsons & Hirasawa, 
2010). Although LL-mediated increase in firing rate of orexin neurones is LL dose-
dependent (EC50 = 2.1mM), other neuronal phenotypes such as arcuate neurones do 
not show the same sensitivity and activity towards LL (Parsons & Hirasawa, 2010). 
Intracellular LL has also been suggested to play an important role in the regulation of 
sleep-wake cycles (Clasadonte, Scemes, Wang, Boison, & Haydon, 2017). Disruption 
of astroglial network by knockout of astrocytic Cx43 expression in the brain resulted 
in wakefulness instability in the active phase as well as extreme sleepiness. Closer 
investigation of the activity of the wake-promoting orexin neurones in the lateral 
hypothalamic area revealed reduced excitability and spontaneous firing frequency 
when Cx43 expression was decreased in astrocytes. A similar inhibitory effect on 
orexinergic neuronal activity was observed during both glucose deprivation and MCT 
blocker application. Exogenous LL addition (2.5 mM) or LL dialyses in a single 
astrocyte (5 mM) could reverse the effect of glucose deprivation on neuronal activity, 
but failed to do so when MCTs had been blocked, indicating that the excitatory effect 
of LL relies on its transport into neurones (Clasadonte et al., 2017). Interestingly, 
application of LL also restored activity to orexin neurones and rescued the disrupted 
sleep-wake cycle when Cx43 expression was depleted in astrocytes. Therefore, these 
results suggest that LL transport through the astroglia network and its further delivery 
to neurones is fundamental to the normal activity of orexin neurones and, 







1.4.2 G protein-coupled receptor 81 
LL has been shown to be an endogenous ligand of G protein-coupled receptor 81 
(GPR81), also referred as hydroxycarboxylic receptor 1 (HCA1) (Cai et al., 2008; Liu 
et al., 2009). LL interaction with GPR81 was firstly described in adipose tissues, and 
resulted in decreased lipolysis rates in adipocytes of mouse, rats and humans  (Cai 
et al., 2008; Liu et al., 2009). GTPγS binding assays suggested that the effect of LL 
on GPR81 was dose-dependent with an EC50 of approximately 1.30 ± 0.32 mM (Cai 
et al., 2008). DL also stimulated GPR81 activation, but with a higher EC50 (3.03 ± 0.21 
mM), indicating potential activity as a partial agonist of the receptor (Cai et al., 2008). 
The EC50 value described by Liu and colleagues using GTPγS binding assays was 
higher than previously described by Cai et al. (2008), ranging from 4 to 7 mM 
depending on the species (Liu et al., 2009). Reduction in cytosolic cAMP levels 
following LL-mediated activation of GPR81 confirmed activation of a signalling 
pathway consistent with a Gi protein-coupled receptor (Figure 1.9) (Cai et al., 2008; 
Liu et al., 2009).  
GPR81 expression in the brain is considerably lower than in adipose tissue and it is 
predominantly found in the hippocampus, cerebellum, neocortex and in the blood-
brain barrier (Lauritzen et al., 2014).  At the cellular level, GPR81 is particularly 
enriched in postsynaptic neuronal membranes and appears at lower level in epithelial 
cells, whereas very few GPR81-expressing astrocytes can be detected (Lauritzen et 
al., 2014). Data from Barres lab using single-cell RNA sequencing indicated equally 
low levels of GPR81 expression in both neurones and astrocytes in the mouse 
cerebral cortex (Zhang et al., 2014). Neurones in the LC area of the brainstem do not 
express GPR81 (Mosienko et al., 2018).  
GPR81 activation by LL was shown by the Chatton group to reduce excitability of 
primary cultured neurones, in which activity was monitored by Ca2+ imaging (Bozzo, 
Puyal, & Chatton, 2013). According to that study, LL application decreased Ca2+ 
spiking frequency by approximately 50% in a reversible and dose-dependent manner, 
with an EC50 of about 4.2 mM. This effect was reproduced by the GPR81 agonist 3,5- 
dyhydroxybenzoic acid, whereas pyruvate did not mimic LL effects on neuronal 
activity, thus excluding the energetic role of LL in this outcome. On the other hand, 






application of pertussis toxin, an inhibitor of Gi-protein. DL application reduced Ca2+ 
spiking frequency to the same extent as LL (IC50 = 4.6 ± 1.2 mM) (Bozzo et al., 2013). 
More recently, a follow-up study from the same group showed that the reduction in 
LL-mediated spontaneous Ca2+ spiking activity in cortical neurones was absent in 
GPR81 knockout mice, which exhibited increased neuronal basal activity (de Castro 
Abrantes et al., 2019). Moreover, activation of GPR81 by LL [5mM] was suggested to 
occur in presynaptic neurones through inhibition of adenylyl cyclase, followed by 
reduction of cAMP levels and inactivation of protein kinase A (PKA) (de Castro 
Abrantes et al., 2019). Since activation of neuronal GPR81 requires supra-
physiological levels of LL, it is unlikely that this signalling pathway takes place unless 
under certain disease conditions such as ischemia and seizures (Mosienko et al., 
2015).  
A recent in vivo study showed that high intensity exercise or subcutaneous LL 
application (18 mmol/kg, 5 days a week for 7 weeks in an attempt to mimic exercise-
induced increase in blood LL in mice) induced GPR81-mediated brain angiogenesis 
(Morland et al., 2017). Following LL applications, the hippocampus exhibited an 
enhanced density of blood capillaries and of the expression of vascular endothelial 
growth factor A (VEGFA). These results were suggested to occur downstream of 
GPR81 activation in pia mater, where the receptor is highly expressed (Morland et al., 
2017).  
 
1.4.3 Olfactory L-lactate receptor  
LL has been reported to activate a class of Gs protein-coupled receptor, the Olfactory 
Receptor Family 51 Subfamily E Member 2 (OR51E2). LL-induced activation of 
OR51E2 raised cAMP levels in a dose-dependent manner with an EC50 of 4 mM 
(Figure 1.9) (Chang, Ortega, Riegler, Madison, & Krasnow, 2015). 
Although OR51E2 is implicitly found in the rodent olfactory bulb, expression of this 
receptor has also been reported in the brain as well as in the periphery (Chang et al., 
2015). Indeed, high levels of OR51E2 have been detected in glomus cells of the 
carotid body, a chemosensory tissue that monitors changes in the composition of the 






the carotid body plays an important role in sensing low oxygen levels. This is because 
hypoxic conditions are linked with increased concentration of LL, which in turn 
activates OR51E2, ultimately leading to stimulation of carotid sinus nerve activity 
(Chang et al., 2015; Torres-Torrelo et al., 2018). Although mRNA analysis indicated 
that this receptor is also expressed in the brainstem,  OR51E2 has not been detected 
in dissociated noradrenergic neurones in the LC (Mosienko et al., 2018; Yuan et al., 
2001). 
 
1.4.4 Putative L-lactate receptor on noradrenergic neurones   
Our group has previously demonstrated that LL can act as an excitatory signalling 
molecule for noradrenergic neurones in the brainstem, an effect that is independent 
of the caloric value of LL (Marina et al., 2015; Mosienko et al., 2018; Tang et al., 
2014). Current-clamp whole-cell recordings demonstrated that both exogenous LL 
application (0.2-20 mM) and optogenetic stimulation of astrocytes promoted 
reversible depolarisation and increased action potential firing of LC noradrenergic 
neurones (Tang et al., 2014). This effect was dose-dependent with an EC50 of 
approximately 680 µM and was avoided by pre-treatment with compounds that 
prevent LL formation (Tang et al., 2014). Moreover, direct measurements of NA 
release with fast-scan cyclic-voltammetry showed that LL application as well as 
optogenetic activation of astrocytes triggered NA release from LC organotypic slices. 
On the other hand, bath-application of DL (0.001-2mM) almost fully abolished 
depolarisations in LC neurones evoked by optogenetic activation of astrocytes, and 
also blocked the stimulatory effect of LL on the release of NA by LC neurones (Tang 
et al., 2014). The excitatory effect of LL was further shown in vivo, where injections of 
LL into the LC increased arterial blood pressure and evoked an arousal response 
comparable to the effect of the excitatory transmitter L-glutamate as measured at the 
level of the cortical electroencephalogram (EEG) (Tang et al., 2014). Pharmacological 
manipulations showed that the LL effect on noradrenergic neurones is mediated by 
the activity of adenylate cyclase and protein kinase A, implying the involvement of 
cAMP as the intracellular second messenger following LL-induced activation of a Gs 






When assessing the role of LL in the rostral ventrolateral medulla (RVLM), it was 
found that bath application of LL in brainstem slices in vitro evoked depolarization and 
elevated rates of action potential firing in C1 neurones (Marina et al., 2015). Moreover, 
in vivo administration of LL on the ventral surface of the medulla oblongata of 
normotensive rats evoked a profound and sustained increase in the sympathetic 
nerve activity and arterial blood pressure (Marina et al., 2015). Thus, overexposure of 
the RVLM to LL may actively contribute to the development and maintenance of 
hypertension by intensifying the activity of pre-sympathetic C1 bulbospinal vasomotor 
neurones and consequently the sympathetic tonus (Marina et al., 2015). 
The receptor underpinning LL actions in the brainstem (LLRx) has not been identified 
yet and it does not fit the properties of the receptors that have already been described 
to be selectively activated by LL. OR51E2, where LL-induced activation also 
increases cAMP,  has not been detected in dissociated noradrenergic neurones in the 
LC, implying that this receptor may not be accountable for the cAMP-mediated 
excitatory effects of LL in neurones of the brainstem (Mosienko et al., 2018). Next 
generation sequencing of isolated noradrenergic neurones in the LC identified 
expression of a range of orphan G protein-coupled receptors in this region, and their 
ability to be stimulated following LL application was further tested using an assay that 
measures cAMP (Mosienko et al., 2018). Amongst the receptors analysed, GPR137 
transiently expressed in HEK293 cells displayed a dose-dependent enhancement of 
intracellular cAMP levels following application of 1-5 mM LL. This response, however, 
was not blocked by the application of the enantiomer DL (0.4 mM), indicating that 






Figure 1.9. LL-mediated signalling pathways in neurones. LL interacts with 
neuronal Gi- or Gs-coupled receptors leading to inhibition or activation of intracellular 
cAMP-dependent signalling pathways, with the potential of ultimately, for example, 
decreasing or inducing neuronal activity and NA release. LL can also be transported 
into the neuronal cytosol to be metabolised. Products of LL metabolism such as NADH 
and ATP can modulate gene expression through NMDA receptor or increase neuronal 
activity by inhibition of KATP channel, respectively. Schematic adapted from Mosienko 
et al. (2018). 
 
1.5 Study of LL-mediated astrocyte-neurone signalling 
Astrocytes are able to modulate neuronal activity through the release of LL. During 
periods of high activity, astrocyte-derived LL is thought to act as an additional 
metabolic supply to neurones. Moreover, LL has signalling roles in the brain and its 
release can affect a range of vital brain functions, including learning and memory and 
the central control of respiration and cardiovascular performance. Studying the effects 
of astrocyte-derived LL in the brain requires tools that limit the long-term release of 
LL selectively from astrocytes as well as the actions of LL in neurones.  
The aim of my PhD project was, therefore, to develop and validate novel genetic tools 
to selectively limit LL-mediated signalling between astrocytes and neurones in vitro 






different aspects of astrocyte-derived LL signalling, which included: (I) reduction of 
intra-astrocytic LL pool; (II) production and release of an antagonist of LL actions in 
noradrenergic neurones; and (III) reduction of astrocytic LL release. Construction and 















Chapter 2 – Technical approaches to study 








2.1 Molecular approaches to manipulate brain cells  
Neuroscience research over the past decades has benefited from advances in 
molecular biology. Development of new tools to target specific brain cells with 
transient or stable expression of transgenes provided the means to address the role 
of astrocytes in supporting and actively modulating brain function.  
A fundamental requirement for specifically studying astrocytes in a physiological 
setting is the ability to selectively manipulate their activity, independently of the 
neurones’. This can be achieved by using astrocyte-selective promoters, which 
restrain transgene expression specifically to astrocytes. Astrocyte-specific promoters 
can drive the expression of genetically encoded reporters such as fluorescent 
nanosensors for high-resolution imaging of intracellular astrocytic physiology.  To 
selectively manipulate astrocytic signalling, expression of optogenetic and 
pharmacogenetic actuators, such as channelrhodopsin and designer receptors 
exclusively activated by designer drugs (DREADDs), respectively, have been used. 
Efficient expression of transgenes in astrocytes requires effective gene delivery tools. 
Apart from transgenic animals, which are restricted to mice in astrocyte research, 
transgene expression or suppression in subpopulations of mature astrocytes in vitro 
and in vivo can be achieved with viral vectors. 
My PhD research has been centred around the development of novel molecular tools 
designed to affect intra-astrocytic levels of LL, with the ultimate goal of expanding the 
knowledge on astrocytic LL dynamics and astrocyte-to-neurone LL signalling in 
different physiological contexts. The strategies to target and deliver the expression of 
these novel LL-limiting tools to astrocytes will be briefly detailed in this chapter. My 
work included the construction of the tools and performance of a range of 
physiological tests on LL dynamics and signalling in the brain in order to validate the 
novel constructs. As also briefly described in this chapter, many of these validation 
techniques relied on the detection of specific metabolites or messengers, which in 






2.2 Approaches to selectively target specific brain cells   
Comprehending the role of astrocytic signalling in modulating brain function requires 
specific and effective manipulation of cell types in the brain. In our case, in order to 
modulate LL production or release specifically in astrocytes, we had to combine the 
efficient transgene delivery system based on viral vectors with a promoter that targets 
transgene expression selectively to astrocytes. Achievement of the proposed 
objective of this project depended, therefore, on the ability of the transgene to be 
expressed in the target cell at a rate that evokes a physiological response. 
 
2.2.1 Viral vectors  
Genetic manipulation of brain cells depends on efficient and controlled gene transfer 
systems. Taking into account the high capability of viruses to infect mammalian 
organisms, the development of viral vectors for gene delivery allowed achievement of 
high transduction efficiency at the same time that viral pathogenicity could be 
overcome by genetic modifications (Merienne, Douce, Faivre, Déglon, & Bonvento, 
2013). Indeed, deletion of parts of the viral genetic material that is linked to the 
pathogenic viral mechanisms increased the cloning capacity of these vectors, 
allowing insertion of longer transgenes into the viral genome. Gene transfer through 
viral vectors is achieved independently of the age of the targeted tissue or organism 
and, in most of the cases, the genetic material does not require cells to divide to be 
successfully delivered (Merienne et al., 2013).  
The most commonly used viral vectors in neuroscience research are adenoviral 
vectors (AVVs), adeno-associated viral vectors (AAVs), and lentiviral vectors (LVVs), 
whose characteristics are further detailed below. AVVs were extensively used in this 
study as a tool to deliver the novel constructs into primary cultured astrocytes and 






2.2.1.1 Adenoviral vectors  
Adenoviruses are medium sized non-enveloped viruses containing approximately 36 
kb of double-stranded (ds) DNA (Graham & Prevec, 1995). Since adenoviruses are 
formed only by a protein shell (capsid) and DNA, their infection process relies on 
interactions between the viral protein fibres with a range of protein receptors 
expressed in the membrane of the host cell (Merienne et al., 2013; Teschemacher, 
Paton, & Kasparov, 2005). This fact determines the tropism of different serotypes of 
adenoviruses to different brain cell types. Indeed, modifications of adenoviral capsids 
leading to shifting of viral tropism has been utilised in order to select the cellular type 
to be transduced (Wickham, 2000). Adenovirus infection is initiated by binding of the 
capsid fibre to the coxsackie adenovirus receptor expressed in the membrane of the 
target cell (Koizumi, Kawabata, Sakurai, & Watanabe, 2006; Merienne et al., 2013). 
Following virus-receptor interaction, viral particles are internalized into the host cell 
through endocytosis. Once uncoated in the cytoplasmic endosomes, viral DNA is 
transported into the nucleus, where it can be transcribed and replicated (Koizumi et 
al., 2006). This virus-receptor-based entry mechanism is shared among many types 
of viruses, while the fate of the viral genetic material once in the host cell varies 
according to the viral vector employed. AVVs DNA genome, for example, remains 
episomal in the host cell nucleus. The failure of the transgene to insert into the host 
genome results in transient expression, which in turn may lead to a quick transgene 
dilution, particularly in dividing cells (Kasparov et al., 2004). On the other hand, 
extrachromosomal localization of the transgene decreases the risk of insertional 
mutagenesis (Merienne et al., 2013). 
Although several serotypes of adenoviruses have been identified, only a few of them 
have been described to infect brain cells. One of the most commonly used adenovirus 
serotypes for CNS applications is derived from the type 5 serotype, whose genes are 
divided according to the stage of the replication cycle they are involved in. Thus, early 
genes, i.e. early region 1 (E1; comprised of E1a and E1b), E2, E3, and E4, are 
expressed prior to DNA replication, while late genes express after the replication has 
started (Graham & Prevec, 1995). Incorporation of large transgene fragments into 
recombinant adenoviruses requires deletion of significant amounts of viral DNA, 






The first gene is involved in viral replication, whereas the latter is a non-essential gene 
associated with immune evasion. E1 deletion renders a replicating-incompetent virus 
that can only be propagated in cells that supply E1 gene products, such as the human 
embryonic kidney 293 (HEK293) cell line (Graham & Prevec, 1995). The increased 
cloning capacity of replication-defective AVVs allows insertion of more than 7kb 
fragments, which is completely adequate to accommodate a transgene containing a 
promoter and 1 or 2 genes (Teschemacher et al., 2005). Although the initial 
construction of AVVs can take months to materialize, any subsequent amplification is 
a matter of days and yields high titres of vector particles (approximately 2.5ml per 
preparation at a concentration ranging from 1010 to 1012 transducing unit (TU)/ml), 
which is sufficient material for a substantial series of imaging and electrophysiological 
experiments (Teschemacher et al., 2005). 
 
2.2.1.2 Lentiviral vectors  
A widely used and described LVV is derived from a subclass of retrovirus, the human 
immunodeficiency virus (HIV)-1. Viral entry into the target cell is initiated by binding 
of the glycoproteins of the viral envelope with receptors expressed in the cellular 
membrane. Therefore, as for the other viral vectors, capsid/envelope-receptor 
interactions dictate the viral tropism, which can be modified through genetic 
alterations of the viral structure (Kay, Glorioso, & Naldini, 2001). Accordingly, in order 
to extend the host-range of LVVs, the majority of the original LVVs envelope has been 
completely substituted by a protein coat from an unrelated virus, a process called 
pseudotyping. A commonly used foreign envelope is the vesicular stomatitis virus 
glycoprotein G (VSVG), which broadens LVV tropism by binding with the ubiquitously 
expressed low-density lipoprotein (LDL) receptor (Amirache et al., 2014).  
Regarding the genetic material, LVVs carry a single-stranded (ss) RNA genome of 7 
to 11 kb. Once within the host cell, the viral RNA is retro-transcribed into ds DNA, 
which is incorporated into the host cell genome resulting in stable and long-lasting 
expression of the transgene (Merienne et al., 2013). Another advantage of LVVs is 
their high cloning capacity. Since only a small segment of the original HIV genome is 
retained during the production of the viral vector, LVVs are in theory able to 






2.2.1.3 Adeno-associated viral vectors  
Adeno-associated viruses are small and non-enveloped particles containing 
approximately 5 kb of ss DNA (Grimm, 2002). Even though the wild-type viral genome 
was almost entirely removed, leaving only essential genes for packaging and 
integration, the cloning capacity of AAVs is rather low due to the short genome length 
(Grimm, 2002). On the other hand, although AAVs are able to naturally infect human 
cells, they haven’t been linked with any human disease. This non-pathogenic feature 
of AAVs make them a quite safe tool for gene delivery, especially for gene therapy in 
the brain (Kay et al., 2001). 
Many serotypes of AAVs have been identified so far, each of them displaying a 
specific tropism towards various types of brain cells. As previously detailed, viral 
tropism may rely on the expression level of a cell surface receptor that recognizes 
and binds to the viral capsid, starting the virus entry process. Accordingly, AAV2 
infection depends on the expression of both the heparan sulphate proteoglycan 
receptor and the fibroblast growth factor receptor 1, which results in a predominant 
tropism for neurones (Merienne et al., 2013). Tropism of AAV5, on the other hand, 
depends on the level of expression of the platelet-derived growth factor receptor 
(Merienne et al., 2013). Several AAV variants have been developed by genetic 
modification of the capsid in order to improve cell specificity. 
Once inside cells, AAVs require a helper virus (adenovirus or herpesvirus) to perform 
their replication cycle (Shin, Yue, & Duan, 2012). Since this infection step is absent 
during transgene transduction, AAVs remain as extrachromosomal ds episomes, 
although some reports suggest a possible integration into the host genome (Kay et 
al., 2001). Different from AVVs, AAVs show long-lasting and stable expression of the 
transgene, which is believed to be due to the formation of circular intermediates and/or  
integration into the host genome (Duan et al., 1998; Schnepp, Jensen, Chen, 







2.2.2 Cell-specific promoters 
The CNS is occupied by an extensive range of cell phenotypes, each of them 
containing an exclusive profile of gene expression. Determination of this spatial and 
temporal expression pattern of genes is mediated by a regulatory region in the DNA 
called the promoter. The promoter enables the transcription of a specific gene by 
binding with the transcription factors needed to transcribe that gene (Nettelbeck, 
Jérôme, & Müller, 1998). Therefore, the different gene expression profiles amongst 
cells in a non-homogenous population such as the brain relies on specific promoters 
and the recruited transcription factors (Betley & Sternson, 2011; Nettelbeck et al., 
1998).  
In the construction of a transgene, a promoter sequence must be added in the 
expression cassette so that the endogenous cellular machinery can transcribe the 
transgene DNA sequence into mRNA. In case the transgene expression is targeted 
throughout the brain, a promoter of an endogenous ubiquitously expressed gene is 
employed. On the other hand, if transgene expression needs to be confined to a 
specific cell type, promoters of genes with restricted expression in this cell type are 
used to confer specificity to transgene expression. The challenge imposed by the 
application of cell-type specific promoters is generally their long size in mammals, 
which may hamper their use with AAVs due to the modest packaging capacity of this 
gene delivery tool (Betley & Sternson, 2011).  
 
2.2.2.1 EF1α promoter 
Human elongation factor-1α (EF1α) is a ubiquitous enzyme that catalyses the 
nucleotide-binding protein implicated in the elongation of polypeptide chains during 
protein synthesis on the ribosome (Riis, Suresh, Derventzi, & Clark, 1990). Cellular 
expression levels of EF1α are considered to be generally high, especially in actively 
dividing cells (Sanders, Brandsma, Janssen, Dijk, & Möller, 1996). As a consequence, 
EF1α gene transcription occurs at high rates, rendering this promoter a high activity, 






Although the precise expression pattern of this promoter in brain cells has not been 
described yet, the crucial housekeeping function of EF1α contributes to its relatively 
continuous expression in the majority of cell types (Tsuchiya, Yoshiki, Kudo, & Morita, 
2002). Utilization of the EF1α promoter to drive green fluorescent protein (GFP) 
expression in rat cortical primary cultures suggested primarily labelling of neuronal 
cells (Tsuchiya et al., 2002). In the brainstem, EF1α-driven expression of enhanced 
GFP (EGFP) targeted neurones as well as some glial cells, suggesting a wide 
spectrum of cells supporting transgene expression driven by EF1α (Kasparov et al., 
2004). 
 
2.2.2.2 CMV promoter 
Cytomegalovirus (CMV) immediate-early promoter is widely used to drive gene 
transcription in a broad range of cell types. Similar to EF1α, CMV promoter is 
considered to be constitutive, i.e. expressing at high levels in cells on account of the 
variety of response elements and enhancers associated (Teschemacher et al., 2005). 
Although function of CMV promoter is affected by regulatory elements of the host cell, 
the extent by which cellular environmental conditions affect promoter activity still 
remains unclear (Teschemacher et al., 2005). Activation of the transcription factor 
cAMP response element-binding (CREB), for instance, leads to increased activity of 
the CMV promoter (Wheeler & Cooper, 2001). This response is suggested to be due 
to the 5 cAMP response elements (CRE) present in the CMV promoter, binding of 
which with CREB results in improved gene transcription (Wheeler & Cooper, 2001). 
Nonetheless, some cells can silence the promoter following long-term expression of 
the transgene (Löser, Jennings, Strauss, & Sandig, 1998; Sinclair, Baillie, Bryant, 
Taylor-Wiedeman, & Sissons, 1992) 
 
2.2.2.3 GFAP promoter 
Glial fibrillary acidic protein (GFAP) is an intermediate filament extensively used as 
an astrocytic marker. GFAP is an essential component of the astrocytic cytoskeleton 
and is suggested to be the main element responsible for maintaining astrocytic shape 






the morphological and structural role of GFAP, changes in its expression levels have 
been suggested to alter other cellular processes such as migration, motility, and 
proliferation (McIver, Faideau, & Haydon, 2013; Middeldorp & Hol, 2011). Moreover, 
reactive changes displayed by astrocytes after CNS injury have been shown to 
include upregulation of GFAP expression (Middeldorp & Hol, 2011). 
Although GFAP-expressing cells have been systematically classified as astrocytes, 
not all astrocytes express GFAP. Evaluation of GFAP distribution within the CNS 
indicated that the brainstem expresses the highest level of this protein, while scarce 
GFAP expression is found in astrocytes residing in the striatum and cortex  (Martin & 
O’Callaghan, 1995). Moreover, reports of GFAP-expressing neural stem cells in the 
subventricular zone challenged the utility of GFAP as an astrocyte-specific marker 
(Chojnacki, Mak, & Weiss, 2009; Doetsch, Caillé, Lim, García-Verdugo, & Alvarez-
Buylla, 1999; Oberheim et al., 2012). In reality, rather than using genetic and 
functional profiles for astrocytic characterization, assignment of brain cells as 
astrocytes has been classically done following phenotypic criteria. This may be due 
to the paucity  of proteins that are selectively and ubiquitously expressed by 
astrocytes (Oberheim et al., 2012) which, in turn, can be explained by an increasing 
body of evidence implying that astrocytes are a heterogenous population of cells 
(Khakh & Deneen, 2019; Matyash & Kettenmann, 2010), a concept that has already 
been thoroughly demonstrated for neurons.  
Nevertheless, GFAP is still a widely accepted astrocytic marker and its regulatory 
elements are extensively used in the development of promoters that direct transgene 
transcription specifically to astrocytes (Brenner, Kisseberth, Su, Besnard, & Messing, 
1994; Lee, Messing, Su, & Brenner, 2008; Liu, Paton, & Kasparov, 2008). An 
expression system based on the GFAP promoter (gfa2) was first developed by 
Brenner et al. (1994). It consisted of a 2.2 kb 5’-flanking fragment of the human GFAP 
gene that successfully drove transgene expression in astrocytes in transgenic mice 
(Brenner et al., 1994). In order to optimize transcriptional activity and shorten the size 
of the GFAP promoter, Lee et al. (2008) developed the variant gfaABC1D, which 
contained 681 bp and achieved nearly double the activity of gfa2 (Lee et al., 2008). 
The approach to generate gfaABC1D relied on identification and removal of promoter 
sequences that hamper astrocyte specificity and decrease transcriptional 






employ recombinant transcriptional activators, also referred to as two-step 
transcriptional amplification (Figure 2.1) (Liu et al., 2006). It relies on the cell-specific 
promoter driven-expression of both a transgene and a recombinant fusion protein, the 
latter consisting on a strong artificial transcriptional activator domain and a DNA 
binding site (Liu et al., 2006). Binding of the transcriptional activator to specific sites 
introduced into the promoter potentiates transcriptional activity, which consequently 
improves transgene expression. However, to achieve simultaneous expression of the 
transgene and the transcriptional activator, inclusion of two copies of the cell-selective 
promoter were necessary, restricting the employment of viral gene targeting 
strategies with smaller cloning capacities (Liu et al., 2008). In order to overcome this 
limitation in the design of a strong astrocyte-selective promoter based on recombinant 
transcriptional activators, our group has used a bidirectional promoter approach, in 
which a minimal CMV (mCMV) core promoter (65 bp) was merged upstream and in 
opposite direction to gfaABC1D promoter (Figure 2.1) (Liu et al., 2008). Expression 
of GAL4p65, a chimeric transactivator formed from a fragment of the transcriptional 
activation domain of the murine NF-κBp65 protein fused to the DNA-binding domain 
of the GAL4 protein from yeast, is driven by the mCMV promoter. GAL4p65 binds to 
its binding domain (5xGAL4) located 5’ to the gfaABC1D promoter, thus enhancing 
astrocyte-specific transgene expression (Liu et al., 2008). 
Figure 2.1. Schematic diagram of the synthetic bidirectional astrocyte-specific 
promoter with enhanced transcriptional activity (sGFAP). Astrocyte-selective 
promoter with enhanced transcriptional activity, also known as sGFAP, contains a 
mCMV core promoter upstream in the expression cassette and in opposite direction 
to drive the synthesis of the strong transcriptional activator GAL4p65. Besides the 
transcriptional activation domain of the NFκB p65 protein, the chimeric transactivator 
GAL4p65 also contains the unique binding domain of the GAL4 protein from yeast, 
which interacts with GAL4 binding sequences in the gfaABC1D promoter. As a result, 
transcription driven by the sGFAP promoter is enhanced (Liu et al., 2008). A 
woodchuck hepatitis post-transcriptional regulatory element (WPRE) at the end of the 






2.2.2.4 PRSx8 promoter  
Since neuroscience research has historically centred on neuronal activity, the 
functional diversity of different neuronal subtypes has long been recognized. 
Neurones have been systematically categorized into groups based on similarities 
between gene expression profile, molecular properties, and function, which facilitated 
the development of subpopulation-restricted gene targeting strategies to manipulate 
each neuronal type independently. In our group, there is long-standing interest in the 
study of astrocytic interactions specifically with noradrenergic neurones since we 
have previously discovered a relevant signalling axis between these two cell types in 
the rat brainstem (Tang et al., 2014). In order to target transgene expression 
selectively in noradrenergic neurones, we used a synthetic promoter developed by 
Hwang et al. (2001), the PRSx8, which carries a noradrenergic-specific cis-regulatory 
element (PRS2) (Hwang et al., 2001).  PRS2 has been identified in the human 
dopamine β-hydroxylase (DBH) promoter and has been described to interact with 
Phox2a/2b, a transcription factor that is crucial for neuronal differentiation into the 
noradrenergic phenotype (Hwang et al., 2001; Kasparov et al., 2004). PRSx8 is  
comprised of 8 binding sites of Phox2a/2b merged with a minimal DBH promoter 
containing a TATA box and a transcription start site (Hwang et al., 2001). Experiments 
in vitro and in vivo using PRSx8 promoter to drive transgene expression through AVV 
or LVV showed high selectivity and transcriptional activity of the promoter, enabling 
characterization of NA release and in vivo modulation of the cardiovascular system 
activity (Chiti & Teschemacher, 2007; Duale et al., 2007; Lonergan et al., 2005).  
 
2.3 Approaches to study compound-specific dynamics in the brain 
The processes related to brain energy metabolism lead not only to the generation of 
cellular energy currency which supports appropriate cell function and tissue viability. 
They also drive the production of metabolites that carry important signalling roles in 
the brain. Therefore, interfering with LL production, release and signalling as 
proposed by this research project requires employment of tools able to analyse the 
fluxes of metabolites within cells and tissues as well as evaluate how these 






By using experimental approaches that combine a range of compound-specific 
sensors with real-time imaging techniques and amperometric recordings, it is possible 
to analyse the effects of transgenic or pharmacological interventions in the glycolytic 
state of individual astrocytes. Employment of these sensor-based procedures also 
allows the assessment of how modifications at the cellular level translate into 
adjustments of the cerebral LL tone and release, as well as into astrocyte-neurone LL 
signalling. Utilization of intracellular or extracellular biosensors are advantageous at 
the temporal resolution since they offer real-time recording of specific molecules 
(Barros et al., 2017). The mechanism of detection includes either a selective binding 
site or enzyme. Modifications in the concentration of the molecule of interest are 
detected by changes in either the fluorescence intensity of the sensor or the amount 
of the product yielded by the enzymatic reaction, respectively.  
 
2.3.1 Genetically-encoded fluorescent nanosensors 
Genetically-encoded fluorescent nanosensors are chimeric proteins that mandatorily 
express two elements: a unique binding site, which confers specificity to a certain 
compound, fused to one or two fluorescent proteins. The detection domain can be 
comprised of a bacterial protein or a transcription factor and undergoes 
conformational change upon binding of the ligand (Barros et al., 2017). Binding and 
fluorescence are conformationally coupled in the nanosensor, so that a structural 
change in the binding domain dynamically modifies fluorescence intensity of the 
fluorophores, which can be detected through microscopy, fluorescence platereader, 
and fluorescence-activated cell sorting (FACS). Microscopy is undoubtedly the most 
suitable method to monitor changes in fluorescence intensity since its high resolution 
allows visualization of single-cells and provides real-time readout of the nanosensor 
in continuous superfusion conditions (Barros et al., 2017). Conversely, in 
platereaders, continuous superfusion is impractical and spatial and temporal 
resolution are reduced. FACS, on the other hand, is not recommended when 
analysing the metabolic state of cells since metabolic properties can change following 
cellular detachment that is required to perform this technique (Hung & Yellen, 2014). 
Many of the genetically-encoded fluorescent nanosensors are based on Förster 






overlapping emission and excitation spectra. If they are in close proximity, i.e. within 
roughly 10nm, the fluorophore in the higher excited state (donor) transfers energy to 
the second fluorophore (acceptor) (Jones & Bradshaw, 2019; Sahoo, 2011). As a 
result, the emission intensity of the donor fluorophore decreases while the emission 
intensity of the acceptor fluorophore increases. Binding of the ligand to the recognition 
domain can either bring the two fluorescent molecules closer together or further apart, 
increasing or decreasing, respectively, the FRET efficiency (Sahoo, 2011). The 
readout from FRET-based nanosensors is the ratio of the fluorescence emitted by the 
fluorophores. 
 
2.3.1.1 FRET-based L-lactate nanosensor 
A genetically-encoded and FRET-based reporter for LL – Laconic – has been widely 
used for the determination of intracellular LL dynamics in vitro and in vivo (Mächler et 
al., 2016; San Martín et al., 2013). The LL-binding domain of Laconic consists of the 
bacterial transcriptional factor LldR from E. coli, which is defined by two elements: a 
LL-binding/regulatory domain and a DNA-binding domain (San Martín et al., 2013). 
The recognition element is attached at one side to the fluorescent protein mTFP and 
at the other side to the fluorescent protein Venus (Figure 2.2A), with emission peaks 
at 492 nm and 526 nm, respectively (San Martín et al., 2013). When LL is unbound, 
mTFP acts as a photon donator to the acceptor Venus upon excitation with the 458nm 
line of an argon laser. However, binding of LL evokes a conformational change in the 
biosensor, increasing the distance between the two fluorophores. FRET efficiency 
then decreases, leading to enhanced ratio of mTFP over Venus (Figure 2.2B). 
Fluctuations in the intracellular concentration of LL can, therefore, be monitored 
through the ratio between the fluorescence emitted by mTFP and Venus (San Martín 
et al., 2013).  
Laconic has been described to exhibit high specificity to LL and to be able to detect 
LL changes over four orders of magnitude (from 1µM to 10mM) with maximum 








Figure 2.2. Characterization of Laconic. (A) Representative Laconic structure: in 
the unbound state, proximity between the 2 fluorophores enable the transfer of 
photons from the donor mTFP to the acceptor Venus. LL binding evokes a 
conformational change in Laconic, increasing the distance between the two 
fluorescent proteins, which causes a decrease in FRET efficiency and enhanced ratio 
of mTFP over Venus. (B) Top – representative FRET recordings showing 
fluorescence intensity of mTFP and Venus in HEK293 cells upon application of 10mM 
LL. Below – resulting FRET ratio. (C) Image of Laconic-transduced cultured astrocyte. 






2.3.1.2 FRET-based pyruvate nanosensor 
Pyruvate is a central molecule in brain energy metabolism. By using the FRET-based 
pyruvate nanosensor Pyronic, we can estimate intracellular pyruvate levels. The 
detection domain of Pyronic consists of the transcriptional regulator PdhR from E. coli, 
which coordinates the pyruvate-induced expression of the pyruvate dehydrogenase 
gene (San Martin et al., 2014). Similar to Laconic, the binding element of the sensor 
is linked to the fluorescent proteins mTFP and Venus, which act as a photon donor 
and acceptor, respectively (Figure 2.3A). Upon pyruvate binding, the sensor assumes 
an open conformation, which decreases the FRET efficiency between the two 
fluorophores. As a result, the fluorescence intensity emitted by mTFP increases while 
that in Venus decreases, causing an increased ratio between mTFP and Venus 
(Figure 2.2B).  
Pyronic has been shown to detect pyruvate at concentrations ranging from 10µM to 
1mM (San Martin et al., 2014). Moreover, the sensor did not show significant pH-
dependence, nor sensitivity to other compounds. The maximum change reported in 
fluorescent intensity was described as approximately 25% in culture conditions and 







Figure 2.3. Characterization of Pyronic. (A) Representative Pyronic structure at the 
bound state depicting the binding element of the sensor (PdhR) and the FRET pair of 
fluorescent proteins – mTFP (photon donor) and Venus (photon acceptor) (San Martin 
et al., 2014). (B) Top – representative FRET recordings showing fluorescence 
intensity of mTFP and Venus in cultured astrocytes upon extracellular application of 
10mM pyruvate. Below – resulting FRET ratio. (C) Image of Pyronic-transduced 






2.3.1.3 Cell-based neurotransmitter fluorescent engineered reporter 
NA in the brain is involved in the modulation of various processes, including arousal, 
attention, anxiety, and nociception (see Chapter 1, section 1.1.3). NA is mostly 
released in the interstitial space, in the absence of synaptic contact, through vesicles 
exocytosis from axonal varicosities as well as from soma and dendrites of 
noradrenergic neurones (Chiti & Teschemacher, 2007; Fuxe et al., 2015; Kasparov & 
Teschemacher, 2008). Real-time detection of NA release is widely performed through 
fast-scan cyclic voltammetry, which consists of applying triangular waveform at high 
scan rate at carbon-fibre microelectrodes, causing the electroactive neurotransmitter 
to rapidly and repeatedly oxidize and reduce (Ribeiro, Fernandes, Pereira, & Silva, 
2016). Although fast-scan cyclic voltammetry offers high temporal resolution, it does 
not distinguish between compounds with similar electrochemical characteristics, such 
as NA and dopamine. To overcome this limitation, Muller et al. (2014) developed an 
imaging-based biosensor technology for detection of specific catecholamines that 
takes into account that NA and dopamine activate different types of G protein-coupled 
receptors. The cell-based neurotransmitter fluorescent engineered reporters 
(CNiFERs) of NA are genetically modified HEK293 cells that constitutively express 
the α1A adrenoceptor and the FRET-based Ca2+ nanosensor TN-XXL (Muller et al., 
2014) (Figure 2.4A). The α1A receptor couples to a Gq protein, and its activation 
triggers a rise in the intracellular Ca2+ concentration through the phospholipase C–
inositol triphosphate pathway. Upon α1A adrenoceptor activation, an increase in Ca2+ 
level is reflected by a change in the FRET ratio of CFP (photon donor) and Citrine 
(photon acceptor) of TN-XXL (Mank et al., 2008). CNiFERs, therefore, translate 
noradrenergic volume transmission into fluorescence signals, which can be quantified 
through microscopy or plate readers.  
In vitro and in vivo characterization showed that these CNiFERs are sensitive to 
nanomolar ranges of NA and do not respond to variable concentrations of other 
neurotransmitters such as serotonin, dopamine and adenosine (Muller et al., 2014). 
Our own recordings showed changes in FRET ratio following application of low 
concentrations of NA, confirming sensitivity of this system (Figure 2.4B). CNiFERs 
have been used to confirm our findings previously obtained by fast-scan cyclic 






2018; Tang et al., 2014). They were then used to test a wide range of LL analogues 
for their ability to mimic LL effects on LC neurones, in an attempt to map the binding 
properties of the putative LL receptor on noradrenergic neurones (Mosienko et al., 
2018; Tang et al., 2014). 
Figure 2.4. Characterization of α1A CNiFERs. (A) Schematic adapted from Muller 
et al. (2014) showing NA detection using CNiFERs expressing α1A-adrenoceptors 
and the FRET-based Ca2+ sensor TN-XXL. NA binds to the receptor leading to an 
increase in Ca2+, which can be quantified by TN-XXL FRET signal. (B) Representative 
recordings showing increase in FRET ratio of CNiFERs following application of 10nM 
and 100nM NA. 
 
2.3.2 Enzyme-based sensors  
Electrochemical approaches to detect non-electroactive biomolecules rely on the 
employment of enzymes that use the analyte of interest as a substrate and drive the 
formation of an electroactive product (Bucher & Wightman, 2015). The enzyme is 
immobilized at the tip surface of an electrode and the enzymatic activity, stability and 
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selectivity while restrained on the electrode will determine the performance of the 
sensor (Bucher & Wightman, 2015).  
The enzyme most employed in sensor-based electrochemical measurements are 
oxidases, and the electroactive product of their enzymatic reaction is hydrogen 
peroxide (H2O2). In the presence of the electron acceptor O2 – endogenous oxygen, 
which is assumed to be available at sufficient concentrations to support the reaction; 
(Wilson & Johnson, 2008) – the analyte of interest in its reduced form is oxidized, 
leading to the formation of H2O2 as following: 
 
𝑆𝑈𝐵𝑆𝑇𝑅𝐴𝑇𝐸 (𝑟𝑒𝑑𝑢𝑐𝑒𝑑) +  𝑂2  → 𝑆𝑈𝐵𝑆𝑇𝑅𝐴𝑇𝐸 (𝑜𝑥𝑖𝑑𝑖𝑧𝑒𝑑) +  𝐻2𝑂2 
 
Enzyme-based sensors are often coupled with amperometry. In this case, the sensors 
are kept at a constant potential that is sufficient to oxidize the electroactive product 
H2O2 and generate a current as following: 
 
𝐻2𝑂2  →  𝑂2 + 2𝐻
+ + 2𝑒− 
 
The resulting current is proportional to the concentration of H2O2, and thus of the 
analyte in the tissue (Wilson & Johnson, 2008). By calibrating the sensor with known 
amounts of the analyte, current values can be converted into specific quantitative 
information about analyte concentration in the biological tissue. It is important to 
highlight, however, that any endogenous electroactive component has a potential to 
generate a non-specific current. This effect can be minimized by using a second 
enzyme-free electrode, the readout of which is subtracted from the current generated 
by the enzyme-based sensor (Bucher & Wightman, 2015). Using a permselective 
membrane to separate the enzymatic layer from the electrode has also been proven 
to be an additional useful strategy to decrease interference from endogenous species 
(Wilson & Johnson, 2008). 
Enzyme-based sensors have been widely used for detection of a range of non-
electroactive compounds, including LL (Karagiannis et al., 2015), glutamate (Gourine 






2000), among others. Enzyme-based LL sensors (Sarissa Biomedical, UK) and 
constant-potential amperometry have been employed in this research project in order 
to electrochemically detect real-time fluctuations in LL concentration in brainstem 
organotypic slices under different circumstances. The detection system of LL sensors 
relies on the enzyme LL oxidase (LOX), which in the presence of O2 converts LL into 
pyruvate and H2O2 (Figure 2.5). Under a constant potential of +500mV, H2O2 is 
oxidised, generating a current that is proportional to the concentration of LL in the 
tissue. A second electrode (null) lacking the enzymatic layer is employed to control 
for non-specific currents.  
Figure 2.5. Structure of a LL electrode. LL electrode comprises of carbon fibre 
surrounded by a glass sheath and an uncovered sensing tip. The enzyme LOX around 
the sensing tip converts LL into H2O2, which creates a quantifiable current under a 
constant potential of +500mV. The electrode incorporates permselective layers as an 
additional aid to avoid interference from electroactive tissue compounds. 
 
Commercially available LL sensors (Sarissa Biomedical, UK) have a limit of detection 
of approximately 200nM, which is way below the physiological LL level, and operate 
at a linear range from 0.5µM to 800µM. Although the majority of our recordings show 






reiterates the need for consistent re-calibration of the electrodes. Pharmacological 
agents used in this study were tested for their potential ability to generate non-specific 
currents through this sensor system. NA (1µM), pyruvate (10mM) and DL (10µM) 
evoked a negligible current compared to the effect of 10µM LL, confirming specificity 
of the sensors to LL (Figure 2.6). 
Figure 2.6. Specificity of LL biosensors (Sarissa Biomedical, UK). Traces at the 
same graphic scale of the current generated by LL electrodes following application of 
LL (10µM), Na (1µM), pyruvate (PYR, 10mM) and DL (10µM). Compared to LL, 
current response evoked by the other compounds was insignificant. 
 
 
In conclusion, the challenge in the investigation of the role of astrocytes in many 
aspects of brain function is to monitor and manipulate the different cell types 
independently. The strategies summarized in this chapter allow the delivery of 
transgene expression in specific brain cells. Moreover, the involvement of astrocytes 
in brain energy metabolism and the communication between astrocytes and neurones 
can be investigated using compound-specific sensors to detect in real-time 




















This chapter details the approaches used for the design, construction, and validation 
of the novel molecular tools developed during my PhD project for modulation of LL-
mediated astrocyte-to-neurone signalling.  
 
3.1 Molecular cloning 
Cloning strategies were designed in silico using Vector NTI Software (Invitrogen, 
USA). DNA sequences of the bacterial enzymes were obtained from Genbank (NCBI), 
optimized for the mammalian codon preference and made to order by either Life 
Technologies (USA) or Invitrogen (USA). The open reading frames (ORFs) were 
incorporated into shuttle vectors for adeno- and lentiviral vectors, i.e. pXCX or pTYF, 
respectively. Expression cassettes were bicistronic with a red or green fluorescent 
protein sequence placed downstream of an internal ribosomal entry site (IRES). 
Different versions also varied according to their promoter - EF1α, CMV, or enhanced 
GFAP (sGFAP). The recombinant shuttle vectors were propagated in competent 
bacteria and analysed by diagnostic restriction digestions and partial DNA sequencing 
(Eurofins MWG, Germany). They were subsequently used for production of viral 
vectors and/or in vitro experimentation. 
 
3.1.1 Restriction enzyme digestion 
Construction of a recombinant plasmid requires that both precursor vector backbone 
and the insert be subjected to restriction digestions with endonucleases so that they 
exhibit DNA ends suitable for being ligated together. Restriction endonucleases 
cleave the DNA in specific palindromic sequences, the restriction sites, resulting in 
analogous blunt or sticky ends in the DNA strands that allow the ligation of the parent 
vectors. In order to achieve high efficiency restrictive digestion, the DNA and 
endonucleases were mixed with a suitable bovine serum albumin (BSA)-containing 
buffer as instructed by the suppliers (New England Biolabs, Promega or Roche). To 
reach a total volume of 50µl, sterile water was added into the reaction mix, which was 
briefly and thoroughly mixed and incubated for 45 min at 37°C (or as indicated by the 






Table 3.1. Standard restriction digestion. 
DNA 1µg 
10X BSA-containing buffer 5µl 
Restriction enzyme (10,000 units/ml) 10 units (1µl) 
Sterile water Up to 50µl 
Total reaction volume 50µl 
 
 
3.1.2 Blunting DNA sticky ends  
In case of lack of compatibility between sticky-ends of vector and insert, a Klenow 
treatment of DNA was carried out. Klenow consists of a large protein fragment of 
Escherichia coli DNA polymerase I, which retains the 5'→3' polymerase and 3'→5' 
exonuclease activity but lacks 5'→3' exonuclease activity. Therefore, by filling in 5’ 
overhangs, Klenow forms blunt ends, which are compatible with other blunt-ended 
DNA fragments and carry a 5’ phosphate group that assists with the ligation process. 
To carry out the Klenow treatment, 1µg of DNA fragment that was purified following 
restriction digestion was mixed with 2µl of an appropriate filling buffer provided by the 
supplier (Roche, 11008404001). 1U of Klenow enzyme (Roche, 11008404001) as 
well as 1mM of deoxynucleotide triphosphate mix (dNTPs, England Biolabs, N0447L) 
were added into the mixture along with nuclease-free water to make up a total volume 
of 40µl. The reaction mix was then incubated for 30 min at 37°C and the resulting 
DNA fragment was again purified using QIAquick PCR Purification Kit (Qiagen, 
28104) as described below. 
 
3.1.3 DNA dephosphorylation 
In order to avoid re-circularization and subsequent re-ligation of linearized DNA 
fragments with blunt or compatible ends, alkaline phosphatase from calf intestine 
(CIAP; Promega, M1821) was used to catalyse the hydrolysis of phosphate groups 






To perform the dephosphorylation reaction, CIAP was firstly diluted in 1x reaction 
buffer to reach a final concentration of 0.01u/µl. One volume of the diluted CIAP was 
then mixed with the same volume of 10x reaction buffer and 4 volumes of the digestion 
reaction mix containing the DNA to be phosphorylated. After 30 min incubation at 
37°C in the water bath, another aliquot of one volume of the diluted CIAP was added 
into the resulting mix, followed by further incubation at 37°C for 30 min. After 
completion of the dephosphorylation process, DNA was recovered through agarose 
gel electrophoresis and subsequently purified using QIAquick PCR Purification Kit 
(Qiagen, 28104). 
 
3.1.4 Polymerase chain reaction 
Polymerase chain reaction (PCR) allows amplification of a specific sequence of DNA 
flanked by sense and antisense oligonucleotide primers that are complementary to 
the target DNA segment. The procedure requires a thermal cycling protocol that 
favours different reactions in the synthesis of DNA, i.e. denaturation, annealing, and 
elongation. PCR also requires nucleotides and DNA polymerase to take place. 
Forward and reverse primers were designed using Vector NTI software (Invitrogen, 
USA) and ordered from Eurofins MWG (Germany). 2.5µl of both forward and reverse 
primers at a concentration of 10µM were added into the PCR tube (Starlab, I1402-
8100) containing 10ng of the template DNA. 1µl of dNTPs [10mM] (New England 
Biolabs, N0447L) was also included in the PCR mix. Finally, 0.5µl of Phusion High-
Fidelity DNA Polymerase and 10µl of 5X Phusion HF Buffer (New England Biolabs, 
B0518S) were added into the mixture and topped up to a final volume of 50µl by 







Table 3.2. Standard components of a PCR. 
Components Volume Final Concentration 
Forward primer [10µM] 2.5µl 0.5µM 
Reverse primer [10µM] 2.5µl 0.5µM 
Template DNA  10ng 
dNTPs [10mM] 1µl 200µM 
5X Phusion HF Buffer 10µl 1X 
Phusion HF DNA 
Polymerase 
0.5µl 1unit 
Nuclease-free water up to 10µl  
 
 
The PCR tube was then placed into a thermal cycler (G-Storm, UK); the tube lid was 
heated (110ºC) to prevent condensation of the sample. Initial denaturation at 98ºC for 
20s was then performed. At this temperature, hydrogen bonds of the ds DNA template 
break, yielding 2 complementary ss DNA. The temperature was then lowered and 
held for 10s to allow annealing of the primers to each strand of the DNA template. 
Annealing temperature varied according to the primers’ Tm, ranging from 
approximately 45ºC to 72ºC. The extension step was then performed at 72ºC, which 
is the optimum activity temperature of DNA polymerase, and lasted for 30s per each 
1kb of DNA. At this stage, DNA polymerase uses the free dNTPs previously added to 
the sample to synthetize in 5’-to-3’ direction a DNA strand that is complementary to 
the ss DNA template. This cycle (denaturation, annealing, and extension) was 
repeated for 25-35 times, yielding exponentially increasing copies of the target DNA 
sequence. In order to certify that any remaining ss DNA is completed extended, a 
single extension step of 10s at 72ºC was performed at the end of the PCR.  
 
3.1.5 Annealing of single-stranded oligonucleotides  
During construction of a construct to drive the expression of a precursor microRNA 
(pre-miRNA), complementary ss DNA oligonucleotides were annealed in order to 






were designed using the BLOCK-iT™ RNAi Designer online tool (Invitrogen) and the 
reagents necessary for the annealing reaction were provided with the BLOCK-iT™ 
Pol II miR RNAi Expression Vector Kit (Invitrogen, K493600). 5µl of both top and 
bottom oligo strands at a concentration of 200µM were added into a PCR tube, 
followed by the addition of 2µl of 10x Oligo Annealing Buffer. To reach a final volume 
of 20µl, 8µl of DNase/RNase-free water were added into the sample tube, which was 
subsequently placed in a thermal cycler (G-Storm, UK). After heating the reaction 
mixture at 95ºC for 4 min, the sample was removed from the thermal cycler and 
allowed to cool down at RT for 5-10 min. The resulting 50µM of ds oligo mixture 
underwent serial dilutions to yield a final concentration of 10nM. The sample was then 
stored at -20ºC until further use for molecular cloning.  
 
3.1.6 DNA purification 
Following cloning procedures, contaminants such as primers, nucleotides, enzymes, 
oil, salts were removed from the DNA sample using the QIAquick PCR Purification Kit 
(Qiagen, 28104). This procedure is based on the adsorption of the DNA to a silica 
membrane, which occurs in the presence of high concentration of salts and optimal 
pH (≤ 7.5).  
Firstly, 5 volumes of the high-salt buffer PB containing a pH indicator was added to 1 
volume of the DNA sample. In case the colour of the mixture did not turn yellow, the 
pH was corrected by the addition of 3M sodium acetate, pH 5.0. The sample was then 
transferred to the QIAquick column placed in a 2ml collection tube. After 30-60s 
centrifugation, impurities that passed through the column were discarded, while the 
DNA kept bound to the silica membrane of the column. To wash away salts, 750µl of 
the ethanol-containing Buffer PE was added to the column, followed by 30-60s 
centrifugation. The flow-through was discarded and an extra centrifugation step was 
applied to remove residual PE Buffer. For DNA elution, which is most efficient at low 
salt concentrations and basic pH, 30µl of nuclease-free water was added to the 
column. The column was then placed in a clean 1.5ml centrifuge tube and centrifuged 







3.1.7 DNA separation by agarose gel electrophoresis 
Following restriction digestion that cleaved the DNA plasmid into distinct sized 
fragments according to the location of the restriction sites in the DNA sequence, 
agarose gel electrophoresis was carried out for separation and selection of the 
fragments of interest. In electrophoresis, nucleic acids, which are negatively charged 
due to their phosphate backbone, migrate to the positively charged anode when 
loaded in agarose gel placed in an electric field. For the purposes of our cloning 
strategies, 1% agarose gel has the appropriate molecular sieving property for the 
movement of the DNA. The speed of DNA migration throughout the gel is proportional 
to the size of the cut segments and, as a result, the shortest pieces of the plasmid run 
furthest through the gel.  
To carry out this procedure, an agarose gel was freshly prepared using 1% of agarose 
powder (New England Biologicals, NBS-AG500) suspended in 1X Tris-acetate-EDTA 
buffer (Sigma, T9650). The mixture was then heated in a microwave until the agarose 
was completely melted. In order to enable visualization of the DNA after 
electrophoresis, 0.01% of SafeView Nucleic Acid Stain (NBS Biologicals, NBS-SV1) 
was added to the solution once the temperature had cooled to about 60°C. This 
compound binds to the DNA and emits green fluorescence under UV-light. The melted 
mixture was then poured into a gel casting tray containing a sample comb. Following 
gel solidification at room temperature (RT), 1 volume of a gel loading dye (Orange G; 
Sigma, O-3756) was mixed with 4 volumes of DNA sample and subsequently loaded 
into the wells of the gel. Orange G also contains glycerol, which, due to its high 
density, eases loading and settlement of the sample at the bottom of the well. For 
reference purposes, a DNA indicator containing fragments of known size (2-Log DNA 
Ladder, 0.1-10.0 kb, 1,000μg/ml; New England Biolabs, N3200S) was added in one 
of the wells and allowed to run in parallel with the samples. The electrophoresis power 
supply was set to an appropriate voltage and the gel was allowed to run until the 
samples had migrated a suitable distance. The gel was then placed into a 
transilluminator and exposed to UV light. A picture was taken for documentation 








3.1.7.1 DNA recovery after agarose gel electrophoresis  
For extraction and purification of the DNA fragments from agarose gel, a QIAquick 
Gel Extraction Kit (Qiagen, 28704) was used. Like the purification process detailed 
previously, it relies on the capacity of the DNA to adsorb to a silica membrane in high 
salt conditions and relatively acidic pH, while the debris can be washed away, followed 
by DNA elution in nuclease-free water. 
Firstly, a sharp and clean scalpel was used to precisely excise the DNA fragment from 
the agarose gel. The gel slice was placed in a centrifuge tube and 3 volumes of the 
high-salt and solubilizing buffer QG was added to 1 volume of the DNA-containing 
gel. The mixture was incubated at 50°C for 10 min in a water bath to allow the gel to 
dissolve. In case the colour of the mixture turned either orange or violet, 3M sodium 
acetate (pH 5.0) was added to the mix to correct the pH. The solubilized gel solution 
was transferred to the silica membrane-containing QIAquick column placed on a 
provided collection tube. Following 30-60s centrifugation, the flow-through was 
discarded and additional 500µl of Buffer QG were loaded onto the column to eliminate 
all traces of agarose from the sample. After 30-60s centrifugation, the flow-though 
was removed and a washing step was performed in order to eliminate the remaining  
salts by the addition of 750µl of the ethanol-containing Buffer PE. The column was 
allowed to stand 2-5 min prior to centrifugation. The resulting flow-through was 
discarded and the column was centrifuged again to remove all remnants of Buffer PE.  
Lastly, for DNA elution, the column was placed in a clean centrifuge tube and 30µl of 
nuclease-free water were added to the centre of the membrane followed by 1 min 
centrifugation.  
 
3.1.8 DNA ligation  
In order to construct a novel recombinant plasmid, the linearized and purified vector 
and insert fragments were ligated together using the Rapid DNA Ligation Kit (Roche, 
11 635 379 001). Ligation of DNA with either sticky or blunt ends relies on the activity 
of the enzyme T4 DNA ligase, which catalyses the formation of phosphodiester bonds 
between 5′-phosphate and 3′-hydroxyl groups. An ideal molar ratio of 1:3 (for blunt-






prior to the ligation, which took into consideration normalized proportions of mass and 




 =  
𝑛𝑔 𝐼𝑛𝑠𝑒𝑟𝑡
𝑘𝑏 𝐼𝑛𝑠𝑒𝑟𝑡
      ×       
1 𝑉𝑒𝑐𝑡𝑜𝑟
3 𝑜𝑟 5 𝐼𝑛𝑠𝑒𝑟𝑡
  𝑅𝑎𝑡𝑖𝑜 
 
To proceed with the ligation reaction, appropriate amounts of vector and insert DNA 
were suspended in 10µl of 2X T4 DNA Ligation Buffer and 2µl of 5X Dilution Buffer in 
a microcentrifuge tube. The volume of the suspension was topped up to 20µl with 
double distilled water (dd) water. Lastly, 1µl of T4 DNA Ligase (5U/µl) was added and 
the ligation reaction mixture was thoroughly but gently mixed and incubated for 20 
min at RT. Since success of this step depends on the integrity of each component of 
the process, appropriate controls were run in parallel with the ligation reaction, such 
as: ‘no insert’ (NI), ‘no vector’ (NV), and ‘no ligase’ (NL) reactions, in which insert, 
vector, or the enzyme T4 DNA Ligase, respectively, were lacking. Following DNA 
ligation, 4µl of the reaction were transformed into competent E. coli for propagation. 
 
3.1.9 Transformation of competent cells with plasmid DNA 
The recombinant plasmid, which carries a gene conferring resistance to either 
ampicillin or kanamycin, was propagated in DH5α E. coli (Life Technologies, 18265-
017). These were made chemically competent to take up plasmid DNA with high 
transformation efficiency following a heat shock.  
DH5α competent cells were thawed on ice, gently suspended and 50µl were mixed 
with 4µl of each ligation or control reaction mix at 0ºC. This allows the DNA plasmid 
to bind to the bacterial membrane ready to penetrate the cell. The suspension was 
then placed in a water bath at 42°C for 45s in order to induce the heat shock, which 
generates pores in the cell wall allowing the plasmid entry. The cells were 
subsequently transferred back to ice for 2min in order to stabilise the membranes and 
trap the DNA plasmid inside, followed by the addition of pre-warmed Luria Bertani 
(LB) broth (Sigma, L3022). The mixture was then incubated at 37°C for 1 hour with 






antibiotic resistance gene from the recombinant plasmid DNA. The bacterial 
suspension was plated on freshly prepared ampicillin- or kanamycin-containing agar 
plates to selectively allow the propagation of E. coli colonies carrying the correct 
plasmid. Following overnight incubation at 37°C, agar plates were checked for the 
presence of bacterial colonies. A single bacterial colony was picked and inoculated 
into antibiotic-containing LB broth.  
 
3.1.10 Isolation of plasmid DNA 
In order to recover amplified plasmid DNA from E. coli, small (Miniprep) or large-scale 
(Midiprep) purification from bacterial suspension was carried out.  
 
3.1.10.1 Miniprep 
The rapid and small-scale method called miniprep was carried out to isolate the 
recombinant plasmid from the host bacterial cells with the ultimate goal of verifying if 
they carry the correct DNA of interest. Miniprep allows analyses of the DNA sequence 
before scaling up the plasmid preparation. 
Single bacterial colonies were picked from the agar plate and inoculated into LB broth 
containing either ampicillin (Sigma, A9518) (100μg/ml) or kanamycin (from 
Streptomyces kanamyceticus, 10mg/ml; Sigma, K0129), depending on the resistance 
expressed by the plasmid of interest. Following overnight incubation at 37°C under 
constant agitation, 1.5ml of the bacterial suspension were transferred to a 
microcentrifuge tube and pelleted for 2 min. Using the GenElute Plasmid Miniprep Kit 
(Sigma, PLN350), the plasmid DNA was isolated as following: 
• Bacterial cells resuspension: The pellet was drained and thoroughly 
resuspended by pipetting up and down 200µl of the RNase A-containing 
Resuspension Solution.  
• Cell lysis: To break the bacterial membrane, 200µl of the alkaline Lysis 
Solution was added to the resuspension solution, which was gently mixed until 






• Neutralization: After 5 min, the cell debris was precipitated by the addition of 
350µl of the Neutralization/Binding Solution. The reaction tube was then gently 
inverted 4-6 times, followed by centrifugation at maximum speed, which 
resulted in the accumulation of cell debris at the bottom of the tube. The 
plasmid-containing supernatant was transferred to a binding column placed in 
a provided collection tube. After centrifugation for 1 min, the flow-through was 
discarded. In order to maximize DNA binding to the silica membrane, 500µl of 
the Column Preparation Solution had been previously added to the column, 
followed by centrifugation and discard of the flow-through liquid. 
• Washing: Two different types of washing solutions were used at this stage to 
completely remove any residual salts and impurities left in the column. Firstly, 
500µl of the Optional Wash Solution were added to the column, followed by 
the addition of 750µl of the ethanol-containing Wash Solution. In each step, 
the column was centrifuged and the flow-through was discarded. In order to 
entirely remove residues of ethanol that may affect DNA quality, another 
column centrifugation was carried out. 
• DNA elution: 50µl of water were added in the centre of the column, which 
was transferred to a clean microcentrifuge tube and centrifuged for 1 min. The 
DNA plasmid present in the eluate was subsequently used for diagnostic 
restriction digestion and stored at -20°C. 
 
3.1.10.2 Midiprep 
To scale up plasmid production, 200µl of the suspension of bacteria containing the 
right plasmid were transferred to a conical flask containing 200ml of LB broth mixed 
with the suitable antibiotic (ampicillin or kanamycin). The bacterial culture was allowed 
to grow overnight under constant shaking at 37°C. In order to pellet the cells, a 
centrifugation (4000 rpm for 15 min at 4°C) was carried out and the plasmid DNA in 
the resulting pellet was isolated using NucleoBond Xtra Midi Plus Kit (Macherey-






• Bacterial cells resuspension: 8ml of the RNase A-containing Buffer RES 
was added to the drained pellet and pipetted up and down to completely 
resuspend the cells. 
• Cell lysis: 8ml of Buffer LYS was added, mixed and incubated for 5min at RT. 
This step relies on the sodium hydroxide/sodium dodecyl sulphate (SDS) 
activity, which denatures proteins and chromosomal DNA.  
• Neutralization: To neutralize the lysate, 8ml of the potassium-containing 
Buffer NEU was added to the suspension and mixed by inverting the tube 3 
times. This caused precipitation of SDS as potassium dodecyl sulphate (KDS), 
which pulled down proteins, chromosomal DNA, and other cell impurities.  
• Column and filter equilibration and loading: A provided filter inserted into 
the NucleoBond Xtra Column was first equilibrated with the addition of 12ml 
of Buffer EQU in the perimeter of the filter and allowed to empty by gravity 
flow. The lysate was then loaded onto the pre-wet filter column. The filter 
retained the cell debris, while the plasmid DNA bound to the column silica 
membrane. 
• Washing: In order to transfer any residual lysate from the filter to the column, 
5ml of Buffer EQU was applied in the rim of the filter, which was subsequently 
discarded. Although RNA and proteins are not supposed to bind to the silica 
membrane due to the high salt concentration of the lysate, an additional 
washing step was carried out to eliminate all traces of impurities. In this stage, 
8ml of Buffer WASH was added throughout the surface of the column. 
• DNA elution: 5ml of pre-heated Buffer ELU was used to elute the plasmid 
DNA, which was collected in a Bijou sample container. The alkaline buffer 
used in this process neutralizes the positive charges of the resin, releasing the 
DNA plasmid from the column membrane. 
• DNA precipitation: 3.5ml of RT isopropanol was added to the DNA eluate, 






• Washing and drying: The precipitation mixture was transferred into a 5ml 
syringe whose outlet had been attached to a NucleoBond Finalizer. The 
plunger was slowly pressed down and the resulting flow-through was 
discarded. The DNA plasmid bound to the finalizer’s silica membrane was 
washed by loading the syringe with 2ml of 70% ethanol (Sigma, 32221), which 
was carefully pressed through the finalizer. The flow-through was discarded 
and the membrane was dried by passing air through the finalizer.  
• DNA reconstitution: For elution of the highly pure plasmid DNA, NucleoBond 
Finalizer was attached to the outlet of a 1ml syringe, which was placed over a 
microcentrifuge tube. The syringe was loaded with 800µl of Buffer TRIS (5mM 
Tris/HCl, pH 8.5) and the plunger was slowly pressed down. The resulting 
eluate was transferred back to the syringe and pressed down again through 
the membrane into the same collection tube in order to maximize DNA yield.  
 
3.1.10.2.1 Ethanol precipitation 
The plasmid DNA was further concentrated and purified using an ethanol precipitation 
protocol. Since DNA is a highly hydrophilic molecule, a salt was used to neutralize the 
negatively charged DNA backbone, which decreased solubility of the molecule in 
water. Ethanol was applied to increase the force of attraction between cations from 
the salt and the DNA backbone, causing it to drop out of the solution especially after 
centrifugation steps. 
To carry out ethanol precipitation, 1 volume of DNA eluate was initially centrifuged for 
2 min, followed by the addition of 2.5 volumes of 100% cold ethanol (Sigma, 32221) 
and 0.1 volume of 3M sodium acetate. The mixture was then stored in the freezer (-
20°C) for at least 10 min and later centrifuged for 5 min. The supernatant was carefully 
discarded, and 2.5 volumes of 70% cold ethanol were added to the DNA pellet. The 
sample was subsequently kept in the freezer (-20°C) for 5 min, followed by 5 min 
centrifugation. The supernatant was again gently discarded, and the resulting DNA 
pellet was allowed to dry at RT until no trace of ethanol could be seen in the collection 






the sample, which was subsequently incubated in the water bath at 37°C for 1 hour. 
The DNA plasmid prep was stored in the freezer (-20°C) until further use.  
 
A sample of the isolated and purified plasmid was submitted for diagnostic restriction 
digestions and sent for sequencing (by Eurofins MWG, Germany). If the restriction 
digestion patterns obtained by electrophoresis and the DNA sequence were both as 
predicted by the vector map, the DNA plasmid was further used for cloning or 
production of viral vectors, or transfection of cell lines or primary cultures of 
astrocytes, as appropriate. 
 
3.1.11 DNA quantification 
DNA yield and purity were determined with a spectrophotometer, which exposes the 
DNA sample to UV light and measures the resulting absorbance through a 
photodetector. Nucleic acids in DNA most strongly absorb UV light at 260nm, while 
RNA and proteins most strongly absorb light at 280nm. The final DNA concentration 
is calculated from a reference absorbance of 1 corresponding to 50µg/ml of ds DNA. 
Light absorbed by the sample is directly proportional to the concentration of DNA. 
Regarding assessment of DNA purity, the absorbance read at 260nm is divided by 
the absorbance detected at 280nm. A 260/280 ratio of 1.8 is considered a highly pure 
plasmid DNA sample. Lower values indicate protein contamination, while higher 
numbers imply RNA presence in the sample. 
The spectrophotometer (NanoDrop ND-1000, Thermo Scientific) was firstly cleaned 
by pipetting 2µl of water onto the lower measurement pedestal. Water was wiped off 
from both upper and lower pedestals after an initial spectral measurement, and the 
same procedure was repeated in order to calibrate the equipment. Since water is the 
solvent used to dissolve DNA, the latter reading was set as the blank in the operating 
software on a computer. After wiping the water off the spectrophotometer, 2µl of the 
DNA sample was loaded into the lower pedestal and the resulting reading taken as 







3.2 Adenoviral vector production 
For the production of AVVs, the shuttle plasmid (pXCX) carrying the expression 
cassette of interest has to spontaneously recombine with the helper plasmid 
(pBHG10), which contains the majority of the adenovirus serotype 5 genome cloned 
in a bacterial plasmid. The external plasmid DNA must contain overlapping 
sequences with the left-end adenovirus genome, including the packaging system 
necessary to generate infectious viral vectors, which has been deleted in the helper 
plasmid (Bett, Haddara, Prevec, & Graham, 1994). Moreover, replication of the viral 
genome is defective due to deletion of E1 gene in pBHG10. Thus, viral propagation 
can only take place in HEK293 cells as they express and supply the E1 gene products 
(Graham & Prevec, 1995). 
 
3.2.1 Co-transfection 
All the recombinant plasmids constructed throughout my PhD project were directed 
to AVV production, in order to enable or maximize the transduction efficiency and 
transgene delivery to mammalian astrocytes, particularly in vitro.  
For the co-transfection step, 5µg of shuttle vector and 5µg of helper plasmid pBGH10 
were combined in a microcentrifuge tube containing 400µl of serum- and antibiotic-
free Dulbecco′s Modified Eagle Medium (DMEM, high glucose, with GlutaMAX; 
Invitrogen, 61965-059). 20µl of FuGENE® transfection reagent (Promega, E2691) 
were added to the mixture and briefly vortexed. Following 5min incubation at RT, the 
transfection mix was added to a T25 flask (Corning, 3289) containing 60-70% 
confluent HEK293 cells. The cells were kept in the incubator at 37°C in 5% CO2 and 
a partial replacement of culture media was performed when its colour turned 
orange/yellow, indicating acidification. When cytopathic effect (CPE) was observed 
(Figure 3.1), crude viral suspension was harvested and frozen at -20°C to lyse the 






Figure 3.1. Progressive impact of AVV replication in HEK293 cells, leading to 
CPE. From left to right, images show the AVV production from the co-transfection 
stage until the cells lose adherence and exhibit swollen and rounded shape indicating 
CPE. Scale bars 60µm.  
 
3.2.2 Re-infections 
The crude cell suspension was defrosted and subsequently centrifuged for 5 min. 
500µl of the virus-containing supernatant was added to a new T25 flask with 60-70% 
confluent HEK293 cells, while the remaining supernatant was returned to the freezer. 
The cells were again left in the incubator until CPE was observed, carrying out partial 
media exchange when necessary. The crude cell suspension was collected and the 
same procedure – freezing, centrifugation, HEK293 cells re-infection, CPE, viral 
suspension collection and freezing – was performed. Following co-transfection, cells 
normally take around 7-11 days to exhibit CPE. Once cells start displaying CPE within 
2-3 days after re-infection, 1ml of the collected crude viral suspension is used to re-
infect a new batch of HEK293 cells in T75 flasks (75 cm² Rectangular Canted Neck 
Cell Culture Flasks with Vent Cap; Corning, 430641) to proceed with the AVV bulking-
up process.  
 
3.2.3 Bulking-up 
When CPE was observed in HEK293 cells in a T75 flask, the crude cell suspension 
was harvested, frozen, and subsequently used to re-infect 10 T150 flasks (150cm² 
Rectangular Canted Neck Cell Culture Flasks with Vent Cap; Corning, 430641) 
containing 70-80% confluent HEK293 cells (1ml of the crude viral suspension was 
added to each flask). After observing CPE, rounded and swollen HEK293 cells were 






centrifugation. The supernatant was discarded, and the resulting pellet was 
resuspended with 2.5ml of 0.1M tris-HCl (Sigma, T-5941) pH 8.0. To lyse the cells 
and release the virus particles, the crude cell suspension was frozen and kept at -
20°C until further use.  
 
3.2.4 Purification 
In order to purify the AVV suspension for use in in vitro experimentation, any residual 
contaminants had to be cleared. This involved a series of sonification and 
ultracentrifugation cycles as well as desalination and filtration as following: 
• Sonification: The suspension containing the infected cells was defrosted and 
kept on ice. To disrupt the cells, a sonificator probe (Vibra-Cell Ultrasonic 
Processor; Sonics, USA) was placed in direct contact with the cell pellet and 
4 sonification cycles were performed lasting 45s each. At the end of each 
cycle, the virus-containing falcon tube was transferred to an ice-filled box for 
1 min to cool down the sample. The viral suspension was then centrifuged at 
3000 rpm at 4°C for 10 min. The clear AVV-containing supernatant was set 
aside while the pellet formed by the cell debris was discarded.  
• 1st ultracentrifugation: To enable virus collection from the supernatant, a 
Cesium Chloride (CsCl; Invitrogen, 15507-023) density gradient 
ultracentrifugation was carried out. 1 volume of the virus suspension and 0.6 
volume of saturated CsCl diluted in 0.1M Tris-HCl pH 8.0 were transferred to 
a Sorvall UCF tube, which was topped up with 0.6 volume of saturated CsCl. 
The tube was then sealed and placed into buckets in the rotor (Sorvall TV-
865B). The same procedure was repeated for the balance tube, which 
contained comparable volume and weight. The samples were then centrifuged 
at 55,000 rpm, overnight, at 15°C, to form a band of AVV within the CsCl 
gradient. 
• 2nd ultracentrifugation: The AVV-containing tube was pierced with a needle 
(21gx1.5”) attached to a 5ml syringe, which was used to extract up to 5ml of 






compensate for the negative pressure due to AVV band collection. The AVV 
suspension was then transferred to a new Sorvall UCF tube, whose volume 
was topped up with CsCl diluted in 0.1M Tris-HCl. Both AVV-containing tube 
and balance tube were then centrifuged at 55,000 rpm for 4 hours at 15°C. 
• Desalination: Prior to the end of the 2nd ultracentrifugation step, a PD-10 
desalting column (GE Healthcare, 17-0851-01) was equilibrated by allowing 
25ml of 10mM Tris/MgCl2 (pH7.5) (Qbiogene, MGCL0500) to flow through it. 
Following centrifugation, a volume of up to 3ml of AVV band was extracted 
using a needle attached to a syringe as described before and transferred to 
the desalting column. This was followed by the addition of 0.5ml of 10mM 
Tris/MgCl2 (pH 7.5) to the column, which was allowed to empty by gravity flow. 
For elution of the desalted AVV, 2.5ml of 10mM tris/MgCl2 (pH 7.5) were 
applied to the column and the eluate was collected in a tube.  
• Filtration: The AVV-containing tube was transferred to a laminar flow hood, 
in which it was sterile filtered using a 0.22μm sterile syringe filter (13 mm 
diameter, Millipore, SLGP033RS). The purified AVV was then aliquoted in 
sterile microcentrifuge tubes (20µl per tube) and stored at -80°C until further 
use.  
 
3.2.5 Titration  
Titration of the newly produced AVV was performed by staining for the adenovirus 
hexon protein, following a protocol adapted from Bewig and Schmidt (2000):  
• Cell infection:  10-fold serial dilutions (10-2, 10-3, 10-4, 10-5, 10-6, 10-7, 10-8) of 
the harvested AVV suspension were prepared in DMEM, 100µl of each was 
added to different wells of a 12-well plate (Greiner Bio-One, 665180) 
containing 70% confluent HEK293 cells. The plate was kept in the incubator 
at 37°C in 5% CO2 for 48h to allow infected cells to express hexon proteins. 
Media was then aspired, and cells were fixed by gently adding 1ml of ice-cold 
100% methanol (Fisher, 67-56-1) to each well. The plate was stored in the 






rinsing 3 times with phosphate buffered saline (PBS; Fisher Scientific, 
BR0014G) containing 1% BSA (Sigma, A9647).  
• Immunostaining: 500µl of 1000x diluted anti-adenovirus hexon protein (goat 
anti Adenovirus; Biodesign, B65140G) were added to each well of the plate, 
which was subsequently incubated at 37°C with constant gentle shaking. The 
first antibody was removed, and the wells were then rinsed 3 times with PBS 
containing 1% BSA. 500µl of 500x diluted secondary horseradish peroxidase 
(HRP)-conjugated antibody (rabbit anti-goat; Zymed, 81-1620) were applied 
to each well, followed by incubation at 37°C for 1h. The antibody was then 
removed, and the wells were washed 3 times with PBS containing 1% BSA. 
All antibody dilutions were performed using PBS + 1% BSA as diluent.  
• 3,3-Diaminobenzidine (DAB) reaction: The DAB reaction mix was freshly 
prepared by adding one tablet of DAB (0.7 mg/mL; Sigma, D4293) to an 
aluminium-foil-wrapped tube containing 15ml of distilled water. Following 
dissolution, a tablet of urea hydrogen peroxide (2 mg/mL; Sigma, U1380) was 
added to the mix, which was hand-shaken several times until the tablets added 
dissolved into the mixture. 500µl of the DAB mix were then added to each well 
and the reaction was evaluated under a microscope. As soon as a dark 
product appeared, the reaction was stopped by the addition of excess PBS, 
which was later exchanged by 1ml of fresh PBS. Stained cells were then 
counted in 5 fields of view at appropriate dilutions and the AVV titre was 
calculated as TU/ml as following: 
 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑓𝑖𝑒𝑙𝑑 𝑋 𝐹𝑖𝑒𝑙𝑑𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙∗
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 (𝑚𝑙)𝑋 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
 
∗ 𝐹𝑖𝑒𝑙𝑑𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 = 157 
 
3.3 Lentivirus vector production  
HIV-derived and VSVG glycoprotein-pseudotyped LVVs were produced as described 
in Hewinson, Paton, and Kasparov (2013). Generation of LVVs relies on the co-






viral packaging into a packaging cell line, followed by various concentration and 
purification steps. The helper plasmids comprised of: (i) the packaging vector (pNHP), 
which provides the HIV-1 genome for expression of the genes required for vector 
assembly; (ii) the envelop vector (VSVG), which encodes VSVG envelope for viral 
pseudotyping; (iii) a vector encoding tat gene, which is the transcriptional enhancer of 
HIV-1; and (iv) the shuttle plasmid (pTYF) carrying the expression cassette of interest. 
The packaging cell line used was Lenti-X 293T cells (Clonthech, 362180), which 
express the SV40 large T antigen, allowing replication of plasmids carrying the SV40 
origin of replication. 
 
3.3.1 Co-transfection 
Lenti-X 293T cells were seeded onto two T150 flask and incubated at 37°C in 5% CO2 
until they reached approximately 50% confluence. 30µg of pNHP, 12µg of pHEF-
VSVG, 2.5µg of pCEP4-tat, and 15µg of the pTYF shuttle vector were added into a 
Bijou sample container containing 1.8ml of serum- and antibiotic-free DMEM culture 
media. 120µl of TurboFect transfection reagent (Thermo Scientific, R0533) were 
added to the transfection mix, which was incubated for 20min at RT. The transfection 
mix was then transferred to a falcon tube containing 22ml of culture media and gently 
mixed. The media of the two T150 flasks seeded with Lenti-X 293T cells was 
discarded and the content of the falcon tube was divided into the two T150 flasks, 
which were overnight incubated at 37°C in 5% CO2. 
 
3.3.2 Media harvest 
Approximately 30 hours after transfection, the culture media covering the Lenti-X 
293T cells in the two T150 flasks was collected and transferred to a falcon tube, which 
was centrifuged at 2000 rpm for 5 min. The supernatant was then transferred to a new 
falcon tube placed on ice, which was subsequently stored at 4°C. 12ml of fresh culture 
media was added into each T150 flasks containing the Lenti-X 293T cells. Following 
approximately 18 hours of incubation at 37°C in 5% CO2, the media was again 







3.3.3 Purification  
In order to remove cell debris, the media was filtered through a 0.45µm 
polyethersulfone membrane vacuum filter (Thermo Scientific, TKV-246-013T) and 
subsequently transferred to ultracone thin wall ultracentrifuge tube (Seton Scientific, 
5067) placed on ice. 1ml of cold and sterile 20% sucrose (Fisher Scientific, S/8600/53) 
in PBS was carefully added into the bottom of the ultracone tube, which was placed 
in an ultracentrifuge alongside a balance tube containing comparable volume and 
weight. Following 20,500 centrifugation at 4°C for 2 hours, the supernatant was 
aspirated off and 25µl of sterile cold PBS were carefully added to the pellet. The tube 
was then placed back on ice and maintained in the fridge at 4°C overnight. In the next 
morning, the viral suspension was aliquoted in microcentrifuge tubes and stored at -
80°C until further use. 
 
3.3.4 Titration 
Determination of LVV titres was performed using an enzyme-linked immunosorbent 
assay (ELISA) and the Lenti-X p24 Rapid Titre Kit (Clontech, 632200), which 
measures the core protein p24 of a HIV-1-based LVV. The assay relies on the binding 
of p24 in the lentiviral sample to anti-HIV-1 p24 capture antibody present in the wells 
of a supplied microtitre plate.  
Firstly, p24 positive control (10ng/ml) was diluted in PBS in order to create 
concentration points ranging from 0 to 200pg/ml. LVV samples were diluted 1,000,000 
and 10,000,000 times in PBS. 20µl of Lysis Buffer was dispensed in each well. 200µl 
of each standard curve as well as the LVV sample and PBS were added in duplicates 
to the wells containing the Lysis Buffer. The microplate was covered to prevent 
evaporation and incubated for 1 hour at 37ºC. The content was then removed, and 
the wells were manually washed by addition of 275µl of 1x Wash Buffer in each well. 
The washing solution was aspirated off, and 100µl of the Anti-p24 biotin conjugated 
antibody was added per well. Following 1 hour incubation at 37ºC, the antibody was 
removed and the wells were washed as previously described. 100µl of Streptavidin-
HRP conjugate was then dispensed to each well and the microplate was incubated 






Protected from light, 100µl of Substrate Solution was quickly added to each well. 
Following incubation at RT for 20min, the reaction was blocked by the addition of 
100µl of Stop Solution, which changed the colour of the solution from blue to yellow. 
The absorbance values were read at 450nm in a microplate reader. The absorbance 
values of the PBS/blank duplicates were averaged and used to subtract the 
background of each standard dilution and sample. The standard curve was then 
constructed and used to convert the absorbance values of the sample into p24 
concentration (pg/ml). Importantly, the values of the LVV samples were corrected for 
the dilution factor of the samples. Conversion of p24/ml values to lentiviral particle 
(LP)/ml was performed considering that 1 LP contains 8x10-5 pg of p24, whereas the 
conversion of LP/ml values took into account that 1 TU corresponds to 148 LP.  
 
3.4 Dissociated cell culture 
Experiments involving cell lines, dissociated culture of rat astrocytes, and organotypic 
brainstem slices were conducted under aseptic conditions in a laminar flow hood. 
Cultures were kept in an incubator at 37ºC in 5% CO2 and regularly fed with 
appropriate growth medium. 
 
3.4.1 Handling and subculturing 
Primary cultured astrocytes and HEK293 cells were cultured in complete growth 






Table 3.3. Components of complete growth media. 
DMEM (high glucose, with GlutaMAX; Invitrogen, 61965-059) 89% 
Foetal Bovine Serum (FBS, Invitrogen, 10108-165) 10% 
Penicillin-Streptomycin (Pen/Strep, 10,000 U/mL, Invitrogen, 15140-122) 1% 
 
 
Cultured cells were maintained in either T25 or T75 flasks until they exhibited 100% 
confluence, when the old media was discarded, and cells were gently rinsed in 
DMEM. To detach cells from the substrate, trypsin (Trypsin, 0.05% (1X) with EDTA; 
Invitrogen, 25300-054) was added to the flask, which was subsequently placed in the 
incubator at 37°C for 3 min. Trypsin is a protease that acts by cleaving the 
extracellular matrix, inducing dissociation of the cell monolayer. Following incubation, 
complete media was added to the flask since serum deactivates trypsin activity. The 
cell suspension was then collected and centrifuged at 2000 rpm for 5 min. The formed 
pellet was resuspended in complete media and the cells were either plated on glass 
coverslips or in multi-well plates for further experimentation, or used to inoculate a 
new flask. Since primary cultures of astrocytes show a lower growth rate, a media 
exchange was gently carried out before cells reached confluence to a continuous 
supply of nutritive growth media. 
 
3.4.1.1 Cell counting and plating 
In some experiments, the number of cells in the suspension had to be precisely 
determined before plating. In these cases, an optically transparent chamber of known 
depth engraved with a grid of known area (haemocytometer) was used and cells were 
counted under a microscope.  
A volume of the suspension containing dissociated cells was diluted in DMEM 
sufficiently to prevent the cells from overlapping in the chamber. 10µl of this 
suspension was transferred by capillarity action to the haemocytometer chamber 
(Neubauer/ Marienfeld, Germany), which had been previously covered with a glass 
coverslip. Cells located in the 4 outer squares were counted using a handheld cell 






area of each square as 1mm2, the final cell density per 0.1mm3 (or 10-4ml) in the 
original suspension was calculated as following:  
 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 (𝑐𝑒𝑙𝑙𝑠 𝑚𝑙⁄ )
=  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
  𝑋 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑋 104   
 
Following determination of cells concentration, 500µl of cell suspension containing 
105 cells were plated onto each well of a 24-well plate (Greiner Bio-One, 662160), 
while 100µl of cell suspension containing from 1x104 to 7x104 cells were plated onto 
each well of a 96-well plate (Greiner Bio-One, 655083). 
 
3.4.2 HEK293 cell line 
HEK293 cell line originated from the transfection of human embryonic kidney cells 
with part of the AVV 5 DNA. HEK293 cells are extensively used in biomedical research 
due to their fast growth and propensity for transfection. They were used in this project 
for AVVs production as well as for the initial stages of the validation process of the 
novel molecular tools.   
 
3.4.2.1 Cell line transfection 
DNA was delivered to HEK293 cells by TransIT-293 transfection reagent (Mirus, MIR 
2700), which provides high transfection efficiency, low toxicity, as well as a 
straightforward protocol. 18-24h prior to transfection, HEK293 cells were seeded onto 
either a 24- or a 96-well plate at a concentration that results in 80-90% cell density at 
the time of transfection. To allow formation of DNA complexes, up to 1.5µg/µl of the 
DNA of interest was added to a microcentrifuge tube containing the appropriate 
amount of Opti-MEM I (Reduced-Serum Medium, Life Technologies, 31985070), 
followed by the addition of TransIT-293 reagent. The quantity of the elements used in 
the complex formation step depended on the culture well size (Table 3.4). Following 






wells (9.4μl/well for a 96-well plate and 52μl/well for a 24-well plate). The plate was 
then incubated at 37ºC in 5% CO2 for 48-72 hours and subsequently used for 
experimentation.  
 
Table 3.4. Elements of DNA transfection using TransIT-293 transfection reagent. 
 
 
3.4.3 Primary culture of rat astrocytes 
To obtain primary dissociated cultured rat astrocytes, protocols adapted from Marriott, 
Hirst & Ljungberg (1995) were adopted as detailed here. Neonates Wistar rats were 
used in the procedure in accordance with the schedule 1 of the UK Home Office 
(Scientific Procedures) Act (1986). All the procedures of the glial preparation were 
performed under aseptic conditions. Sterilisation of tools and instruments was 
ensured by either autoclaving or UV treatment. Two fresh solutions were prepared 
preceding the prep: DNase I solution, which contained 3mg/ml of BSA (Sigma, A3294) 
and 0.04mg/ml of Deoxyribonuclease I (DNase I, from bovine pancreas; Sigma, 
D5025) diluted in 40ml of Hank’s Balanced Salt Solution (HBSS; Invitrogen, 14175-
129); and Trypsin solution, which was prepared by transferring 15ml of the DNase I 
solution to a new falcon tube and adding 0.25mg/ml of trypsin (from bovine pancreas; 
Sigma, T9935). 
Wistar rat P2 pup was overdosed with isoflurane 5% (Isoflurane-Vet, Merial Animal 
Health Ltd), followed by exsanguination through decapitation using sharp scissors. 
The head was then transferred to a well of a 6-well plate (Greiner Bio-One, 657160) 
containing cold HBSS in a laminar flow hood. After placing the head in a petri dish 
(60mm x 15mm; Corning, 430166), the skin was removed, and the skull was exposed, 
Culture vessel 96-well plate 24-well plate 
Complete growth medium 100µl 500 µl 
Opti-MEM I 9µl 50µl 
DNA (1µg/µl) stock 0.1µl 0.5µl 
TransIT-293 reagent 0.3µl 1.5µl 






followed by extraction of the brain tissue. Excess of brain cortex was eliminated, while 
the remaining tissue containing part of the midbrain and the brainstem was crudely 
cross-chopped and immersed in the trypsin solution for 15min under gentle and 
constant agitation. Trypsination was terminated by the addition of 15ml of complete 
culture media, followed by centrifugation at 2000rpm for 5min. The supernatant was 
discarded, and the pellet formed was resuspended in 10ml of the solution DNase I. 
The cell suspension was allowed to settle down, and the debris-free supernatant was 
collected and reserved in a new falcon tube. Another 10ml of the solution DNase I 
was used to resuspend and triturate the remaining tissue, and the resulting debris-
free supernatant was combined with the previous collection. The same procedure was 
repeated using the remaining 5ml of the solution DNase I. The collected suspension 
was then filtered with a 40μm cell strainer (Falcon, 352340), and subsequently 
centrifuged at 2000rpm for 5min. The supernatant was discarded, and complete 
growth media was used to resuspend the pellet. The cell suspension was then 
transferred to a T75 flask and incubated at 37°C in 5% CO2 for 7 days, allowing the 
glia culture to grow, and astrocytes to attach to the substrate. To eliminate microglia 
and oligodendrocytes from the primary culture, flasks were gently shaken overnight 
at 37°C in a temperature-controlled chamber. The culture media containing non-
astrocytic cells was discarded and the primary astrocytes attached to the flask’s wall 
were subcultured as previously described. The primary cultured rat astrocytes were 
kept in the incubator at 37°C in 5% CO2 until further use and subcultured whenever 
needed up to 21-25 days after prep. 
 
3.4.3.1 Primary culture transduction with AVVs 
DNA delivery to primary cultures such as rat astrocytes yields higher transduction 
efficiency using AVVs when compared to transfection reagents. Multiplicity of infection 
(MOI), which in an overly simplistic description is the ratio of the number of viral 
particles to the number of cells targeted in a culture, was optimised to avoid cytotoxic 
effects while achieving a high transduction efficiency. Cultured astrocytes were 
transduced with a range of titres of AVVs and astrocyte morphology and density were 
daily examined for signs of deterioration. Once an appropriate MOI was established 






3.4.3.2 Determination of astrocyte viability 
The novel molecular tools developed in this project have the potential to affect the 
viability of cells in which they are expressed, either by compromising their metabolic 
state or by formation of potentially harmful by-products. Cell viability tests were 
performed in order to quantify any cytotoxic effects of astrocytic transduction with 
AVVs, in order to optimise transduction titres. 
 
3.4.3.2.1 Trypan Blue exclusion assay 
Trypan blue is an impermeable dye which can only penetrate damaged membranes 
of either dying or dead cells. It is, therefore, a dye exclusion assay that distinguishes 
between live and dead cells. Primary astrocytes were plated in a 96-well plate at a 
concentration of 3x104 cells/100µl and transduced with the appropriate AVV at various 
MOIs as previously described. Following 2-3 days of incubation at 37ºC in 5% CO2, 
the complete media was aspirated from the wells, which were subsequently rinsed 
with 100µl of DMEM in order to remove any remaining serum. 40µl of trypsin were 
then dispensed into each well and the plate was transferred to the incubator. After 
3min incubation at 37ºC, 40µl of complete media were added to the cell suspension 
to terminate trypsin action, followed by the addition of 80µl of sterile-filtered trypan 
blue solution 0.4% (Sigma, T8154). 10µl of the resulting suspension solution 
containing dye-stained cells were transferred to a haemocytometer chamber, which 
was subsequently placed on a microscope stage for cells counting purposes. Cells 
showing blue colour were counted as unviable, while non-stained cells were 
considered to be alive. The total number of blue and unstained cells was determined, 
and cell viability was calculated as following: 
 
% 𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑢𝑛𝑠𝑡𝑎𝑖𝑛𝑒𝑑 (𝑙𝑖𝑣𝑖𝑛𝑔)𝑐𝑒𝑙𝑙𝑠 
𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 







3.4.3.2.2 XTT cell viability assay  
The XTT assay infers cell viability by detecting the metabolic activity of the cell. It 
relies on the action of dehydrogenase enzymes present in functional mitochondria to 
reduce the yellow tetrazolium salt XTT to a highly coloured formazan dye (Figure 3.2), 
which is soluble in aqueous solution and can be quantified by measuring the sample 
absorbance at wavelength 450nm. Tetrazolium salt XTT is negatively charged and 
does not easily penetrate the cell membrane (Berridge, Herst, & Tan, 2005). The 
assay requires, therefore, addition of an intermediate electron acceptor, which 
crosses the membrane and picks up electrons in the cytosol of viable cells. Once 
exited from these cells, the intermediate electron acceptor donates its electrons for 
the conversion of tetrazolium salt XTT into the soluble and coloured formazan product 
(Berridge et al., 2005). Since dehydrogenase mitochondrial enzymes are inactivated 
shortly following cell death, the amount of formazan produced is proportional to the 
viability of the cells in the sample. 
Figure 3.2. Reduction of XTT tetrazolium salt into formazan. Dehydrogenase 
enzymes in viable cells reduce the slightly yellow XTT tetrazolium salt into the bright 
orange and soluble dye formazan. Since this reaction relies on the performance of 
enzymes that are active only in viable cells, formazan absorbance at wavelength 
450nm is proportional to the amount of viable cells in the sample. 
 
To perform this assay, primary astrocytes were plated in 96-well plate at a density of 
3x104 cells/100µl. Various quantities of the appropriate AVVs were added to the 
complete media containing astrocytes in order to achieve a range of different MOIs. 
The plate was kept in the incubator at 37ºC in 5% CO2 for 2-3 days to allow the gene 
to be delivered and properly expressed by the cells. Prior to the experiment, reagents 
from the XTT cell viability kit (Cell Signalling Technology, 9095) were defrosted and 
checked for absence of precipitation. A fresh detection solution was prepared by 






increases efficiency of the reduction reaction, and 50 volumes of the XTT reagent. 
50µl of the detection solution was then transferred to each well of the 96-well plate, 
which contained astrocytes seeded in 100µl/well of complete growth media. The 
reaction of formazan formation was allowed to proceed for 2 hours, during which time 
the plate was kept in the incubator at 37ºC. 100µl of the supernatant were then 
transferred to a new 96-well plate and the sample’s absorbance was read at 450nm 
using a microplate reader (Tecan Infinite M200 PRO, Labtech).  
 
3.5 Organotypic cultured brainstem slices 
Preparation of organotypic brainstem slice cultures followed the protocol previously 
described by Teschemacher, Paton, and Kasparov (2005). The procedure was 
performed under sterile conditions and all tools used were previously autoclaved or 
treated with UV light. Male Wistar rat P7-8 pups were used in the procedure in 
accordance with the schedule 1 of the UK Home Office (Scientific Procedures) Act 
(1986). The animals were overdosed with isoflurane 5% (Isoflurane-Vet, Merial 
Animal Health Ltd), followed by exsanguination through decapitation using sharp 
scissors. The rat’s brain was then transferred to a laminar flow hood, where the caudal 
part of cerebellum and the entire brainstem were isolated and bathed in a cold 
dissection medium containing HBSS enriched with 20 mM glucose (Fisher Chemical, 
G/0500/60), 10 mM MgCl2 (Fluka, 63020), 1 mM HEPES (Sigma, H3375-250G), 1 
mM kynurenic acid (Sigma, K3375-1G), 0.5% phenol red (Sigma, P0290), 100 U/ml 
penicillin and 0.1 mg/ml streptomycin (Sigma, P4333). To function as a supporting 
base for the brainstem, the cerebellum was glued with cyanoacrylate adhesive 
(Loctite) onto a vibratome stage, which was mounted onto the platform of the vibrating 
microtome 7000 (Campden Instruments, UK) in a bath filled with cold dissection 
medium. 200μm-thick coronal slices were cut at the level of the locus coeruleus (LC). 
Using a rubber bulb attached to the tip of a 1ml pipette, each section was carefully 
transferred to a 24-well plate containing ice-cold dissection medium. LC slices were 
deposited onto organotypic culture inserts (Millicell-CM, Millipore) placed in a six-well 
plate filled with 1ml/well of the Optimem+ plating media, which is comprised of 49% 
of Opti-MEM Reduced Serum Medium (GlutaMAX Supplement, Life Technologies, 






and 25mM glucose. Slices were kept at the interface between media and the 
humidified and carbonated air in an incubator (37ºC, 5% CO2). Plating media was 
exchanged twice a week. 
 
3.5.1 Transduction of organotypic slice cultures 
Since cultured organotypic slices comprise a more integrated preparation that allows 
ideal viral gene transfer and high-resolution imaging (Teschemacher et al., 2005), 
slice cultures were transduced with AVVs for further experimental applications. 
Transduction of organotypic cultured slices occurred immediately following the slice 
prep, when AVVs were directly added into the plating media. In case the slices had to 
be transduced with different AVVs that targeted distinct cell populations, the neuronal-
driven AVV was handled as just described and the slices were kept in the incubator 
for 24-40h. Following incubation time, the old media was discarded and a fresh plating 
media containing the astrocyte-targeting AVV was dispensed into the wells. After 3 
days, the old media was removed from the wells and replaced with fresh plating 
media. Slices were used for experimentation from the 7th day after the preparation, 
allowing for fully established expression of the transgene cassette. 
 
3.6 Immunofluorescence  
In order to detect expression and distribution of certain proteins throughout the brain 
tissue or in primary cultured astrocytes, an immunofluorescence (IF) protocol was 
carried out. This widely used technique relies on specific antibodies to target antigens 
with fluorophores, which can be visualized under a fluorescent microscope. Indirect 
IF, as adopted in this study, requires a primary antibody that recognises and binds 
specifically to the target molecule, as well as a secondary antibody, which is 
conjugated to a fluorophore and binds to the primary antibody. The following steps 
were applied to IF in primary cultured astrocytes seeded in glass coverslips placed 
into a 24-well plate, as well as organotypic brainstem slices in membrane inserts 






• Tissue preparation: The samples were rinsed 3 times in PBS for 5min, 
followed by fixation with paraformaldehyde 4% (Sigma, 441244) for 15min at 
RT. Excess of the fixative compound was removed with a washing step - 3 
times 5min rinse in PBS. Organotypic brain slices were excised from the 
culture membrane and placed on a microscope slide (22x50mm, VWR, 631-
0137). Using a pen with hydrophobic content (Pink PAP Pen Mini, Zytomed 
Systems, ZUC065), a circle around the samples was drawn so that the 
solutions would be pooled in a small droplet. 
• Permeabilization and blocking: A solution containing 0.3% Triton X-100 
(Sigma, T8787) in PBS (PBST) and 10% serum (from the species the 
secondary antibody was raised in) was added to the sample, which was 
incubated at RT for 1 hour. Triton X-100 is a detergent that improves access 
of antibodies to intracellular targets. Serum was used to block nonspecific 
binding sites in the tissue sample that can be targeted by the secondary 
antibody. Following incubation, samples were washed in PBS for 5 min 3 
times. 
• Immunostaining: Primary antibody mix, which contained appropriate 
amounts of the primary antibody diluted in PBST and 1% serum, was 
dispensed into the samples and incubated overnight at 4ºC. The primary 
antibody used in this study was anti-red fluorescent protein (RFP, Rockland, 
600-401-379). Samples were subsequently rinsed in PBS for 5min 3 times. A 
secondary antibody mix was prepared by adding 2 drops/ml of Alexa Fluor 
488 (Life Technologies, R37116) or Alexa Fluor 594 (Life Technologies, 
R37117) to PBST and 1% serum. The secondary antibodies were directed 
against the species in which the primary antibody was raised in. The mix was 
then dispensed into the samples and incubated for 1h at RT protected from 
light, followed by a washing step with PBS. 
• Mounting: The samples were placed on the top of an adhesion microscope 







3.7 Quantitative fluorometric determination of L- and D-lactate 
The successful expression and activity of the novel constructs in cell lines and primary 
cultured astrocytes was tested through a fluorometric enzymatic assay for detection 
of LL (EnzyFluo L-Lactate Assay Kit, BioAssay Systems, EFLLC-100) and DL 
(EnzyFluo D-Lactate Assay Kit, BioAssay Systems, EFDLC-100). These commercial 
assays measure the concentration of LL or DL based on their oxidation by LDH or 
DLDH, respectively, which builds up NADH as by-product. NADH is used by 
diaphorase to reduce a probe to a fluorescent product (Figure 3.3A). The fluorescence 
intensity, which can be detected using a microplate reader, is proportional to the 
concentration of either LL or DL in the sample.   
HEK293 cells were transfected with 0.5-1.5μg/μl of the novel recombinant plasmids 
under the control of either CMV or EF1α promoters using TransIT-293 as previously 
described. Primary cultured astrocytes were transduced with AVVs under the control 
of a sGFAP promoter as described above. Following 2-3 days in the incubator, in 
order to allow for transgene expression to proceed, media were aspirated, and cells 
were rinsed in serum- and antibiotic-free DMEM, followed by the addition of 300µl of 
DMEM per well. The plate was then transferred to the incubator, where HEK293 cells 
were kept for 2h, while an incubation time of 6h was adopted for astrocytes. DMEM 
was harvested and samples which were used to determine DL levels underwent 
deproteination using a 10 kDa spin filter (Microcon-10kDa Centrifugal Filter Unit with 
Ultracel-10 membrane, Merk, MRCPRT010). As recommended by the manufacturer, 
this step was necessary to deplete any potential activity of endogenous LDH enzyme 
that may interfere with DL measurements. The following steps were applied for 
determination of both DL and LL. Samples were diluted 3 to 10 times with distilled 
water and 50µl of the final diluted sample were transferred into a black 96-well plate 
(Greiner Bio-One, 655077). To generate a standard curve that allowed translation of 
fluorescence intensity onto LL or DL concentration, the provided 20mM LL or DL 
Standard was diluted in DMEM to yield 4 different concentrations in a curve ranging 
from 0µM-250µM for LL assay and 0µM-40µM for DL assay (Figure 3.3B and C, 
respectively). 50µl of each LL or DL dilution for the standard curve was transferred 
into the black 96-well plate. For each sample and standard curve well, a reagent mix 
comprised of 40μL of assay buffer, 1μL of enzyme A (lactate dehydrogenase), 1μL of 






and quickly added to the wells. The plate was then tapped gently to mix and incubated 
for 60 min at RT protected from light. Following incubation, fluorescence was 
measured in a microplate reader using wavelength 530nm for excitation and 585nm 
for emission. The concentration of LL or DL in each sample was determined by 
comparison to a calibration curve as follows: 
 
[𝐿𝑎𝑐𝑡𝑎𝑡𝑒](µ𝑀)  =  
𝐹𝑠𝑎𝑚𝑝𝑙𝑒 −  𝐹𝑏𝑙𝑎𝑛𝑘
𝑆𝑙𝑜𝑝𝑒
 × 𝑛 
 
where Fsample and Fblank represent the fluorescence intensity values of the sample and 
0μM LL or DL, respectively. Slope is the slope of the standard curve and n is the 
dilution factor. 
Figure 3.3. Determination of LL and DL concentration in media conditioned by 
transfected HEK293 cells and transduced astrocytes. (A) Lactate oxidation 
reaction catalysed by lactate dehydrogenase results in the formation of NADH, which 
is used by diaphorase to reduce a probe of the EnzyFluo LL or DL Assay Kit into a 






reader is proportional to the concentration of LL or DL in the sample. (B) Example of 
a LL standard curve from a single assay in culture media (slope = 0.160, R2 = 0.99). 
(C) Example of a DL standard curve from a single assay in culture media (slope = 
0.957, R2 = 1). 
 
3.8 L-lactate amperometry 
Real-time determination of LL levels in organotypic brainstem slices was performed 
using amperometric enzymatic LL biosensors (Sarissa Biomedical, UK, SBS-LAC-05-
50). The potential at the electrode surface was controlled by a potentiostat (Duo-Stat 
ME200+) and the signal detected was further processed and analysed using a 1401 
interface and Spike 2 software (Cambridge Electronic Design, UK). In order to 
minimize the effects of any non-specific electroactive interference, a null sensor 
(Sarissa Biomedical, UK, SBI-NUL-05-50) lacking the enzymatic layer was used as a 
control in the amperometric recordings in conjunction with the LL biosensor in a dual 
recording configuration scheme (Figure 3.4A). Both electrodes were placed in contact 
with the surface of the slice and the null sensor currents were automatically subtracted 
from the LL biosensor currents using Spike 2 software. An Ag/AgCl2 reference 
electrode was connected to the potentiostat and acted as an earth.  
For recordings, slices transduced with appropriate AVVs were removed from the 
incubator, excised from the membrane, and transferred to the recording chamber of 
the amperometry set up, which was continuously superfused with HEPES-buffered 
solution (HBS) (Table 3.5) at a rate of 2.5 ml/min. To immobilise the slice under the 
flow in the chamber, a small horse-shoe-shaped weight holding nylon threads was 
placed on top of the slice. Null and LL biosensor were removed from the storage pot 
kept in the fridge at 4ºC in HBS and immediately connected to the electrode holders, 
which were attached to micromanipulators mounted on magnetic bases. Electrodes 
were then rapidly placed under the flow in the chamber since dryness of electrodes 
can compromise their sensitivity. Prior to the recordings, electrodes were allowed to 
stabilize their baseline for at least 30 min and the current was set to zero in order to 
remove any background noise. With the aid of a stereomicroscope (GSZ 2, Germany), 
null and LL biosensors were inserted into a region of the slice containing transduced 
noradrenergic neurones. Electrodes were then allowed to settle until the LL tone was 






fairly constant. Drugs were delivered to the chamber using an infusion pump at a rate 
of 3ml/hour. To calibrate the electrodes, known amounts of LL were applied in the 
chamber at the beginning and at the end of each recording. The values were averaged 
and used to convert the biosensor currents to LL concentration (Figure 3.4B). All 
pharmacological substances used in this experiment were first tested for their ability 
to be detected by the LL biosensor system, which confirmed the electrodes to be 
selectively sensitive to LL only. 
Figure 3.4. Measurement of extracellular LL levels with LL sensors and 
constant-potential amperometry. (A) Schematic depicting the amperometric setup 
for recordings with LL sensors. LL and null sensors were placed in direct contact with 
the tissue in a chamber under constant flow. A constant voltage of +500mV vs 
AgCl/Ag reference was applied and controlled through a potentiostat (brown box in 
the figure). (B) Example of a calibration curve of a LL electrode determined while off-
slice. 
Table 3.5. Chemical constituents of HBS. For preparation of 1 litre of the buffer, 
25ml of each 40x concentrated stock solution were added to a beaker and the volume 












COMPONENT CONCENTRATION (mM) 
NaCl 137 






HEPES (free acid) 10 






3.9 Confocal imaging  
Confocal images from live dissociated astrocytes and organotypic brain slices were 
obtained using upright Leica SP1 and SP5 confocal laser scanning microscopes with 
10x, 25x or 40x water immersion objective lenses. For imaging experiments, primary 
cultured astrocytes were seeded onto sterile glass coverslips, which were directly 
placed into a recording chamber mounted on the confocal microscope (Figure 3.5). 
Organotypic slices, on the other hand, were excised from the membrane using a 
sterile scalpel and instantly transferred to the recording chamber. The chamber 
temperature was kept at 32.5 ± 1ºC and the coverslips were continuously superfused 
with HBS (Table 3.5) with pH 7.4 at a rate of 2.5 ml/min. An infusion pump coupled to 
the chamber was used to deliver drugs for experimentation at a rate of 3ml/hour. The 
pair of fluorophores used in the FRET imaging experiments were excited with the 
458nm line of an Argon ion laser. Cyan fluorescent protein (CFP) emission was 
detected at wavelength 465-500nm, while yellow fluorescent protein (YFP) emission 
was collected at wavelength 515-595nm. Other variants of GFP were excited with 
488nm line of the Argon ion laser and the red fluorescent protein tdTomato was 
excited with 561nm of yellow laser. Leica Software in time-lapse mode was employed 
to record the fluorescence intensity dynamics over time, such as in FRET imaging 
experiments. In these cases, 512x512 resolution images were taken every 3 or 4 
seconds in xyt mode. Images were quantitatively analysed using the quantifying tool 
of Leica software and the data were exported to Excel and GraphPad Prism software 
for further statistical analyses. Note that once the ideal pinhole and photomultiplier 
tube (PMT) were defined for each of the fluorophores of the FRET sensors, these 
parameters were kept the same throughout the study. 
In order to obtain high resolution confocal images, 1024x1024 resolution stack images 
were obtained in xyz series, in which approximately 4 images per confocal plane were 







Figure 3.5. Imaging setup in an upright SP5 confocal. (A) Leica SP5 confocal with 
integrated imaging stage, which contains: 1 – heating device; 2 – perfusion cylinder; 
3 – recording chamber. Arrows show the direction of HBS flow through polyethylene 
tubing. (B) Magnified image of the chamber where astrocytes seeded on coverslips 
and brainstem cultured slices were placed for imaging under continuous superfusion 
with HBS using water immersion objective lenses. 
 
3.9.1 Imaging of Laconic and Pyronic  
Primary cultured astrocytes at a concentration of 2x105 cells/ml were seeded onto 
collagenised (Sigma, C3867) and sterile 13mm glass coverslips placed into a 24-well 
plate. AVVs driving the expression of the FRET sensors Laconic or Pyronic (AVV-
CMV-Laconic or AVV-CMV-Pyronic, respectively) were directly added to the culture 
media at the time of plating. Wherever appropriate, co-transduction with the novel 
molecular tools was performed at the same time. Following 2-3 days incubation at 
37ºC in 5% CO2, coverslips were transferred to the recording chamber and images 
were taken as described above. At the end of the recordings, cells in the field of view 
were selected as region of interest and the fluorescence intensity of the two FRET 
fluorophores was computed by the Leica software over time. For analysis, the FRET 
ratio (mTFP/Venus) was calculated and the average ratio between 0 to 150 seconds 
was set as the baseline. The FRET ratio at each time point was then divided by the 







4.9.2 Imaging of CNiFERs  
CNiFERs (see Chapter 2, section 2.3.1.3) were employed in order to evaluate the 
effect of the LL-limiting tools on LL-induced NA release (Mosienko et al., 2018; Muller 
et al., 2014). Organotypic brainstem slices containing the LC were transduced with 
AVV-PRSx8-eGFP in order to visualize noradrenergic neurones. Co-transduction with 
AVVs carrying the expression of the LL-limiting tools to astrocytes were performed 
whenever appropriate. Release of NA was recorded following a protocol previously 
described in Mosienko et al. (2018). One day prior to the recordings, 25µl of CNiFERs 
resuspended in Optimem+ plating media at a concentration of 4x105 cells/ml were 
plated on top of each cultured slice (Figure 3.6). Following overnight incubation at 
37ºC in 5% CO2, the slices were excised from the membrane and placed in the 
recording chamber of the SP5 confocal microscope, which was continuously 
superfused with HBS (Table 3.5). Each slice received a first application of 2mM LL 
(Sigma, L1750) to evoke NA release from LC neurones (Tang et al., 2014), followed 
by a second application of pyruvate 10mM (Alfa Aesar, A11148). At the end of the 
recordings, changes in CNiFERs FRET ratio (Citrine/CFP) over time were calculated 
and NA release was quantified by analysing the area under the FRET emission curve. 
NA released by the pyruvate-induced LL release was normalised to the response 
triggered by the application of LL 2mM in each cultured slice. Statistical significance 
was assessed using paired Student’s t-test, which compared the response from the 
application of LL 2mM to the response evoked by the application of pyruvate 10mM. 
Figure 3.6. Measurement of NA release with the cell-based neurotransmitter 
fluorescent engineered reporter (CNiFER) system. Schematic of NA-sensitive 
CNiFERs cells seeded on a cultured brainstem slice preparation containing 






image stack. Scale bar 100µm. Note that even though both noradrenergic neurones 
and CNiFERs express green fluorescence, their depth in the tissue and shape make 
it straightforward to distinguish between these 2 cells types. 
 
3.10 Statistical analyses  
Data were compared using One-way ANOVA followed by Bonferroni's Multiple 
Comparison post hoc test, or Student’s t-test paired or unpaired as indicated. 
Calibration curves were analysed by linear regression. Values are presented as 
average ± standard deviation and plotted in box and whisker diagrams. The edges of 
the boxes illustrate the upper and lower quartile values, the central horizontal line 
defines the median, the central plus sign represents the mean, and whiskers indicate 
the minimum and maximum range of the data. Statistical tests were performed using 
GraphPad Prism 5 and 8. Statistical difference of p<0.05 between the experimental 














Chapter 4 – Interfering with L-lactate signalling 






4.1 Metabolic and signalling functions of astrocytic L-lactate 
Understanding the metabolic and signalling interactions between neurones and 
astrocytes requires the employment of tools that monitor and/or modulate their 
intrinsic physiological activity. Although pharmacological approaches have been long 
available and are unquestionably valuable for neuroscience research, their effects are 
generally transitory. Comprehension of the role of an endogenous compound in the 
modulation of aspects of brain function requires, therefore, genetic tools that change 
its dynamics in specific brain cells long-term. LL, in particular, which in the brain is 
considered to be derived mainly from astrocytes, has attracted increasing attention 
due to its signalling roles and the consequent implications in many brain activities. 
Moreover, LL levels respond dynamically to neuronal activity and metabolic needs 
and may act as an additional energy supply to neurones during periods of high activity. 
Nonetheless, research in this field lacks the means to selectively manipulate 
astrocyte-derived LL for further investigation of its actions in the brain.  
In order to explore how astrocytic LL supply contributes to central network function, 
we have developed molecular tools to reduce LL pool size selectively in astrocytes. 
These tools aim to chronically limit the effects of astrocyte-derived LL by restricting 
the availability of this compound in the brain, rather than directly interfering with 
astrocytic LL production and release. For this purpose, we have identified bacterial 
enzymes that use LL as a substrate for irreversible reactions. We postulated that, 
once expressed specifically in astrocytes, enzymatic activity may decrease LL 
concentration in these cells and, consequently, constitutive and reactive LL release 
to the extracellular space and its action on neuronal cells.   
This chapter will explore the construction and in vitro validation of novel molecular 
tools based on bacterial enzymes to decrease LL concentration specifically in 
astrocytes. Preliminary results on the effects of one of these novel tools in vivo in 
collaboration with Professor Mikhail Pletnikov at Johns Hopkins University and Dr. 







4.2 L-lactate breakdown by bacterial enzymes 
In order to thrive under conditions of limited oxygen, microorganisms have developed 
fermentation for generation of energy, in which glucose is metabolised to pyruvate 
that can be further processed to either LL or ethanol (Berg et al., 2002). This high 
capacity of bacteria to handle LL led us to search in these microorganisms for 
enzymes that are specialized in breaking down LL irreversibly. We have identified 2 
different bacterial enzymes that catalyse reactions using LL as substrate: L-lactate 
oxidase (LOX; E.C. 1.1.3.15) and L-lactate 2-monooxygenase (LMO; 1.13.12.4). 
Although these enzymes are expressed in many bacteria, we selected the species 
whose activity of LOX and LMO were better described: Aerococcus viridans for LOX 
and Mycobacterium smegmatis for LMO.  
These two microbial enzymes, once adapted to mammalian codon preference, were 
expressed selectively in astrocytes in order to inhibit astrocyte-derived LL effects in 
the brain. 
 
4.2.1 L-lactate oxidase  
LOX from the bacterium Aerococcus viridans has been widely employed in the 
production of biosensors, which are used to detect and quantify LL concentration for 
a range of purposes, including clinical diagnoses, food quality control, and sports 
medicine (Hiraka et al., 2018).  
LOX is a flavoenzyme that catalyses the FMN-dependent oxidation of LL. Molecular 
oxygen is used in the oxidation reaction, which yields pyruvate and hydrogen peroxide 
as products (Figure 4.1). An intermediate species is formed between the oxidized and 
reduced forms of LOX, indicating that the reaction process does not occur in one step 
(Maeda-Yorita et al., 1995). Indeed, LOX firstly catalyses the oxidation of LL into 
pyruvate by reducing FMN, which in turn is reoxidized by molecular oxygen. The latter 
compound functions as an electron acceptor, which culminates in the production of 
hydrogen peroxide (Maeda-Yorita et al., 1995). It is important to note that pyruvate is 
released very rapidly from the reduced enzyme-pyruvate complex, a feature that 






analysis revealed that LOX is a tetramer enzyme that reacts specifically with the L-
isomer of lactate (Umena et al., 2006). Although DL can also bind to the active site of 
LOX, the opposite chirality of this molecule is not ideally accommodated by the 
enzyme and, as a consequence, it does not trigger the enzymatic reaction. Therefore, 
DL may act as a LOX inhibitor (Furuichi et al., 2008). 
 
Figure 4.1. Reaction catalysed by LOX. Using molecular oxygen as co-substrate, 
LL is oxidized by LOX, generating pyruvate and hydrogen peroxide.   
 
De Bari et al. (2010) suggested the existence of a putative flavin-dependent LOX in 
the intermembrane space of purified rat liver mitochondria. According to the study, 
addition of LL to peroxisome-free mitochondrial samples evoked oxygen consumption 
as well as production of pyruvate and hydrogen peroxide in a 1:1 stoichiometry (de 
Bari et al., 2010). The authors also suggested that the process was independent of 
the respiratory chain since application of respiration inhibitors did not disrupt hydrogen 
peroxide generation (de Bari et al., 2010). Nonetheless, taking into consideration that 
a LOX sequence has not been identified yet in the mitochondrial genome and little is 
known about the enzymatic properties of the putative mammalian LOX, we decided 



































4.2.2 L-lactate 2-monooxygenase 
Another bacterial enzyme which breaks down LL in an irreversible manner is LMO, 
which catalyses the FMN-dependent oxidation reaction of LL into acetate, carbon 
dioxide and water (Figure 4.2).  
 
Figure 4.2. Reaction catalysed by LMO. Using molecular oxygen as co-substrate, 
oxidation of LL by LMO irreversibly generates acetate, carbon dioxide and water. 
 
The LMO enzymatic reaction shares many properties with that of LOX, including the 
oxidation of LL at the expense of flavin cofactor reduction. Accordingly, LL oxidation 
in the first half-reaction of LMO forms the reduced enzyme-pyruvate complex (Maeda-
Yorita et al., 1995). However, in contrast with LOX, the intermediate species in the 
LMO reaction is highly stable, which makes the pyruvate dissociation from the 
reduced enzyme complex a markedly slower process (Maeda-Yorita et al., 1995). Due 
to this higher kinetic stability, the reaction of the reduced enzyme-pyruvate complex 
with the co-substrate molecular oxygen culminates in pyruvate decarboxylation 
(Maeda-Yorita et al., 1995). The differences between the overall reactions catalysed 
by LOX and LMO relies, therefore, on the stability of a common intermediate species. 
While oxidation of LL by LOX is a very fast reaction, LMO catalyses the dissociation 
of LL approximately 7000-fold slower than LOX (Maeda-Yorita et al., 1995). 
 
4.3 Construction of LOX- and LMO-carrying recombinant plasmids 
Expression of enzymes of microbial origin in mammalian astrocytes required 
adaptation of the DNA sequence to mammalian codon usage. This is because 
different organisms are biased towards employment of particular codons over others 
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for the same amino acid. Therefore, to improve the yield of gene expression, the 
bacterial DNA sequence was optimised for the codon that is more frequently used by 
mammals (human or rodent). Codon optimization was performed by the company the 
enzymes sequences were ordered from (Invitrogen, USA, for both LOX and LMO) 
using provided amino acid sequence input.  
Different regulatory elements were included in the expression cassettes, depending 
on the cell type targeted for gene expression. For some applications, a 
transcriptionally enhanced fragment of GFAP (sGFAP) promoter was employed in 
order to selectively drive expression of the enzymes in astrocytes (Liu et al., 2008). 
For gene transcription in a wider range of cell types, e.g. HEK293 cells, the CMV 
promoter was used. To enable visualization of the transgene-expressing cells, a 
sequence of inert fluorescent protein – either EGFP or tdTomato – was also included 
in the expression cassette, 3’ of an internal ribosome entry site (IRES). The IRES 
element enables translation initiation, allowing independent translation of the 
microbial enzyme and the fluorescent protein, while, at the same time, both ORFs are 
regulated by the same promoter. 
Once constructed, the recombinant plasmids or AVVs driving the expression of either 
LMO or LOX were used for transfection or transduction of a mammalian cell line, 
primary cultured astrocytes, or organotypic brainstem slices for testing purposes. 
 
4.3.1 pCMV-LOX-IRES-EGFP 
The mammalianised ORF sequence of LOX from Aerococcus viridans, preceded by 
a Kozak sequence, was first cloned under the control of the promiscuous promoter 
CMV to form the recombinant plasmid pCMV-LOX-IRES-EGFP. The CMV promoter 
was required in the initial stages of this project to test if the enzyme was functionally 
active in the mammalian cell line HEK293, swapping to sGFAP promoter for astrocyte-
selective expression and proceeding with the time-consuming process of AVV 
production. The LOX sequence was received in a pMA-T vector backbone and 
subjected to a double-digestion with the restriction enzymes BglII & PstI so that the 
DNA fragment of the gene of interest received sticky ends, allowing its ligation with 






pCMV-GPR4-IRES-EGFP, for which restriction digestion with the enzymes BglII & 
PstI resulted in the removal of GPR4 sequence from the cassette and made it suitable 
to be replaced by LOX. Subsequent ligation of 5.0kb DNA fragment of the vector 
backbone with 1.1kb DNA fragment from the insert formed the recombinant plasmid 
pCMV-LOX-IRES-EGFP (Figure 4.3A). Assessment of the plasmid sequence through 
diagnostic digests with BstBI as well as SalI & NheI confirmed a correct outcome 
(Figure 4.3B), which was further proven by sequencing (Eurofins MWG) using the 
following primers: CMV forward (ATGGGCGGTAGGCGTGTA) and IRES reverse 
(CCAAGTCAGTGGCTGCAC). In silico alignment of the DNA sequence of the novel 
recombinant plasmid using Vector NTI showed the expected outcome. 
 
Figure 4.3. Construction of pCMV-LOX-IRES-EGFP. (A) Vector map of the 
recombinant plasmid carrying LOX (Loxav) and EGFP under the control of a CMV 
promoter. (B) Gel electrophoresis image of the diagnostic restriction digestion with 







Another variant of LOX recombinant plasmid containing sGFAP as the astrocyte-
selective promoter and tdTomato as a RFP was cloned into a pXCX adenoviral vector 
shuttle plasmid (Bett et al., 1994). Changing from EGFP to RFP was necessary to 
avoid interference with emission spectrum of FRET sensors. Among the RFPs 
available, TdTomato was employed because it has been shown to exhibit increased 
stability and fluorescence intensity (Shaner, Patterson, & Davidson, 2011). LOX and 
IRES sequence were isolated from the newly constructed pCMV-LOX-IRES-EGFP by 
restriction digestion with the enzymes BstBI & AgeI, generating an insert fragment of 
1.5kb. The same restriction digestion was carried out on pXCX-sGFAP-DLDH-IRES-
tdTomato, which resulted in an 11.4kb vector backbone fragment. Ligation of both 
vector and insert created the recombinant plasmid pXCX-sGFAP-LOX-IRES-
tdTomato (Figure 4.4A), which underwent diagnostic restriction digestion with the 
enzyme EcoRV (Figure 4.4B) and subsequent sequencing (Eurofins MWG) using 
specific primers to IRES (IRES forward: CCACTCATCTTATAGCTTTC, and IRES 
reverse: CCAAGTCAGTGGCTGCAC) and a forward GFAP primer 
(ATGGGTGAGGGGAGAGCT). The pattern of bands from the restriction digestion 
matched the one predicted by the sequence of the recombinant plasmid. 
Figure 4.4. Construction of pXCX-sGFAP-LOX-IRES-tdTomato. (A) Vector map of 
the recombinant plasmid carrying LOX (Loxav) and tdTomato under the control of a 
sGFAP promoter. (B) Gel electrophoresis image of the diagnostic restriction digestion 








To generate a construct driving the expression of LMO, similar cloning strategies as 
used to produce LOX recombinant plasmids were employed. Firstly, the 
mammalianised ORF sequence of LMO from Mycobacterium smegmatis on a pMA-T 
vector backbone as well as the precursor vector backbone pCMV-IRES-eGFP were 
double-digested with the endonucleases BglII & PstI to generate sticky ends in their 
DNA sequence. The 1.2kb and 5.0kb resultant fragments of insert and vector, 
respectively, were ligated together to form the novel recombinant plasmid pCMV-
LMO-IRES-EGFP (Figure 4.5A). In order to analyse the clone, diagnostic restriction 
digestions with the enzymes XhoI & NotI, XhoI & NotI and PvulI were performed, 
yielding the expected bands (Figure 4.5B). Moreover, the partial DNA sequence using 
specific primers for CMV promoter (forward: ATGGGCGGTAGGCGTGTA) and IRES 
(reverse: CCAAGTCAGTGGCTGCAC) aligned with the expected sequence. 
 
Figure 4.5. Construction of pCMV-LMO-IRES-EGFP. (A) Vector map of the 
recombinant plasmid carrying LMO (LMOmsm) and EGFP under the control of a CMV 
promoter. (B) Gel electrophoresis image of the diagnostic restriction digestion with 









To generate a recombinant plasmid driving the expression of LMO and tdTomato 
specifically in astrocytes, both LMO and IRES sequences were isolated from pCMV-
LMOmsm-IRES-EGFP through restriction digestion with the enzymes BstBI & AgeI, 
yielding an insert fragment of 1.6kb. For the vector backbone, pXCX-sGFAP-DLDH-
I-tdTomato was digested with the same restriction enzymes as the insert, which 
yielded a fragment of 11.4kb. Vector and insert fragments were ligated together, 
generating the recombinant plasmid pXCX-sGFAP-LMO-IRES-tdTomato (Figure 
4.6A). Based on the digestion pattern using the endonucleases SalI and EcoRV, the 
clone sequence was found accurate (Figure 4.6B). The recombinant plasmid was also 
partially sequenced by Eurofins MWG using specific primers to IRES (forward: 
CCACTCATCTTATAGCTTTC, and reverse: CCAAGTCAGTGGCTGCAC) and to 
GFAP promoter (forward: ATGGGTGAGGGGAGAGCT). 
 
 
Figure 4.6. Construction of pXCX-sGFAP-LMO-IRES-tdTomato. (A) Vector map 
of the recombinant plasmid carrying LMO (LMOmsm) and tdTomato under the control 
of a sGFAP promoter. (B) Gel electrophoresis image of the diagnostic restriction 






4.4 Functional validation of LOX and LMO expression in vitro 
In order to functionally validate the novel constructs, recombinant plasmids or AVVs 
carrying the expression cassettes for LOX or LMO were transfected or transduced 
into a mammalian cell line, primary cultured astrocytes and organotypic brain slices. 
A range of functional tests in vitro were then carried out in order to assess the capacity 
of these bacterial enzyme-based molecular tools for viable expression and functional 
activity in mammalian cells. Once the basic functionality was confirmed, validation 
experiments also elucidated metabolic and signalling effects of the decreased 
astrocytic LL pool that resulted from expression of the LL catabolic enzymes. 
 
4.4.1 LOX and LMO of bacterial origin are expressed in mammalian cells  
Activity of the promoters used to drive the expression of the bacterial enzymes was 
assessed through the expression of the reporter gene. Transfection of HEK293 cell 
line with 1.0 µg/µl of pCMV-LOX-IRES-EGFP or pCMV-LMO-IRES-EGFP resulted in 
adequate levels of green expression when examined under an epifluorescence 
microscope (Figure 4.7), indicating that these cassettes can be successfully 
expressed in mammalian cells. 
Figure 4.7. LOX- and LMO-transfected HEK293 cells express the reporter gene 
EGFP. (A) Domain structure of the cassette for expression of LOX in cell lines. Below: 







expression of LMO in cell lines. Below: HEK293 cells expressing the construct. Scale 
bars: 100μm. 
 
On the other hand, primary dissociated cultured astrocytes or astrocytes in 
organotypic brainstem slices either did not exhibit any detectable red fluorescence or 
exhibited it at very low levels when transduced with AVV-sGFAP-LOX-IRES-
tdTomato or AVV-sGFAP-LMO-IRES-tdTomato. Considering that researchers have 
consistently reported lower expression levels of the ORF downstream of the IRES 
element (Jang et al., 1988; Kaufman, Davies, Wasley, & Michnick, 1991), which in our 
case is the fluorescent protein, we performed immunohistochemistry staining using 
RFP antigen in an attempt to amplify any tdTomato signal. Results confirmed 
tdTomato expression in astrocytes in both primary culture and organotypic brain slices 
transduced with AVV-sGFAP-LOX-IRES-tdTomato (Figure 4.8) and AVV-sGFAP-







Figure 4.8. LOX-transduced astrocytes express the reporter gene tdTomato. 
Domain structure of the cassette for expression of LOX in astrocytes through AVV. 
Below: Confocal stacks showing (a) dissociated astrocytes, scale bar 80µm; and (b 
and c) astrocytes in organotypic slice culture expressing the construct, scale bar 
25µm. Signal of the reporter gene has been amplified by anti-RFP staining with Alexa 
488 (green) for dissociated astrocytes and Alexa 594 (red) for astrocytes in 
organotypic slice culture. 
Figure 4.9. LMO-transduced astrocytes express the reporter gene tdTomato. 
Domain structure of the cassette for expression of LMO in astrocytes through AVV. 
Bellow: Confocal stacks showing (a) dissociated astrocytes, scale bar 100µm; and (b, 
c and d) astrocytes in organotypic slice culture expressing the construct, scale bar 
50µm, 15µm, and 10µm, respectively. Signal of the reporter gene has been amplified 








by anti-RFP staining with Alexa 488 (green) for dissociated astrocytes and Alexa 594 
(red) for astrocytes in organotypic slice culture. 
 
4.4.2 Analysis of astrocytic viability following expression of LOX and LMO 
Expression of foreign gene products, interference with astrocytic metabolic pathways, 
as well as by-products of the enzymatic processes can potentially lead to harmful 
consequences for cells. Since it was the aim of this project to develop tools for use in 
physiological contexts in vitro and in vivo, it was important to establish and avoid 
potential toxicity of the constructs. A range of MOIs of AVV-sGFAP-LOX-IRES-
tdTomato and AVV-sGFAP-LMO-IRES-tdTomato were used to transduce primary 
cultured astrocytes, whose morphology and density were daily examined for signs of 
deterioration. Visual assessment by microscope did not reveal any anatomically 
distinguishable abnormalities in the cells at lower MOIs. Viability assays were 
performed in order to determine the range of safe MOIs to be used in future functional 
experiments. 
Cell death was assessed through Trypan Blue exclusion assay, which, as previously 
described, consists of an impermeable blue dye that can only cross cellular 
membranes that are damaged as a result of cell death (for details, see Chapter 3, 
section 3.4.3.2.1). Viability of cultured primary astrocytes was tested 3 days following 
transduction with AVV-sGFAP-LOX-IRES-tdTomato and AVV-sGFAP-LMO-IRES-
tdTomato. Two control conditions were used: non-transduced astrocytic cultures and 
cultures transduced with the control vector AVV-sGFAP-EGFP, which drives the 
expression of the well tolerated green fluorescent protein. The Trypan Blue assay 
indicated that AVV transduction per se, in the range of MOIs used, did not change 
viability of astrocytes (Figure 4.10). Moreover, comparison of the percentage of viable 
astrocytes expressing the control AVV with astrocytes transduced with either AVV-
sGFAP-LOX-IRES-tdTomato or AVV-sGFAP-LMO-IRES-tdTomato at MOI 15 
confirmed absence of any significant effect on cell viability under these conditions. 
However, transduction of astrocytes with AVV-sGFAP-LOX-IRES-tdTomato and 
AVV-sGFAP-LMO-IRES-tdTomato at MOI 50 resulted in a substantial decrease in the 
percentage of viable astrocytes, as compared to astrocytes transduced with the same 






Figure 4.10. Effect of LOX and LMO expression on the viability of primary 
cultured astrocytes as measured with Trypan Blue exclusion assay. Non-
transduced astrocytes (no AVV) and astrocytes transduced with AVV-sGFAP-EGFP 
(Control), AVV-sGFAP-LOX-IRES-tdTomato (LOX) or AVV-sGFAP-LMO-IRES-
tdTomato (LMO) at MOIs 15 and 50 were compared with regard to the % of viable 
cells. No changes were observed between no AVV (90.0±5.9%, n=6) and Control at 
all MOIs tested (15: 89.0±3.9%, n=5; 50: 86.0±6.6%, n=6). LOX and LMO at MOI 15 
did not evoke significant astrocytic cell death (82.8±9.4%, n=6, and 81.4±7.4%, n= 5, 
respectively) as compared with Control. LOX and LMO at MOI 50 significantly 
decreased the % of viable astrocytes (42.3±15.7%, n=5, and 44.6±9.6%, n=5, 
respectively) as compared to Control. ANOVA (Bonferroni's Multiple Comparison 
Test) was used to compare: 1) against No AVV the effects of MOIs 15 and 50: Non-
significant (ns) - p>0.05 (MOI 15 and MOI 50); 2) against Control the effects of LOX 
and LMO at MOIs 15 and 50. MOI 15: ns - p>0.05 (LOX and LMO); MOI 50: *** - 
p≤0.0001 (LOX and LMO). Data pooled from independent experiments. 
 
Although Trypan Blue exclusion assay is one of the simplest and most routinely 
employed procedures to assess cell viability, it has limited sensitivity for detecting 
early damage to cell function. Therefore, in addition, we used the more sensitive XTT 
cell viability assay, which takes into consideration that viable cells express 
dehydrogenase enzymes, which reduce XTT tetrazolium salt to the bright and soluble 
product formazan, as detailed in chapter 3, section 3.4.3.2.2. These enzymes are 
inactivated shortly after cell death, decreasing the absorbance readout from the 
formazan product. Results from XTT assay confirmed that employment of AVV as a 































Astrocytic viability was only significantly decreased with transduction of AVV-sGFAP-
LMO-IRES-tdTomato at MOI 50 (Figure 4.11). 
 
Figure 4.11. Effect of LOX and LMO expression on the viability of primary 
cultured astrocytes as measured with XTT assay. Non-transduced astrocytes (no 
AVV) and astrocytes transduced with AVV-sGFAP-EGFP (Control), AVV-sGFAP-
LOX-IRES-tdTomato (LOX) or AVV-sGFAP-LMO-IRES-tdTomato (LMO) at MOIs 5, 
15 and 50 were compared with regard to the cell viability. No changes were observed 
between No AVV (0.73±0.06AU) and Control at all MOIs tested (5: 0.84±0.20AU; 15: 
0.84±0.17AU; 50: 0.86±0.23AU). LOX and LMO at MOIs 5 and 15 did not alter cell 
viability (LOX - MOI 5: 0.76±0.15AU, MOI 15: 0.74±0.16AU; LMO - MOI 5: 
0.77±0.16AU, MOI 15: 0.77±0.15AU) as compared with Control. At MOI 50, LOX 
decreased cell viability (0.54±0.18AU), while LMO showed a trend towards a cytotoxic 
effect (0.63±0.19AU). ANOVA (Bonferroni's Multiple Comparison Test) was used to 
compare: 1) against No AVV the effects of Control at MOIs 5, 15 and 50: ns - p>0.05; 
2) against Control the effects of LOX and LMO at MOIs 5, 15 and 50. MOI 5 and MOI 
15: ns - p>0.05 (LOX and LMO); MOI 50: ** - p<0.01 (LOX), ns - p>0.05 (LMO). N=6 
(No AVV) and N=9 (Control, LOX and LMO). Data pooled from independent 
measurements. 
 
Since both viability assays revealed that transduction of cultured astrocytes with AVV-
sGFAP-LMO-IRES-tdTomato and AVV-sGFAP-LOX-IRES-tdTomato at MOI 15 was 
safe, all the functional experiments carried out to validate these novel constructs were 
performed at MOI 15. 
 































4.4.3 LOX or LMO expression reduces constitutive L-lactate release from 
HEK293 cells and primary cultured astrocytes 
The effect of the expression of the novel molecular tools on constitutive LL release 
was tested in HEK293 cells and primary cultures of dissociated rat astrocytes. LL 
accumulation in culture media was determined using a fluorimetric assay (Chapter 3, 
section 3.7). Following 2 hours of incubation, HEK293 cells transfected with 1µg/µl of 
either pCMV-LOX-IRES-EGFP or pCMV-LMO-IRES-EGFP released 33.2% and 
31.6%, respectively, less LL to the extracellular space as compared to HEK293 cells 
transfected with 1µg/µl of the control vector pCMV-IRES-EGFP (Figure 4.12A). Media 
conditioned for 6 hours by dissociated astrocytes transduced with either AVV-sGFAP-
LOX-IRES-tdTomato or AVV-sGFAP-LMO-IRES-tdTomato showed significantly 
decreased LL levels, to 88.8% and 87.3%, respectively, as compared to AVV-sGFAP-
EGFP-transduced astrocytes (Figure 4.12B). 
Figure 4.12. LOX and LMO expression in HEK293 cells and cultured astrocytes 
decrease constitutive release of LL. (A) Media conditioned for 2 hours by HEK293 
cells transfected with 1µg/µl of pCMV-LOX-IRES-EGFP or pCMV-LMO-IRES-EGFP 
contained lower LL levels (LOX, 300.6±84.2µM, n=9; and LMO, 307.6±91.4µM, n=9, 
respectively)  than media conditioned for the same period by HEK293 cells 
transfected with pCMV-IRES-EGFP (Control, 450.1±41.5µM, n=6). (B) Media 
conditioned for 6 hours by primary cultured astrocytes transduced with AVV-sGFAP-
LOX-IRES-tdTomato or AVV-sGFAP-LMO-IRES-tdTomato presented reduced 
concentration of LL (LOX, 502.4±90.8µM, n=9; and LMO, 493.5±58.1µM, n=8, 
respectively) as compared to media conditioned for the same period by astrocytes 










































Multiple Comparison Test) was used to compare against Control the effect of LOX 
and LMO expression on LL concentration in the culture media (* - p<0.05, ** - p<0.01). 
 
4.4.4 LOX or LMO expression decreases forced L-lactate release from primary 
cultured astrocytes 
Estimation of intracellular LL levels in astrocytes was performed by depletion of the 
cytosolic LL stock through trans-acceleration of MCTs. As detailed in Chapter 1, 
section 1.3.1, trans-acceleration relies on the application of an inward gradient of 
pyruvate (10mM) to trigger MCT-mediated extrusion of LL from the intracellular pool. 
Intracellular levels of LL were monitored with the FRET sensor Laconic 2-3 days 
following transduction of primary dissociated astrocytes with AVV-CMV-Laconic alone 
or in combination with either AVV-sGFAP-LOX-IRES-tdTomato or AVV-sGFAP-LMO-
IRES-tdTomato.  
As expected, bath application of pyruvate [10mM] evoked a substantial drop in the 
intracellular concentration of LL in primary cultured astrocytes (Figure 4.13A).  By 
measuring the intracellular LL dynamics with Laconic and the relative drop in LL levels 
following its depletion by application of pyruvate [10mM], we estimated the initial 
resting levels of LL in astrocytes. Trans-acceleration-induced LL depletion was 
significantly decreased in LOX- and LMO-expressing astrocytes as compared to 
control cells (Figure 4.13B). This reduced decrease in LL release is in agreement with 






Figure 4.13. Forced LL release is decreased in LOX- and LMO-expressing 
astrocytes. (A) Estimation of cytosolic LL release using Laconic and a trans-
acceleration protocol showed modest LL release from LOX- and LMO-expressing 
astrocyte as compared to the substantial intracellular LL drop in control cells following 
application of pyruvate [10mM]. Trace represents average Laconic FRET ratio of 
astrocytes expressing AVV-CMV-Laconic alone (Control, n=62) or in combination with 
either AVV-sGFAP-LOX-IRES-tdTomato (LOX, n=53) or AVV-sGFAP-LMO-IRES-
tdTomato (LMO, n=52). Data pooled from 7 (Control) and 6 (LOX and LMO) 
independent experiments. Shaded regions around the trace represents SEM. (B) 
Pooled data for the average Laconic FRET ratio from 300 to 500 seconds to the 
extrusion of LL with pyruvate [10mM] as compared with the baseline (Control: -
16.1±5.1%; LOX: -5.0±4.9%, LMO: -10.1±5.0%). ANOVA (Bonferroni’s Multiple 
Comparison Test) was used to compare against Control the effect of LOX and LMO 
expression on Laconic FRET ratio (*** - p<0.0001). 

























































































4.4.5 Expression of LOX or LMO changes the handling of metabolites by 
astrocytes 
Production and/or release of LL from astrocytes can be triggered by a range of stimuli. 
Since LL that has been newly produced can be almost simultaneously released from 
astrocytes, the intracellular LL dynamics reflect the sum of both, glycolytic flux and LL 
release. We, therefore, blocked the efflux of LL through MCT1, the major extrusion 
route in astrocytes, in order to reveal potential effects of LOX or LMO expression on 
the glycolytic state of primary cultured astrocytes. 2-3 days following AVV 
transduction, MCT1 was inhibited with AR-C155858 [1µM] and intracellular LL and 
pyruvate accumulation was monitored with the FRET sensors Laconic and Pyronic, 
respectively.   
Blockade of MCT1 increased intracellular concentration of LL, indicating that this 
carrier is essential for constitutive release of LL (Figure 4.14). The level of intracellular 
LL accumulation upon MCT1 blockade reached a plateau. To investigate whether this 
plateau corresponds to the saturation of the FRET sensor LACONIC, LL [10mM] was 
co-applied. Interestingly, LL penetrated the cell probably via MCT4 or other less 
characterized pathways and evoked a further increase in Laconic FRET ratio (Figure 
4.14).  
Figure 4.14. MCT1 is essential for constitutive release of LL. Time course of the 
average Laconic FRET ratio upon application of the MCT1 inhibitor AR-C155858 
[1µM] (from 100s to 820s) and LL [10mM] (from 480s to 820s) in primary cultured 
astrocytes expressing AVV-CMV-Laconic. The plateau in LL level which developed 





































following AR-C155858 application was not due to reporter saturation. Data pooled 
from 13 astrocytes from a single recording. Shaded regions around the trace 
represents SEM. 
 
Once MCT1 had been checked for its ability to block constitutive LL release, we then 
investigated the rate of LL accumulation in primary cultured astrocytes upon blockade 
of MCT1 with AR-C1555858 [1µM] in LOX- and LMO-expressing astrocytes. We 
employed a linear least-square fitting approach to stablish the line of best fit and 
slopes relative to the linear part of the rising slope, which reflects the rate of LL 
production (280-600s in Control, 200-550s in LOX, and 330-650s in LMO) (Figure 
4.15A).The rates of LL accumulation in LOX- or LMO-expressing astrocytes were not 
significantly different from that in control astrocytes, although LMO-expressing 
astrocytes showed a slight trend towards a decreased LL accumulation rate (Figure 
4.15B). 
 
Figure 4.15. LOX- or LMO-expression does not change the rate of LL 
accumulation in astrocytes. (A) Time course of the average Laconic FRET ratio 
upon MCT1 inhibition with AR-C155858 [1µM] in primary cultured astrocytes 
transduced with AVV-CMV-Laconic alone (Control, n=59) or in combination with either 
AVV-sGFAP-LOX-IRES-tdTomato (LOX, n=37) or AVV-sGFAP-LMO-IRES-tdTomato 
(LMO, n=46). The dotted red lines are the slopes of LL accumulation fitted by linear 
regression. Data pooled from 3 independent experiments. Shaded regions around the 
trace represents SEM. (B) Pooled data for the rate of LL production suggested no 
significant difference in astrocytes expressing LOX (4.0±1.2 x10-4 ΔF/s) and LMO 
(3.3±1.9 x10-4 ΔF/s)  as compared to control astrocytes (3.9±1.5 x10-4 ΔF/s). ANOVA 



























































(Bonferroni’s Multiple Comparison Test) was used to compare against Control the 
effect of LOX and LMO expression on the rate of LL accumulation. ns – p>0.05. 
 
On the other hand, analysis of the time course of Pyronic FRET ratio upon MCT1 
blockade with AR-C155858 [1µM] suggested that the rate of pyruvate build-up in the 
astrocytic cytosol was reduced in both LOX- and LMO-expressing astrocytes as 
compared to control astrocytes (Figure 4.16). The line of best fit and slopes were 
calculated using linear least-square fitting method for the linear part of the curve that 
characterizes the rate of pyruvate build-up (370-620s in Control, and 300-900s in LOX 
and LMO). 
 
Figure 4.16. LOX- and LMO-expressing astrocytes display decreased rate of 
pyruvate accumulation. (A) Time course of the average Pyronic FRET ratio upon 
MCT1 inhibition with AR-C155858 [1µM] in primary cultured astrocytes transduced 
with AVV-CMV-Pyronic alone (Control, n=53) or in combination with either AVV-
sGFAP-LOX-IRES-tdTomato (LOX, n=77) or AVV-sGFAP-LMO-IRES-tdTomato 
(LMO, n=69).The dotted red lines are the slopes of pyruvate accumulation fitted by 
linear regression. Data pooled from 3 independent experiments. Shaded regions 
around the trace represents SEM. (B) Pooled data for the rate of pyruvate production 
suggested reduced rate in LOX (2.9±0.8 x10-4 ΔF/s) and LMO (2.6±0.9 x10-4 ΔF/s) 
astrocytes as compared to control astrocytes (7.1±1.2 x10-4 ΔF/s). ANOVA 
(Bonferroni’s Multiple Comparison Test) was used to compare against Control the 
effect of LOX and LMO expression on the rate of LL accumulation. *** - p<0.0001.






























































4.4.6 Astrocytic expression of LOX or LMO decreases L-lactate tone of 
organotypic brainstem slices 
The effects of the novel genetically-encoded enzymatic tools on LL metabolism and 
signalling was further investigated using rat organotypic brainstem slices, which 
provide a more complex and intact context of interactions between astrocytes and 
neurones. For experimentation in slice culture, we focused on a noradrenergic centre 
in the brainstem, i.e. the LC, since our group has previously shown that astrocyte-
derived LL plays an important excitatory role in neurones residing in this region (Tang 
et al., 2014). Organotypic brainstem slices containing LC were transduced with either 
AVV-sGFAP-LOX-IRES-tdTomato or AVV-sGFAP-LMO-IRES-tdTomato to drive 
expression of LOX or LMO, respectively, specifically to astrocytes. In order to locate 
noradrenergic neurones in the tissue, the slices were co-transduced with an AVV 
carrying the expression cassette for EGFP under the control of the PRSx8 promoter 
(AVV-PRSx8-EGFP) (Figure 4.17). Slices were used for experimentation 8-11 days 
following AVV transduction. 
Figure 4.17. Transduction of AVVs in neurones and astrocytes for 
experimentation in organotypic brainstem slices. Noradrenergic neurones in 
organotypic brainstem slices containing the LC were transduced with AVV-PRSx8-
EGFP (top confocal stack image, scale bar 25µm), whereas astrocytes in the same 
slice were transduced with either AVV-sGFAP-LOX-IRES-tdTomato or AVV-sGFAP-







The impact of astrocytic expression of LOX or LMO on LL dynamics in organotypic 
brainstem slices was assessed using LL amperometry, as detailed in Chapter 3, 
section 3.8.  The active LL biosensor was placed in direct contact with the surface of 
the LC region in an organotypic slice previously transduced with AVV-PRSx8-EGFP 
and either AVV-sGFAP-LOX-IRES-tdTomato or AVV-sGFAP-LMO-IRES-tdTomato. 
The null sensor was placed in the adjacent side of the LC to account for non-specific 
currents. Conversion of current values to LL concentration was performed through 
interpolation with a calibration curve that was generated by application of known 
amounts of LL to the tissue chamber at the beginning and end of each recording.   
Initial contact of the LL biosensor with the surface of the slice results in a current spike 
thought, in part, to represent a mechanical artefact, which declines to a constant level, 
reflecting the constitutive LL release or the extracellular LL tone (Figure 4.18A). 
Transduction of organotypic brainstem slices with AVV-sGFAP-LOX-IRES-tdTomato 
or AVV-sGFAP-LMO-IRES-tdTomato resulted in a significantly decreased LL tone as 







Figure 4.18. Reduced extracellular LL tone in organotypic brainstem slices 
expressing LOX and LMO. A) Amperometric recording of contact and stabilisation 
of the enzyme-based LL electrode with the surface of the LC in an organotypic 
brainstem slice. The LL tone was determined once steady-state had been reached, 
and converted into LL concentration using a calibration curve. (B) Pooled data for the 
extracellular LL tone of organotypic brainstem slices transduced with AVV-PRSx8-
EGFP alone (Control, n=14) or in combination with either AVV-sGFAP-LOX-IRES-
tdTomato (LOX, n=12) or AVV-sGFAP-LMO-IRES-tdTomato (LMO, n=9) showed 
significant reduction in LOX (10.0±3.7µM) and LMO (13.9±10.3µM) slices as 
compared to control (34.3±18.1µM). ANOVA (Bonferroni’s Multiple Comparison Test) 
was used to compare against Control the effect of LOX and LMO expression on LL 

























on the slice 
Electrodes out 









4.4.7 LOX or LMO expression in astrocytes reduces forced L-lactate release 
from organotypic brainstem slices  
Organotypic brainstem slices transduced with AVV-sGFAP-LOX-IRES-tdTomato or 
AVV-sGFAP-LMO-IRES-tdTomato were exposed to high doses of pyruvate short-
term, in order to trigger LL release from brain cells through trans-acceleration of 
MCTs. Amperometric recordings using LL biosensors confirmed that pyruvate [10mM] 
evoked an immediate and distinct peak in the extracellular concentration of LL in all 
slices recorded (Figure 4.19A). The net amplitude of trans-acceleration-driven LL 
release (trans-acceleration amplitude) was reduced in organotypic brainstem slices 
containing LOX-expressing astrocytes (Figure 4.19B), which may be in accordance 
with the decreased LL tone in these cells as previously demonstrated. In contrast, 
although organotypic brainstem slices expressing LMO also exhibited a reduced LL 
tone, the trans-acceleration amplitude following pyruvate [10mM] application was not 
significantly different from the control.  
Pyruvate-driven LL release is followed by a transient decrease in LL tone, reaching a 
minimum that may reflect the depletion of LL stock within the tissue (depletion 
amplitude, Figure 4.19A). LL is then produced intracellularly and released to the 
extracellular space at a reduced rate until intracellular LL stocks are restored to the 
baseline level and the initial tone is re-established. The amplitude of LL depletion 
triggered by application of pyruvate [10mM] was reduced in organotypic brainstem 
slices containing LOX- and LMO-expressing astrocytes as compared to control slices 







Figure 4.19. Astrocytic expression of LOX in organotypic brainstem slices 
reduces pyruvate-driven LL release. (A) LL amperometric recording depicting 
fluctuations in the current following application of pyruvate [10mM]. LL biosensor was 
placed in the LC region of the brainstem organotypic slice. The current generated is 
proportional to the extracellular LL concentration. (B) Pooled data for the trans-
acceleration amplitude following pyruvate [10mM] application in organotypic 
brainstem slices transduced with AVV-PRSx8-EGFP alone (Control, n=11) or in 
combination with either AVV-sGFAP-LOX-IRES-tdTomato (LOX, n=12) or AVV-
sGFAP-LMO-IRES-tdTomato (LMO, n=8).  LOX slices exhibited significant decrease 
in the amplitude of pyruvate-driven LL release (5.3±3.1µM) as compared to control 
slices (15.4±8.5µM), while no significant change was observed in LMO slices 
(12.4±15.5µM). (C) Pooled data for LL depletion amplitude following pyruvate [10mM] 
application in organotypic brainstem slices transduced with AVV-PRSx8-EGFP alone 
(Control, n=11) or in combination with either AVV-sGFAP-LOX-IRES-tdTomato (LOX, 
n=12) or AVV-sGFAP-LMO-IRES-tdTomato (LMO, n=8). Both LOX (-4.5±1.7µM) and 
LMO (-5.7±5.0µM) slices showed significant reduction as compared to control slices 




















































compare against Control the effect of LOX and LMO expression on LL trans-
acceleration and depletion amplitude (* - p<0.05; *** - p<0.001). 
 
4.4.8 Release of noradrenaline from neurones in organotypic LC is decreased 
in slices containing astrocytes transduced with LOX 
Among the multiple metabolic and signalling effects of astrocyte-derived LL in the 
brain, our group is particularly interested in the mechanisms underpinning LL-driven 
NA release in the brainstem. Since our results so far indicated that astrocyte-specific 
expression of the bacterial enzymes LOX and LMO modifies LL handling in primary 
cultured astrocytes and reduces LL tone and release from organotypic brainstem 
slices, we  decided to investigate the extent by which these alterations interfere with 
LL-triggered NA release from neurones in the LC.  
In order to measure NA release from organotypic brainstem slices transduced with 
either AVV-sGFAP-LOX-IRES-tdTomato or AVV-sGFAP-LMO-IRES-tdTomato, 
CNiFERs were seeded on top of the slices prior to image recordings. As previously 
described in Chapter 2, section 2.3.1.3, CNiFERs are genetically engineered HEK293 
cells that detect NA through changes in the FRET ratio of the Ca2+ indicator TN-XXL. 
Increase in intracellular Ca+2 concentration is caused by NA-mediated activation of α1 
adrenoreceptors expressed in the membrane of  the CNiFERs (Mosienko et al., 2018; 
Muller et al., 2014). In order to visually identify the LC region, organotypic slices were 
also transduced with AVV-PRSx8-EGFP to label noradrenergic neurones with EGFP. 
To test the ability of LL to stimulate NA release from noradrenergic neurones, each 
slice received a first application of 2mM of LL (Figure 4.20). The next step was to 
induce LL release from the intra-astrocytic reservoir and evaluate if endogenous LL-
driven NA release is statistically different from the NA released through exogenous 
application of LL. LL export from astrocytes was triggered by application of pyruvate 
[10mM], which creates an outward LL gradient by trans-acceleration of MCTs.  NA 
released in response to the application of LL [2mM] was then compared with the 






Figure 4.20. Effect of LL in the release on NA from noradrenergic neurones. 
Representative FRET trace of a single CNiFER seeded on top of a LC organotypic 
slice following application of 2mM LL. 
 
Results indicated that application of LL [2mM] and pyruvate [10mM] had a comparable 
effect on NA release in both control and LMO slices (Figure 4.21). Since pyruvate, at 
least up to 2mM, has been previously reported to be ineffective in prompting release 
of NA from LC neurones (Tang et al., 2014), and pyruvate [10mM] had no effect on 
isolated CNiFERs (V. Mosienko, personal communication), the pyruvate effect on NA 
release observed here is best explained by trans-acceleration-driven LL release from 
the slice tissue. LOX-expressing slices, on the other hand, showed reduced NA 
release following application of pyruvate [10mM] as compared to the NA released 
following addition of exogenous LL [2mM]. 
































Figure 4.21. LC organotypic slices containing LOX-expressing astrocytes show 
decreased release of NA. Pooled data for the area under the curve (integral [NA]) of 
CNiFERs FRET ratio (ECFP/Citrine) following application of LL [2mM] and pyruvate 
[10mM] in organotypic brainstem slices expressing AVV-PRSx8-EGFP alone 
(Control, n=5) or in combination with either AVV-sGFAP-LOX-IRES-tdTomato (LOX, 
n=5) or AVV-sGFAP-LMO-IRES-tdTomato (LMO, n=10). In LOX slices, NA release 
triggered by pyruvate-driven LL extrusion was reduced as compared to the response 
from the application of exogenous LL (100.0±21.3% in LL [2mM] vs. 40.6±23.9% in 
PYR [10mM]; * - p<0.05). Control and LMO slices did not show significant difference 
on NA released following application of LL [2mM] and pyruvate [10mM] (Control: 
100.0±62.8% in LL [2mM] vs. 117.4±89.7% in PYR [10mM], ns - p=0.80; LMO: 






































































































































4.5 Functional validation of LOX expression in vivo  
The LOX construct is currently being tested in vivo by Professor Mikhail Pletnikov at 
Johns Hopkins University. For this purpose, the AVV shuttle plasmid backbone 
(pXCX) from the LOX construct was swapped with the LVV shuttle backbone (pTYF), 
forming pTYF-sGFAP-LOX-IRES-tdTomato, which was then directed towards LVV 
production.  LVV-sGFAP-IRES-tdTomato or LVV-sGFAP-LOX-IRES-tdTomato were 
bilaterally injected in the hippocampus of mice and expression of the reporter gene in 
cells with clear astrocytic morphology was confirmed (Figure 4.22). A range of 
behavioural tests are still ongoing. 
 
Figure 4.22. In vivo expression of tdTomato following transduction with LVV-
sGFAP-IRES-tdTomato of astrocytes in the hippocampus. Representative 
images of hippocampal astrocytes kindly provided by M. Pletnikov. Scale bar 20µm. 
 
The effect of the expression of LOX in vivo is also being tested with Dr. Valentina 
Mosienko at University of Exeter. LVV-sGFAP-IRES-tdTomato or LVV-sGFAP-LOX-
IRES-tdTomato were bilaterally injected into the amygdala of mice (AP -1.5mm, ML 
±3.4mm, DV -4.0mm and 3.6mm; 200nl, 3-8x1010 TU/ml). In order to assure adequate 
gene expression, behaviour experiments were carried out 4 weeks following surgery. 
Mice were firstly exposed to 6 hours of restraint stress and, 24 hours later, were 
subjected to the elevated plus maze test. Mice were then sacrificed, and the brain 






morphology indicated that the majority of cells expressing the construct are astrocytes 
(Figure 4.23A). Evaluation of mouse behaviour in the elevated plus maze revealed 
that expression of LOX in the amygdala decreased the number of entries to the open 
arm, suggesting increased sensitivity to stress displayed as elevated anxiety (Figure 
4.23B). Importantly, the total number of entries in the arm was similar between control 
and LOX mice, which indicates that the overall motor activity was not affected by LOX 
expression (Figure 4.23C).  
Figure 4.23. In vivo expression of LOX in astrocytes in the amygdala of mice 
enhances anxiety-like behaviour. Mice were subjected to bilateral injection of either 
LVV-sGFAP-IRES-tdTomato (Control, n=4) or LVV-sGFAP-LOX-IRES-tdTomato 
(LOX, n=5) into the amygdala. Behavioural and histological analysis were performed 
4 weeks following surgery. (A) Representative confocal stack of pTYF-sGFAP-LOX-
IRES-tdTomato expression in the amygdala in vivo. Signal of the reporter gene was 
amplified by anti-RFP staining. Scale bar 50µm. (B) Preliminary results on the effects 
























































maze. (C) Overall motor activity in the elevated plus maze test of control and LOX 
mice. * - p<0.05, Student’s unpaired t-test. 
 
4.6 Discussion of LOX and LMO effects 
The main aim of this project was to develop and validate novel molecular tools to 
investigate the LL-mediated metabolic coupling and signalling between astrocytes 
and neurones. Rather than directly interfere with astrocytic LL production and release, 
which are still subject of study and debate, we have developed molecular tools that 
aim to limit LL effects by restricting the availability of this compound in the brain. The 
genetically-engineered molecular tools created in this project degrade LL specifically 
in astrocytes and, consequently, reduce the constitutive and reactive LL release as 
tested in vitro. 
The innovation behind these tools was to take advantage of the high capacity of 
bacteria to metabolize LL. We have identified two bacterial enzymes that irreversibly 
degrade LL: LOX and LMO, whose activities are better described in Aerococcus 
viridans and Mycobacterium smegmatis, respectively. The ORF sequence of these 
enzymes was adapted to the mammalian codon usage and cloned under a sGFAP 
promoter to drive their expression selectively to astrocytes.  Then, we needed to 
determine if the enzymes of microbial origin can be in fact expressed in mammalian 
cells and, if so, whether they are enzymatically active. A combination of specific 
assays using dissociated astrocytes or organotypic brainstem slices were performed 
in order to address these questions and validate the functional effects of these novel 
constructs when expressed in rat astrocytes.  
The first evidence of functional activity of the bacterial enzymes came from 
assessment of LL content in media conditioned by HEK293 cells and dissociated 
astrocytes expressing LOX or LMO. In both cell types, concentration of LL in the 
media decreased, indicating a reduced constitutive release of LL. The level of 
reduction in LL tone was more profound in HEK293 cells than in dissociated 
astrocytes, which may be due to the high glycolytic profile of astrocytes (see Chapter 
1, section 1.2.4), particularly under the given conditions of an elevated glucose 






production may be higher in astrocytes than in HEK293 cells is suggested by the 
increased LL levels in the astrocyte-conditioned media as compared to HEK293 cell 
media (see Figure 4.12), and this difference may be expected to partially mask the LL 
breakdown through the activity of LOX and LMO in astrocytes. Constitutive LL release 
was also decreased in organotypic brainstem slices containing astrocytes transduced 
with LOX and LMO, as measured with LL amperometry.  
The next step in the validation process was to determine the effects of astrocytic 
expression of LOX and LMO on the amount of LL that can be released upon acute 
stimulation. To force maximal LL extrusion from primary dissociated astrocytes and 
organotypic brainstem slices, we employed trans-acceleration of MCTs by bath 
application of pyruvate [10mM]. This approach, which in a simplistic explanation relies 
on exchanging cytosolic LL for pyruvate, has been established by others as a means 
to deplete cells of LL (Mächler et al., 2016; San Martín et al., 2013). Although trans-
acceleration of MCTs has been recurrently used in vitro and in vivo to force LL 
release, cellular overload with pyruvate could be thought to result in LDH-mediated 
conversion of pyruvate to LL, increasing cytosolic LL concentration rather than 
reducing it by trans-acceleration.  However, astrocytes were constantly superfused 
with a solution low in glucose (2mM) in order to limit generation of NADH through 
glycolysis, which is an essential component of LDH reaction. Therefore, in this case, 
activity of LDH may be limited by the availability of NADH in spite of the excess of 
pyruvate applied (Hung, Albeck, Tantama, & Yellen, 2011; San Martín et al., 2013; 
Yuzheng Zhao et al., 2011).  
Upon pyruvate application, intracellular levels of LL in astrocytes were monitored with 
the FRET sensor Laconic, whereas LL extracellular concentration in organotypic 
brainstem slices was monitored with LL amperometry. In dissociated astrocytes, 
trans-acceleration-driven LL release was substantially decreased when cells were 
expressing LOX or LMO. In organotypic brainstem slices, trans-acceleration-driven 
LL release was only significantly decreased with LOX expression, while slices 
expressing LMO exhibited large variability in their response to trans-acceleration, 
resulting in no significant effect overall. It is nonetheless important to keep in mind 
that intracellular recordings with the biosensor Laconic were performed in primary 
astrocytic culture where only the cells expressing the constructs were analysed. LL 






neurones and other glia cells that did not express the enzymes were present but that 
would also have contributed to the trans-acceleration-induced LL release. Moreover, 
LOX and LMO enzymes exhibit different kinetic properties, with LOX breaking down 
LL approximately 7000-fold faster rate than LMO (Maeda-Yorita et al., 1995). This 
raises the possibility that the LL production stimulated by the trans-acceleration-
evoked pyruvate load in the cell contributed to the LL peak detected with 
amperometry, and that only LOX as the faster catabolic enzyme affected the LL 
transient. Combined, Laconic and amperometric recordings imply that besides 
decreasing LL tone, astrocytic expression of the bacterial enzymes also reduces the 
amount of LL released upon stimulation – an outcome that is more pronounced with 
LOX expression than LMO.  
Importantly, validation experiments carried out in this project were performed within 
the safe range of MOIs for the AVVs carrying the expression cassettes for LOX or 
LMO. Through evaluation of astrocytic viability with different assays, we established 
the ideal MOI by which AVV transduction and the expression of LOX and LMO did not 
lead to harmful consequences for cells, avoiding any potential intrinsic toxicity of the 
constructs.  
Once the basic functionality of the novel genetically-encoded bacterial enzyme tools 
was confirmed, we then examined their effects on the astrocytic metabolism. At 
steady-state level, an enzymatic reaction is at equilibrium, i.e. there is no net change 
in the concentration of both substrate and product (Nelson & Cox, 2017). Equilibrium 
of a reaction does not mean that concentration of substrate and product are equal. In 
the case of LDH-mediated LL production, many factors contribute to the equilibrium 
of the reaction at steady-state, such as the glycolytic rate and, consequently, the 
NADH/NAD+ ratio, as well as LL release and oxidative phosphorylation. In order to 
evaluate the rate of LL production and pyruvate accumulation in dissociated 
astrocytes expressing LOX or LMO, we blocked monocarboxylate extrusion to disturb 
the reaction equilibrium so that we could evaluate the reaction rate. MCT1 was 
blocked with AR-C155858, which can inhibit MCT1 at nanomolar range, but is 
ineffective against MCT4 (Ovens, Davies, Wilson, Murray, & Halestrap, 2010). Since 
the AR-C155858 binding site on MCT1 is located intracellularly in the C-terminal 
domain (Ovens et al., 2010), a latency response was observed following application 






implying an important role of MCT1 in controlling the steady-state levels of these 
monocarboxylates. Increase in cytosolic LL reached a plateau, suggesting that a new 
thermodynamic equilibrium was established. In this situation, other LL carriers such 
as MCT4, or pannexins and connexin hemichannels may be playing a role in keeping 
the steady-state LL, albeit at a higher level. As for the accumulation of pyruvate upon 
MCT1 blockade, it has not been tested if the plateau of the curve reflects the 
saturation of the sensor Pyronic and, therefore, conclusions in this regard cannot be 
drawn. Evaluation of the rate of LL production showed no change in LOX- and LMO-
expressing astrocytes, suggesting that LDH remains highly active under these 
conditions. Nonetheless, expression of the bacterial enzymes substantially decreased 
the rate of pyruvate accumulation. The following factors may be involved in this 
response: 
(i) Activity of LOX decreases cytosolic levels of LL, used as substrate, and it is 
expected to increase the concentration of the reaction product pyruvate 
(Figure 4.24A). However, pyruvate accumulates at a slower rate in LOX-
expressing astrocytes. In fact, the rate of pyruvate accumulation in astrocytes 
expressing LOX is similar to LMO, which does not produce pyruvate (Figure 
4.24B).   
(ii) In a scenario of reduced intracellular LL concentration due to LOX or LMO 
expression, LDH reaction is expected to be shifted towards LL formation. LL 
generated, on the other hand, is constantly degraded by the bacterial 
enzymes. Therefore, there is a sink driving LL formation – which may explain 
the decreased rate of pyruvate accumulation in astrocytes expressing LMO or 
LOX.  
(iii) Formation of pyruvate through LOX activity does not replenish NADH, which 
is required for LDH-mediated conversion of pyruvate to LL (Figure 4.24A). 
Since the LDH-mediated LL production, however, seems to be unaffected by 
LOX, availability of NADH does not appear to be a limiting factor under these 






Figure 4.24. Overview of LL metabolism in astrocytes expressing the novel LL-
limiting tools. LL generated through glycolysis is degraded into (A) pyruvate and 
hydrogen peroxide in LOX-expressing astrocyte and (B) acetate, carbon dioxide, and 
water in LMO-expressing astrocytes. 
 
In fact, cell metabolism is tightly regulated and changes in one pathway may be 
accompanied by many regulatory changes in other pathways. Through analysis of the 
rate of LL and pyruvate accumulation, we can infer that astrocytes expressing the 
bacterial enzymes undergo metabolic changes, but it was not possible to identify the 
specific nature of those changes based on the analysis of the metabolites LL and 
pyruvate alone, and by the method employed (blockade of MCT1). 
In order to investigate whether the decreased intracellular LL pool and release that 
results from the expression of LL catabolic enzymes affects astrocytes-to-neurone LL 






containing astrocytes expressing LOX or LMO. Comparison of NA released from bath 
application of LL [2mM] with NA released from trans-acceleration-driven LL extrusion 
implied that astrocytic expression of LOX decreases LL-induced NA release. This 
result is consistent with a decreased constitutive and forced LL release from slices 
expressing LOX in astrocytes. In contrast, astrocytic expression of LMO had no effect 
on the NA released from organotypic LC slices, which is also consistent with 
unchanged trans-acceleration driven LL release from organotypic brainstem slices as 
measured with LL amperometry. 
H2O2 is the by-product of LOX activity and, as a ROS, has the potential to oxidize 
cellular components such as DNA, protein, and membrane lipids, causing a number 
of deleterious events in the cell. ROS are naturally produced by cells, mainly as a 
result of aerobic metabolism, when electrons passing down the mitochondrial 
respiratory chain reduce oxygen prematurely and incompletely, generating 
superoxide radicals (Nelson & Cox, 2017). Astrocytes are reported to exhibit several 
fold higher production of ROS than neurones (Lopez-Fabuel et al., 2016). However, 
astrocytes can efficiently handle oxidative stress as they express high levels of 
antioxidant scavengers and enzymes that avoid ROS-mediated cellular damage 
(Dringen, Kussmaul, Gutterer, Hirrlinger, & Hamprecht, 1999; Fernandez-Fernandez, 
Almeida, & Bolaños, 2012; Sagara, Miura, & Bannai, 1993). Detoxification of H2O2 
takes place through a series of mechanisms, which mostly require glutathione (GSH) 
as cofactor (Fernandez-Fernandez et al., 2012). Glucose metabolism, for example, 
largely contributes to antioxidant processes since it regenerates NADPH(H+) through 
the phosphate-pentose pathway (PPP). NADPH(H+), in turn, mediated by GSH, 
transfers its reducing equivalents to H2O2, forming H2O (Nelson & Cox, 2017). 
Astrocytes have been shown to exhibit a high GSH content, which can also be 
exported  to neurones, as well as a robust capacity for GSH-dependent detoxification 
processes (Bolaños, 2016; Dringen, Brandmann, Hohnholt, & Blumrich, 2015). 
Therefore, taking into account the high capacity of astrocytes to handle oxidative 
stress, astrocytes are likely to support LOX expression at the MOI used.  
Acetate is the breakdown product of LL with LMO activity. In the brain, acetate is 
described to accumulate mainly in astrocytes, where it is degraded by the enzyme 
acetyl-CoA synthetase to acetyl-CoA, which engages the TCA cycle and increases its 






been shown to be an additional metabolic substrate during periods of brain activation 
(Dienel & Cruz, 2006). Oxidation of acetate is widely reported to occur in cancer cells, 
which require metabolic adaptations in order to overcome limited nutrient availability 
and the high biosynthesis demand of growth (Lin, Zhang, & Lin, 2018; Liu et al., 2018; 
Qiu et al., 2019). The additional acetate produced by LMO is, therefore, likely to simply 
be absorbed into oxidative phosphorylation.  
In conclusion, this chapter describes the construction and validation of innovative 
molecular tools based on enzymes of microbial origin to break down LL and study its 
functions in the brain. Tests in vitro showed that the LL-processing enzymes are active 
when expressed in astrocytes and modify LL dynamics and action in the brain. 
Successful expression in astrocytes in vivo suggested that these tools show potential 














Chapter 5 – Interfering with L-lactate signalling 






5.1 D-lactate-sensitive signalling through astrocytic L-lactate in cardio-
respiratory regulation 
Despite the multifactorial and complex pathophysiology of cardiorespiratory diseases, 
there is a consensus that increased activity of the sympathetic nervous system has a 
profound impact on the development and progression of hypertension and heart 
failure (Kasparov & Teschemacher, 2008). Presympathetic neuronal circuits in the 
hypothalamus and brainstem receive inputs from the periphery and from different 
regions of the CNS, which are translated into tonic descending sympathetic drive 
(Kasparov & Teschemacher, 2008; Marina, Teschemacher, Kasparov, & Gourine, 
2016). Dysregulation of this system may result in enhanced sympathoexcitation, 
which is detrimental to the maintenance, for instance, of healthy arterial blood 
pressure.  
Increasing experimental evidence shows that astrocytes closely associated with 
sympathoexcitatory or respiratory neural networks can directly influence synaptic 
neurotransmission and neuronal activity, and are strongly involved in the modulation 
of the sympathetic nervous system (Gourine et al., 2010; Marina et al., 2015, 2016; 
Tang et al., 2014). Astrocyte-derived LL has been shown to activate a putative Gs-
coupled LL receptor (LLRx) in noradrenergic neurones in the LC, inducing 
depolarisation and NA release (See Chapter 1, section 1.4.4) (Mosienko et al., 2018; 
Tang et al., 2014). Moreover, excitability of C1 neurones has also been shown to be 
modulated by ventral brainstem astrocytes via the release of LL, which triggered 
depolarization and increased action potential firing rate (Marina et al., 2015). Although 
the nature of the proposed LL receptor, LLRx, has yet to be identified, Tang et al. 
(2014) have reported that DL blocks the activation of this receptor and the effect of 
LL on noradrenergic neurones (Tang et al., 2014). Application of DL to brainstem 
slices almost fully abolished NA release and neuronal depolarization induced by 
astrocyte-derived LL in the LC (Tang et al., 2014). This inhibitory response led us to 
propose that increasing the DL/LL ratio in astrocytes may represent an effective tool 
to interfere with LL-mediated signalling, and potentially attenuate excessive 
sympathoexcitation. Therefore, in order to better understand LL-mediated signalling 






astrocyte-derived LL, we designed and constructed a molecular tool to selectively 
induce astrocytes to produce and release DL. 
This chapter will explore DL production and handling in mammals and bacteria, as 
well as the design, construction and in vitro validation of a novel molecular tool based 
on bacterial enzyme to produce DL specifically in astrocytes. 
 
5.1.1 D-lactate source in mammalian cells 
DL is the laevorotary compound of the chiral molecule lactate. Under physiological 
conditions in mammals, DL is formed by the methylglyoxal pathway in the nanomolar 
range (Ewaschuk, Naylor, & Zello, 2005). The glyoxalase system consists of a 2-step 
reaction catalysed by the ubiquitously expressed enzymes glyoxalase I and II, which 
convert methylglyoxal into DL via the intermediate S-lactoylglutathione (Figure 5.1). 
Methylglyoxal is an inevitable by-product of fatty acid, amino acid, and glucose 
metabolism and must be removed from the cells due to its highly reactive and 
cytotoxic nature (Ewaschuk et al., 2005). In the mouse brain, glyoxalase enzymes 
have been shown to be expressed at higher levels in primary astrocytes, which also 
exhibited higher DL levels as compared to neurones (Belanger et al., 2011).  
In addition to the glyoxalase system, another proposed mechanism of DL production 
in mammalian tissues is a putative mammalian DL dehydrogenase (EC 1.1.2.4), 
which catalyses the reversible conversion of pyruvate to DL using ferricytochrome c 
as co-substrate and FAD as coenzyme (de Bari, Atlante, Guaragnella, Principato, & 
Passarella, 2002; Flick & Konieczny, 2002) (Figure 5.1). Analysis of the expression of 
the putative mammalian DL dehydrogenase indicated its presence mainly in the 
kidney and liver, and at lower rates in the brain, heart, and skeletal muscle. At the 
cellular level, mammalian DLDH is localized in the inner face of the inner 







Figure 5.1. Pathways for DL production in mammals. DL can be endogenously 
formed in mammals through the glyoxalase system, which detoxify cells of 
methylglyoxal by its conversion into DL, as well as through the activity of a putative 
mammalian DL dehydrogenase, which converts pyruvate into DL in the inner face of 
the inner mitochondrial membrane. 
 
DL concentration in mammals is kept at low levels in healthy subjects unless a 
disease state has been established.  Subclinical elevation of DL concentration can be 
detected in diabetic rats, whose blood have doubled the amount of DL compared with 
healthy subjects (Kondoh, Kawase, Kawakami, & Ohmori, 1992). In this case, DL has 
been suggested to be produced from methylglyoxal, which in turn has been generated 
by the ketone metabolism (Christopher, Broussard, Fallin, Drost, & Peterson, 1995). 
 
Unfortunately, the processes used by mammals to produce DL endogenously cannot 
be employed as strategies for the development of molecular tools to induce astrocytic 
DL production. Increasing activity of the glyoxalase system may be a delicate 
approach since it involves the formation of methylglyoxal, a highly reactive and toxic 
compound. It may also be complex to design a strategy to effectively overexpress the 
putative mammalian DL dehydrogenase in astrocytes due to the lack of research 
describing its activity and function. Moreover, the human DL dehydrogenase is a 
transmembrane enzyme which reaction requires mitochondrial elements to take 
place. Therefore, besides the challenge of delivering the enzyme expression to the 
position it is initially found in the cells – at the inner face of the inner mitochondrial 
membrane – the enzymatic reaction may be limited, resulting in low DL production 






5.1.1.1 D-lactate transport  
DL produced outside the CNS can reach the cerebral tissue from the bloodstream. 
The transport of DL is mediated by the gradient-driven MCT1 and MCT4, although 
with relatively lower binding affinities when compared with other monocarboxylates 
(Halestrap, 2011). MCT1 is present in endothelial cells of the blood brain barrier as 
well as in astrocytes and neurones and translocate DL with a Km of 27.5 mmol/L 
(Halestrap, 2011). MCT4 in astrocytes has been shown to carry DL with a Km of 519 
mmol/L (see Table 1.2) (Halestrap, 2011). 
 
5.1.2 D-lactate source in bacteria  
DL plays an important role in energy metabolism in bacteria. Through fermentation, a 
wide and heterogenous group of bacteria, the lactic acid bacteria, can efficiently 
convert glucose into LL and/or DL. Lactobacilli are widely employed in food, 
pharmaceutical and chemical industries. Bacterial production of LL and DL is 
catalysed by LDH and D-lactate dehydrogenase (DLDH; EC 1.1.1.28 – Figure 5.2), 
respectively, which are both stereospecific NAD-dependent enzymes. 
Figure 5.2. Reaction catalysed by DLDH. DLDH utilizes the coenzyme NADH to 
reversibly reduce pyruvate to DL. 
 
The ratio of LL and DL production varies according to the bacteria specie and strain 
(Huang, You, & Liu, 2017). In Lactobacillus delbrueckii subspecies bulgaricus (L. 
bulgaricus), for example, DL is the most produced stereoisomer, accounting for over 
85% of the total lactic acid generated by lactose fermentation (Manome, Okada, 
Uchimura, & Komagata, 1998). L. bulgaricus is worldwide used for yogurt production. 






be positively selected, most likely due a persisting domestication process (Zhang, 
Gong, Wang, Zhang, & Tian, 2015). 
Lactic acid bacteria are part of the human gastrointestinal microbiota. A rare metabolic 
condition, the short-bowel syndrome (SBS), has been associated with D-lactic 
acidosis in humans, in which serum DL rises ≥ 3 mmol/L (Uribarri, Oh, & Carroll, 
1998). In subjects whose intestines are shorter, carbohydrate digestion is incomplete 
and non-metabolized sugars can reach the colon. As a consequence, pH at the 
colonic lumen decreases due to the elevated microbial production of organic acids. 
Acid environment favours overgrowth of lactic acid bacteria, which culminates in the 
increased production of LL and DL. While LL can be efficiently metabolized, the 
metabolism and excretion capacity of DL by humans are limited, leading to the 
accumulation of this compound in the blood (Ewaschuk et al., 2005). Clinical 
manifestations of D-lactic acidosis include neurological dysfunction such as irritability, 
hallucinations, abusive behaviours, among others (Uribarri et al., 1998). Other 
conditions in humans such as infection, ischemia, traumatic shock, and diarrhoea 
evoke bacteria-mediated increase in blood DL levels, but at concentrations that do 
not result in D-lactate acidosis (<1mmol/L) (Ewaschuk et al., 2005). 
Even though some bacteria do not express DLDH, DL can still be produced due to 
the activity of DL-lactate racemase, which converts LL into its enantiomer DL (Figure 
5.3) (Ferain et al., 1996; Ferain, Garmyn, Bernard, Hols, & Delcour, 1994). 
Characterization of lactate racemization activity showed that transformation of LL into 
DL is controlled by the LL/DL ratio in the sense that the presence of LL induces 
racemisation, while DL has the opposite effect (Goffin et al., 2005). DL-racemase is a 
nickel-dependent enzyme whose activity depends on the expression of 4 and 6 genes 






Figure 5.3. Pathways for DL production in bacteria. DL is produced by bacteria 
though the activity of the enzymes DLDH and DL-racemase, the latter catalysing the 
direct transformation of LL to DL. 
 
Although expression of DL-racemase seems an attractive approach for producing DL 
while decreasing LL levels, expression of this enzyme would have been too complex 
and its activity requires nickel as cofactor, which rendered this strategy unrealistic. On 
the other hand, activity of bacterial DLDH, which has been extensively described due 
to its broad industrial utilization, seems feasible once expressed in astrocytes. These 
cells naturally provide the precursor pyruvate through glycolysis and are equipped 
with the transport machinery necessary for DL extrusion. Therefore, we chose to 
express DLDH from L. bulgaricus in astrocytes, based on its high efficiency in 
converting pyruvate into DL. 
 
5.2 Construction of DLDH-carrying plasmids 
Since DLDH activity has been well described in L. bulgaricus, we used its ORF 
sequence for the design of molecular cloning strategies. The sequence was optimised 
to the mammalian codon usage by Life Technologies (USA) using the amino acid 
sequence provided by us. Several recombinant plasmids containing the 
mammalianised DNA sequence of DLDH were constructed in this project in order to 
accommodate the different experimental approaches employed. Accordingly, 
plasmids were cloned into either adenoviral (pXCX) or lentiviral (pTYF) shuttle 
plasmids under the control of either ubiquitous (EF1α) or astrocyte-specific (sGFAP) 
promoters. Recombinant plasmids also differed in the fluorescent protein they carried 






performed. An IRES element was included in the bi-cistronic vector for independent 
translation of DLDH and the reporter gene.  
Following construction, DLDH-carrying recombinant plasmids were used for 
transfection of HEK293 cells or directed to the production of viral vectors to be further 




The mammalianised ORF sequence of DLDH was isolated from the original pMA-T 
vector backbone and cloned into a pTYF shuttle vector driving the expression of 
EGFP under the control of the ubiquitous EF1α promoter. IRES was added between 
DLDH and EGFP to allow these two genes to be separately translated, forming pTYF-
EF1α-DLDH-IRES-EGFP. For molecular construction of the recombinant plasmid, 
pTYF-EF1α-SOD1-IRES-EGFP and pMA-T-DLDH were double-digested with the 
restriction enzymes NheI & SalI. The SOD1 sequence was excised from the vector 
cassette, resulting in a 9.8kb vector fragment that was subsequently ligated together 
with the 1kb insert fragment of DLDH (Figure 5.4A). Diagnostic digestions were 
carried out on pTYF-EF1α-DLDH-IRES-EGFP using NheI & SalI, which confirmed an 
accurate outcome (Figure 5.4B). The construct was also partially sequenced by 
Eurofins MWG with specific primers for the pTYF backbone (pTYF forward: 
GGGTTTATTACAGGGACAGCAG, and pTYF reverse: 
AGTGGCTAAGATCTACAGCTGCCTTG), EF1-α forward 
(ATTATGGAGGACGCGGCGCT), and reverse GFP (CCGTTTACGTCGCCGTC). 
The DNA sequence output was aligned in silico using Vector NTI, which confirmed 






Figure 5.4. Construction of pTYF-EF1α-DLDH-IRES-EGFP. (A) Vector map of the 
recombinant plasmid carrying DLDH and EGFP under the control of an EF1α 
promoter. (B) Gel electrophoresis image of the diagnostic restriction digestion with 




Another variant of DLDH-carrying recombinant plasmid driving the co-expression of 
tdTomato was created in order to allow FRET imaging with cyan and yellow 
fluorescent proteins in DLDH-expressing cells. For this cloning strategy, both pTYF-
EF1α-DLDH-IRES-EGFP and pXCX-PRS-tdTomato were double-digested with the 
restriction enzymes BamHI & NotI. The resultant fragments of 10kb of the vector 
pTYF-EF1α-DLDH-IRES and 1.5kb of the insert tdTomato were ligated together, 
creating pTYF-EF1a-DLDH-IRES-tdTomato (Figure 5.5A). The pattern of DNA 
fragments from diagnostic digestion of the recombinant plasmid using the restriction 
enzymes BamHI & NotI matched the expected bands (Figure 5.5B). Sequencing of 
pTYF-EF1a-DLDH-IRES-tdTomato with EF1-α and pTYF primers 
(ATTATGGAGGACGCGGCGCT and AGTGGCTAAGATCTACAGCTGCCTTG, 
respectively) by Eurofins MWG also confirmed the correct outcome. 
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Figure 5.5. Construction of pTYF-EF1α-DLDH-IRES-tdTomato. (A) Vector map of 
the recombinant plasmid carrying DLDH and tdTomato under the control of an EF1α 
promoter. (B) Gel electrophoresis image of the diagnostic restriction digestion with 
BamHI & NotI and the resulting bands, which confirmed the correct outcome.  
 
5.2.3 pXCX-sGFAP-DLDH-IRES-EGFP  
To create a recombinant cassette to drive the expression of DLDH specifically in 
astrocytes, the DLDH ORF sequence was cloned into a pXCX-shuttle backbone 
under the control of sGFAP promoter. In order to construct pXCX-sGFAP-DLDH-
IRES-EGFP, pXCX-sGFAP-tdTomato was digested with the restriction enzyme AgeI, 
while pTYF-EF1a-DLDH-IRES-EGFP was digested with NheI. Both plasmids were 
then submitted to a Klenow treatment in order to generate blunt DNA ends. A second 
restriction digestion with the enzyme NotI was performed, which resulted in a 10.4kb 
vector fragment and a 2.1kb insert fragment containing the coding sequences of 
DLDH, IRES and EGFP. Vector backbone and insert were ligated together, forming 
the recombinant plasmid pXCX-sGFAP-DLDH-IRES-EGFP (Figure 5.6A). Diagnostic 
restriction digestion was carried out using SalI, which yielded the expected bands 
(Figure 5.6B). The new construct was sequenced by Eurofins MWG with a reverse 
pXCX primer (ACCTTCCAGGGTCAAGGAAG) and a primer for GFAP 
(ATGGGTGAGGGGAGAGCT). Following in silico alignment of the DNA sequence, 
the new shuttle vector was considered to be correct. 
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Figure 5.6. Construction of pXCX-sGFAP-DLDH-IRES-EGFP. (A) Vector map of 
the recombinant plasmid carrying DLDH and EGFP under the control of sGFAP 
promoter. (B) Gel electrophoresis image of the diagnostic restriction digestion with 
SalI yielded the correct pattern of bands.  
 
5.2.4 pXCX-sGFAP-DLDH-IRES-tdTomato 
This cloning strategy created a red fluorescent variant of the novel recombinant 
plasmid driving the expression of DLDH in astrocytes. For the construction of pXCX-
sGFAP-DLDH-IRES-tdTomato, EGFP sequence from pXCX-sGFAP-DLDH-IRES-
EGFP was swapped for the tdTomato isolated from pXCX-PRS-tdTomato by 
restriction digestion using the enzymes AgeI & NotI. 11.4kb and 1.4kb of vector and 
insert fragment, respectively, were ligated together, resulting in the recombinant 
plasmid pXCX-sGFAP-DLDH-IRES-tdTomato (Figure 5.7A). For diagnostic purpose, 
pXCX-sGFAP-DLDH-IRES-tdTomato was digested with the restriction enzymes AgeI 
& NotI and the bands in the electrophoresis agarose gel were found to be as expected 
(Figure 5.7B) The recombinant plasmid was then partially sequenced by MWG 
Eurofins using specific primers to IRES (IRES forward: 
CCACTCATCTTATAGCTTTC, and IRES reverse: CCAAGTCAGTGGCTGCAC) and 
a reverse pXCX primer (ACCTTCCAGGGTCAAGGAAG). Following in silico 
















































Figure 5.7. Construction of pXCX-sGFAP-DLDH-IRES-tdTomato. (A) Vector map 
of the recombinant AVV shuttle plasmid carrying DLDH and tdTomato under the 
control of sGFAP promoter. (B) Gel electrophoresis image of the diagnostic restriction 
digestion with AgeI & NotI and the resulting bands, which confirmed the correct 
outcome. 
 
5.3 Functional validation of DLDH expression in vitro 
DLDH-carrying recombinant plasmids containing the EF1α promoter were used for 
transfection of HEK293 cells. On the other hand, pXCX-sGFAP-DLDH-IRES-EGFP 
and pXCX-sGFAP-DLDH-IRES-tdTomato were used for generation of AVVs for 
astrocyte-specific expression of DLDH in rat primary dissociated astrocytic cultures 
and organotypic brain slices. Expression and activity of DLDH in mammalian cells 
was determined in vitro with a range of specific functional assays. Once DL production 
in DLDH-expressing cells had been confirmed, its effects on intracellular LL pool as 
well as LL signalling were analysed. 
 
5.3.1 DLDH of bacterial origin is expressed in mammalian cells  
The ability of the novel DLDH-containing expression cassette to be transcribed in 
HEK293 cells was initially assessed by monitoring the expression of the reporter 
gene. Evaluation of EGFP fluorescence in HEK293 cells following transfection with 















































principle, expressed in mammalian cells (Figure 5.8), although it does not as such 
confirm that the microbial enzyme is in fact active. 
Figure 5.8. DLDH-transfected HEK293 cells express the reporter gene EGFP. 
Domain structure of the cassette for expression of DLDH in cell lines. The bi-cistronic 
vector carries the expression of DLDH and EGFP under the control of EF1α promoter. 
Below: Fluorescence microscopy image of HEK293 cells transfected with 1.5µg/µl of 
the construct. Scale bar is 100µm. 
 
Transduction of cultured primary astrocytes as well as astrocytes in organotypic 
brainstem slices with AVV-sGFAP-DLDH-IRES-tdTomato resulted in tdTomato 
expression being detected only in some scattered astrocytes. In order to amplify the 
signal of the reporter gene, anti-RFP staining was carried out, which confirmed wide-
spread astrocytic expression of the red fluorescent protein in both primary culture and 







Figure 5.9. DLDH-transduced astrocytes express the reporter gene tdTomato. 
Domain structure of the cassette for expression of DLDH through AVV. Below: 
Confocal image stacks showing (a) dissociated astrocytes, scale bar 60µm; and (b 
and c) astrocytes in organotypic slice culture expressing the construct, scale bars 
25µm. Signal of the reporter gene has been amplified by anti-RFP staining with Alexa 
488 (green) for dissociated astrocytes and Alexa 594 (red) for astrocytes in 
organotypic slice culture. 
 
5.3.2 Astrocytic DLDH expression has no detrimental impact on cell viability  
Any potential toxicity that expression of the foreign enzyme and its enzymatic product 
can cause to astrocytes was assessed with cell viability assays. Establishment of a 
safe range of MOI of AVV used for astrocytic DLDH transduction was essential so 
that all the validation experiments could be performed within a physiological context.  
Cell death 3 days following transduction of primary cultured astrocytes with different 
MOIs of AVV-sGFAP-DLDH-IRES-tdTomato was assessed with Trypan Blue 
exclusion assay. As described in the previous chapter, AVV-sGFAP-EGFP was used 
as a control since it drives the expression of a well-established inert protein. Results 









with AVV-sGFAP-DLDH-IRES-tdTomato was not significantly different from control 
astrocytes at MOIs 15 and 50 (Figure 5.10). 
 Figure 5.10. DLDH expression does not affect the viability of primary cultured 
astrocytes as measured with Trypan Blue exclusion assay. Comparison of the % 
of viable astrocytes transduced with AVV-sGFAP-EGFP (Control) and AVV-sGFAP-
DLDH-IRES-tdTomato (DLDH) showed no significant difference at MOI 15 (Control: 
89.0±3.9%, n=5; vs. DLDH: 85.5±14.5%, n=6) and MOI 50 (Control: 86.0±6.6%, n=6; 
vs. DLDH: 86.1±9.8%, n=6). ns – p>0.05, Student’s unpaired t-test.  
 
In addition, we performed a more sensitive assessment of cell damage using the XTT 
assay. Similar to Trypan Blue, the XTT assay also measures cell death. However, as 
it relies on the activity of endogenous enzymes that are inactivated soon after cell 
death, this assay is able to detect earlier changes in cell viability. Comparison 
between primary cultured astrocytes transduced with AVV-sGFAP-EGFP and 
astrocytes transduced with AVV-sGFAP-DLDH-IRES-tdTomato revealed no 




























 Figure 5.11. DLDH expression does not affect the viability of primary cultured 
astrocytes as measured with XTT assay. Absorbance readout is proportional to cell 
viability. Comparison of the viability of astrocytes transduced with AVV-sGFAP-EGFP 
(Control) and AVV-sGFAP-DLDH-IRES-tdTomato (DLDH) showed no significant 
difference at MOI 5 (Control: 0.84±0.20, n=9; vs. DLDH: 0.79±0.13, n=9), MOI 15 
(Control: 0.84±0.17, n=9; vs. DLDH: 0.78±0.14, n=9), and MOI 50 (Control: 0.86±0.23, 
n=9; vs. DLDH: 0.85±0.14, n=9). ns – p>0.05, Student’s unpaired t-test. 
 
5.3.3 Mammalian cells expressing DLDH constitutively release D-lactate 
Whether transduction of DLDH constructs in mammalian cells translates into 
functional production of DL was determined through a fluorometric DL assay, as 
detailed in Chapter 3, section 3.7. DL levels in culture media conditioned for 2 hours 
by HEK293 cells transfected with 0.5 µg/µl of pTYF-EF1α-DLDH-IRES-EGFP showed 
a 6.5-fold increase in DL concentration, whereas transfection with 1.5 µg/µl of the 
same recombinant plasmid resulted in a 25.8-fold rise in the constitutive DL release 






















 Figure 5.12. DLDH expression increases constitutive release of DL from 
HEK293 cells. DL concentration in media from HEK293 cells transfected with pTYF-
EF1α-DLDH-IRES-EGFP is increased (0.5µg/µl: 58.6±11.1µM, n=3; 1.5µg/µl: 
232.2±101.6µM, n=9, respectively) as compared to non-transfected HEK293 cells 
(Control, 9.0±2.4µM, n=9). ANOVA (Bonferroni’s Multiple Comparison Test) was used 
to compare against control the effects of 1) DLDH (0.5µg/µl): ns - p>0.05; and 2) 
DLDH (1.5µg/µl): *** - p<0.0001. 
 
The concentration of DL was also quantified in culture media exposed for 6 hours to 
primary cultured astrocytes transduced with AVV-sGFAP-DLDH-IRES-tdTomato. 
Compared to non-transduced astrocytes, DLDH-expressing cells exhibited a 
significant 2.6-fold increase in DL constitutively released to the extracellular space 
(Figure 5.13). Combined, these results imply that DLDH is enzymatically operational 





























 Figure 5.13. Primary cultured astrocytes expressing DLDH increase 
constitutive release of DL. DL levels in media conditioned for 6 hours by primary 
cultured astrocytes transduced with AVV-sGFAP-DLDH-IRES-tdTomato (DLDH) is 
increased (DLDH, 9.1±2.2µM, n=13) as compared to non-transduced astrocytes 
(Control, 3.5±1.2µM, n=11). *** - p<0.0001, Student’s unpaired t-test.  
 
5.3.4 DLDH expression decreases constitutive release of L-lactate from HEK293 
cells but not from astrocytes  
Although the strategy of targeting DLDH expression in astrocytes was initially 
designed to interfere with LL signalling through DL production rather than by altering 
LL levels, DLDH activity consumes pyruvate and NADH, which are also required for 
LDH reaction. Therefore, to test any potential interference of DLDH expression with 
LL generation, we measured constitutive release of LL with a quantitative fluorometric 
assay (Chapter 3, section 3.7).  
In HEK293 cells transfected with 1µg/µl of pTYF-EF1α-DLDH-IRES-EGFP, the 
concentration of LL in culture media following 2 hours of incubation was slightly but 
significantly reduced as compared to HEK293 cells transfected with the control vector 
pCMV-IRES-EGFP (Figure 5.14A). On the other hand, astrocytes transduced with 
AVV-sGFAP-DLDH-IRES-tdTomato show no difference on the amount of LL released 
to the culture media following 6 hours incubation as compared to astrocytes 



























Figure 5.14. Constitutive release of LL is reduced in DLDH-expressing HEK293 
cells and unchanged in astrocytes expressing DLDH. (A) Media from HEK293 
cells transfected with 1µg/µl of pTYF-EF1α-DLDH-IRES-EGFP exhibited lower LL 
concentration (DLDH, 353.8±79.7µM, n=9) than media from HEK293 cells transfected 
with 1µg/µl of pCMV-IRES-EGFP (Control, 450.1±41.5µM, n=6). (B) LL level is not 
significantly different in media from primary cultured astrocytes transduced with AVV-
sGFAP-EGFP (Control, 587.4±84.1µM, n=17) and AVV-sGFAP-DLDH-IRES-
tdTomato (DLDH, 588.6±118.6µM, n=11). * - p<0.05, Student’s unpaired t-test. 
 
5.3.5 Expression of DLDH reduces forced L-lactate release from primary 
cultured astrocytes  
To estimate the levels of LL released from DLDH-expressing primary cultured 
astrocytes upon an acute stimulation, we applied high doses of pyruvate (10mM) while 
cytosolic LL levels were monitored with the FRET sensor Laconic 2-3 days following 
astrocytic transduction with AVV-CMV-Laconic and AVV-sGFAP-DLDH-IRES-
tdTomato. Pyruvate-driven trans-acceleration of MCTs leads to the extrusion of 
intracellular LL as discussed in previous chapters.  
In DLDH-expressing primary cultured astrocytes, pyruvate [10mM] caused a reduced 
decrease in cytosolic LL levels as compared to the amount of trans-acceleration-












































Figure 5.15. Forced LL release is decreased in astrocytes expressing DLDH 
enzyme. (A) Estimation of relative cytosolic LL levels using Laconic and a trans-
acceleration protocol showed reduced intracellular LL in DLDH-expressing astrocytes 
as compared to the substantial drop in LL concentration in control cells following 
application of pyruvate [10mM]. Trace represents average Laconic FRET ratio of 
astrocytes expressing AVV-CMV-Laconic alone (Control, n=62) or in combination with 
AVV-sGFAP-DLDH-IRES-tdTomato (DLDH, n=56). Data pooled from 7 independent 
experiments. Shaded regions around the trace represents SEM. (B) Pooled data for 
the average Laconic FRET ratio from 300 to 500 seconds to the extrusion of LL with 
pyruvate [10mM] as compared with the baseline (Control: -16.1±5.1%; DLDH: -
7.4±4.6%). *** - p<0.0001, Student’s unpaired t-test.  




















































































3.5.6 Astrocytic expression of DLDH does not affect L-lactate dynamics in 
organotypic brainstem slices 
 
Amperometric measurements with LL electrodes were performed in organotypic 
brainstem slices in order to investigate if alterations detected in DLDH-transduced 
primary cultured astrocytes translate into changes in LL dynamics in a more complex 
and intact brain tissue preparation. Since the signalling role of astrocyte-derived LL in 
noradrenergic neurones and the antagonistic effect of DL in these cells have been 
previously shown in the LC (Tang et al., 2014), brainstem slices were cut at the LC 
level and transduced with AVV-PRSx8-EGFP to guide the insertion of LL electrodes 
precisely into this noradrenergic region. Organotypic slices were also transduced with 
AVV-sGFAP-DLDH-IRES-tdTomato to target DLDH expression specifically to 
astrocytes. 
Contact of the LL electrode with the surface of the organotypic brainstem slice 
generated a constant and steady current, which corresponds to the tonic LL efflux 
from the tissue. Comparison of LL tone of slices containing astrocytes expressing 
DLDH with slices whose astrocytes have not undergone transduction suggested that 
DLDH expression does not significantly modify the extracellular LL tone (Figure 5.16).  
 Figure 5.16. Expression of DLDH in astrocytes does not interfere with LL tone 
of organotypic brainstem slices. Pooled data for the extracellular LL tone of 
organotypic brainstem slices transduced with AVV-PRSx8-EGFP alone (Control, 























showed no significant effect of astrocytic DLDH expression on LL (Control: 
34.3±18.1µM; DLDH: 33.7±23.6µM) as measured with LL amperometry. ns – p>0.05, 
Student’s unpaired t-test. 
 
Real-time analysis of extracellular LL concentration with amperometric LL biosensors 
was also employed to quantify the amount of LL released from organotypic brainstem 
slices following application of pyruvate. Due to the trans-acceleration of MCTs, 
extracellular levels of LL increased rapidly after superfusion of the slice culture with 
10mM of pyruvate. The amplitude of trans-acceleration-driven LL release was not 
significantly different in organotypic brainstem slices containing astrocytes transduced 
with DLDH as compared with control slices (Figure 5.17A). Accordingly, the amplitude 
of LL depletion that takes place in the slice following the trans-acceleration protocol 
was similar in both control and DLDH slices (Figure 5.17B).  
 
Figure 5.17. DLDH expression in astrocytes does not affect pyruvate-driven LL 
release from organotypic brainstem slices. A) Pooled data for the amplitude of 
trans-acceleration-driven LL released from organotypic brainstem slices showed no 
significant difference between control (15.4±8.5µM, n=11) and DLDH (19.1±15.7µM, 
n=12). (B) Pooled data for the amplitude of LL depletion following cessation of 
pyruvate application showed absence of significant changes in DLDH slices (-
23.3±18.6µM, n=12) as compared to control (-21.0±11.4µM, n=11). ns – p>0.05, 








































5.3.7 DLDH expression decreases the rate of pyruvate accumulation in primary 
cultured astrocytes  
Since DLDH enzymatic activity culminates in the reduction of pyruvate to DL, 
intracellular pyruvate levels are likely to be affected. To gain insight into intracellular 
pyruvate handling in cultured astrocytes expressing DLDH, we employed the FRET 
sensor Pyronic and blocked pyruvate extrusion with the MCT1 inhibitor AR-C155858 
(Figure 5.18A). As previously described (Chapter 1, section 1.3.1.1), MCT1 has a high 
affinity to pyruvate and its blockade allows analysis of the dynamics of intracellular 
pyruvate build-up.  
Monitoring of pyruvate levels with Pyronic showed that upon MCT1 blockade with AR-
C155858, astrocytes expressing DLDH significantly decrease the rate of pyruvate 
accumulation (Figure 5.18B). The line of best fit and slopes were calculated using 
linear least-square fitting for the linear part of the curve that characterizes the rate of 
pyruvate build-up (370-620s in Control, and 300-800s in DLDH). 
Figure 5.18. DLDH-expressing astrocytes exhibit reduced rate of pyruvate 
accumulation. (A) Time course of the average Pyronic FRET ratio upon MCT1 
inhibition with AR-C155858 [1µM] in primary cultured astrocytes transduced with 
AVV-CMV-Pyronic alone (Control, n=53) or in combination with AVV-sGFAP-DLDH-
IRES-tdTomato (DLDH, n=58). The dotted red lines are the slopes of pyruvate 
accumulation fitted by linear regression. Data pooled from 3 independent 
experiments. Shaded regions around the trace represents SEM. (B) Pooled data for 
































x10-4 ΔF/s) as compared to control cells (7.1±1.2 x10-4 ΔF/s). *** - p<0.0001, Student’s 
unpaired t-test. 
 
5.3.8 Release of noradrenaline from neurones in organotypic LC slices is 
unaffected by astrocytic expression of DLDH 
To test if DL production through expression of DLDH in astrocytes limits LL-mediated 
NA release, CNiFERs were seeded on top of organotypic LC slices transduced with 
AVV-sGFAP-DLDH-IRES-tdTomato and/or AVV-PRSx8-EGFP. The first AVV targets 
DLDH expression specifically to astrocytes, whereas the latter drives EGFP 
expression to noradrenergic neurones for visualization purposes. NA release was 
monitored through changes in FRET ratio of CNiFERs (see Chapter 2, section 
2.3.1.3). The ability of LL to trigger NA release from LC neurones was firstly verified 
through application of LL [2mM] in each slice, which later received a second 
application of pyruvate [10mM]. Addition of high dose of pyruvate into the recording 
chamber was necessary to force LL extrusion from the slice pool through trans-
acceleration of MCTs. The response of NA released following application of pyruvate 
was then compared with the response from the application of LL in each slice.  
Evaluation of NA release in control organotypic slices revealed that both exogenous 
and endogenous LL (pyruvate-driven LL extrusion) triggered similar levels of NA 
release (Figure 5.19). Similar pattern of response was also observed in organotypic 
brainstem slices transduced with DLDH, indicating that astrocytic expression of DLDH 






Figure 5.19. Astrocytic expression of DLDH in organotypic brainstem slices 
does not affect NA release. Pooled data for the area under the curve (integral [NA]) 
of CNiFERs FRET ratio (ECFP/Citrine) following application of LL [2mM] and pyruvate 
[10mM] in organotypic brainstem slices expressing AVV-PRSx8-EGFP alone 
(Control, n=5) or in combination with AVV-sGFAP-DLDH-IRES-tdTomato (DLDH, 
n=8). Control and DLDH slices did not show any significant difference in NA released 
following application of LL [2mM] and pyruvate [10mM] (Control: 100.0±62.8% in LL 
[2mM] vs. 117.4±89.7% in PYR [10mM], ns – p>0.05; DLDH: 100.0±70.6% in LL 
[2mM] vs. 153.4±90.3% in PYR [10mM], ns – p>0.05). Student’s paired t-test. 
 
5.4 Discussion of DLDH effects 
An increasing body of evidence suggests that astrocytes in the brainstem regulate the 
activity of presympathetic neurons and, consequently,  play a pivotal role in the control 
of the sympathetic drive (Marina et al., 2018). One of the signalling mechanisms 
underlying communication between astrocytes and neurones in the brainstem is 
proposed to involve the release of astrocyte-derived LL, which acts through a Gs-
coupled receptor in noradrenergic neurones to induce NA release and neuronal 
depolarization (Tang et al., 2014). Since these effects are blocked by DL, we 
developed a novel molecular tool to prompt astrocytes to produce and release DL in 




























































































Although DL is naturally generated in mammals, the pathways for DL production either 
requires transmembrane expression in the mitochondria of an enzyme the existence 
of which is still under scrutiny or involve highly cytotoxic compounds. Moreover, it was 
necessary to create a mechanism for DL degradation since its accumulation in the 
CNS is associated with varied neuronal disorders (Uribarri et al., 1998). Therefore, as 
for the molecular tools to break down LL, we took advantage of the diverse 
metabolism of microorganisms. Lactic acid bacteria, for example L. bulgaricus, 
express DLDH that efficiently converts pyruvate into DL in a reversible reaction, 
providing a mechanism for DL generation and degradation. Through conversion of 
the bacterial DLDH ORF sequence to that of mammals, we created a molecular tool 
to deliver microbial DLDH expression specifically to astrocytes. Evaluation of the 
cytotoxicity caused by DLDH expression demonstrated that this construct does not 
have harmful consequences for cells. 
The most striking evidence that DLDH is enzymatically active in mammalian cells 
came from the determination of DL concentration in media collected from seeding 
cells transfected with DLDH-carrying constructs. The high content of DL in the media 
after only a few hours of incubation indicated that cells are producing DL and are 
endowed with the means to release it to the extracellular space. Constitutive release 
of DL was considerably higher from HEK293 cells than from astrocytes (approximately 
232µM in HEK293 cells against 9µM in astrocytes). This difference may be a matter 
of transfection rate since HEK293 cells are generally considered to be more efficiently 
transfected. 
Validation of the novel DLDH-based molecular tool was challenging due to the lack of 
means to directly measure intra-astrocytic and extracellular DL dynamics. Since DL 
is an allegedly non-metabolizable substrate, not much interest has been given to the 
development of technologies for DL measurement in different biological contexts. 
Therefore, most of the in vitro validation experiments performed here assessed the 
indirect effects of DLDH expression. LL dynamics were particularly worthy of 
investigation since DLDH and LDH reactions are analogous with respect to the 
substrate and coenzymes utilized and, therefore, DLDH activity may indirectly 






Analysis of the constitutive LL release from cells expressing the novel molecular tool 
showed reduction only in HEK293 cells, whereas tonic release from astrocytes 
expressing DLDH was unchanged. On the other hand, trans-acceleration driven LL 
release was significantly reduced in dissociated astrocytes, implying a decreased LL 
reserve available upon acute stimulation. These contrasting results between 
constitutive and reactive release of LL hampered any conclusions on LL handling by 
astrocytes expressing DLDH. Therefore, in order to better elucidate LL dynamics in a 
region of physiological relevance for the study of LL/DL signalling, we employed LL 
amperometric recordings in the LC area of organotypic brainstem slices. Analysis of 
LL tone as well as trans-acceleration driven LL release in slices indicated that 
astrocytic DLDH expression does not interfere with these parameters. Combined, 
these data indicate that production of DL does not affect LL dynamics.  
We also evaluated the rate of intracellular pyruvate accumulation in primary cultured 
astrocytes upon MCT1-mediated blockade of monocarboxylate extrusion, which was 
slowed down when astrocytes expressed DLDH. The most likely reason for this is that 
pyruvate may be driven towards DL production in DLDH-expressing astrocytes, 
decreasing its rate of accumulation in the cytosol. However, care should be taken 
when drawing this conclusion since pyruvate metabolism is complex and involves 
other pathways and regulatory mechanisms that were not evaluated in this study. 
Finally, the effect of DLDH expression in astrocytes in the brainstem on NA release 
from LC neurones was analysed using CNiFERs. FRET imaging indicated that NA 
released upon bath application of LL [2mM] was similar to the NA released from the 
application of pyruvate [10mM], which forces LL extrusion from all cells in the slice 
which express MCTs. Although these results suggest that the initial aim of reducing 
LL-induced activation of noradrenergic neurones through DLDH expression was not 
achieved, we have to consider that the methodological approach of trans-acceleration 
with pyruvate may not entirely reflect LL release triggered by physiological stimuli. 
Moreover, since DL has lower affinity for MCTs than LL, the DL efflux evoked by trans-
acceleration may not have been sufficient to block LLRx.  
Therefore, an unresolved issue in the in vitro validation of the DLDH-based molecular 
tool is the question whether the levels of DLDH expression and DL production 






for measurements, constitutive release of DL has only been evaluated in HEK293 
cells and primary astrocytes. If considering the baseline release of DL from 
dissociated astrocytes, even though it is only about 9µM, DL has been described to 
be able to antagonize the excitatory action of LL when applied at concentrations 10 
to 100 times lower than LL (Tang et al., 2014). In fact, concentration as low as 1µM 
of DL was able to slightly shift to the right the LL dose-response curve to NA release 
(Tang et al., 2014). In conclusion, two major factors may be playing a role in the non-
existent reduction in LL-induced NA release from LC neurones in slices containing 
DLDH-expressing astrocytes: non-physiological procedure to evoke DL efflux and/or 
uncertain intra-astrocytic DL concentrations.  
In summary, this chapter describes the development and in vitro validation of a novel 
molecular tool to induce astrocytic production and release of DL by the expression of 
the DLDH enzyme, which is originally found in bacteria. DLDH expression in 
mammalian cells successfully leads to the production of DL and can be potentially 
applied in the study of mechanisms that are DL-sensitive. Our laboratory is currently 














Chapter 6 – Interfering with L-lactate release 






6.1 Connexins and the transport of L-lactate in astrocytes   
Connexin hemichannels have been suggested to actively participate in LL release 
from brain cells in vitro and in vivo (Karagiannis et al., 2015). Although neither the 
brain source of LL nor the connexin subtype involved in this response have been 
investigated, we proposed that the major glycolytic cells in the brain – astrocytes – 
through the activity of the main connexin expressed in these cells – connexin 43 
(Cx43) – may play a significant role in this effect. In order to uncover the actual 
function of Cx43 in the regulation of astrocytic LL pool sizes and signalling, we 
developed a molecular tool to decrease Cx43 expression selectively in astrocytes. As 
further detailed in this section, cell-to-cell LL transport through Cx43-forming gap 
junctions has already been described. However, whether astrocytic Cx43 
hemichannels in astrocytes are contributing to the release of LL to the extracellular 
space remains to be explored. 
 
6.1.1 Connexins and their expression pattern in astrocytes 
Connexins consists of four transmembrane domains with one cytoplasmic and two 
extracellular loops and both N- and C-terminals in the intracellular space (Delvaeye, 
Vandenabeele, Bultynck, Leybaert, & Krysko, 2018) (Figure 6.1). When assembled, 
connexins allow cellular communication by two means: (i) intracellular-extracellular 
exchange through hemichannels, also known as connexons, which are formed by the 
aggregation of six connexins; (ii) cell-to-cell communication through gap junctions, 







Figure 6.1. Molecular structure of connexins. Aggregation of six connexin subunits 
forms a connexin hemichannel, which allows exchange between intracellular and 
extracellular compartments. Docking of a connexin hemichannel to another from the 
adjacent cell forms a gap junction, which provides an intercellular passageway 
between both cells. Schematic adapted from Delvaeye et al. (2018). 
 
In the central nervous system, 11 different connexin types can be found in rodents 
out of 20 family members described so far in mice and 21 in humans (Esseltine & 
Laird, 2016). Astrocytic and neuronal expression of connexins fluctuate according to 
the brain area and period of development (Zhao, Xin, He, & Hu, 2018). Astrocytes 
have been shown to predominantly express Cx43, although astrocytes localized in 
the grey matter mainly express connexin 30, whereas connexin 26 expression is 
restricted to astrocytes in subcortical areas (Dermietzel, Hertberg, Kessler, & Spray, 
1991; Nagy, Patel, Ochalski, & Stelmack, 1999; Verkhratsky & Nedergaard, 2018). 
Neurones, on the other hand, do not express Cx43. Instead, these cells have been 
described to express connexin 36 mostly during the earlier stages of postnatal 
maturation, and connexins 57 and 45 in both adult and developing rat brain 
(Condorelli, Trovato-Salinaro, Mudò, Mirone, & Belluardo, 2003). 
 
6.1.2 L-lactate transport through astrocytic gap junctions  
While the capacity of non-junctional hemichannels to release compounds to the 
extracellular space was still under debate, the functional role of astrocytic gap 
junctions was already established and included the ability to deliver metabolites, 






Tabernero, Giaume, & Medina, 1996). Roauch et al. (2008) showed that gap junctions 
play an important role in the astrocyte-neurone metabolic coupling. Their evidence 
suggested that glutamatergic synaptic activity evoked energetic demand-driven 
diffusion of metabolites through astrocytic gap-junctions. In this case, glucose initially 
taken up by astrocytes is metabolized into LL which, in turn, can traffic through 
astrocytic gap junction networks to sustain the high energy demand of excitatory 
synaptic transmission (Rouach et al., 2008). The physiological role of LL trafficking 
through astrocytic gap-junctions was further investigated in mice where Cx43 was 
specifically knocked out in astrocytes (Clasadonte et al., 2017). This study showed 
that blocking the trafficking of LL through the astrocytic gap-junction network led to 
impairment in the sleep-wake cycle due to deficiency in energy supply to the wake-
promoting orexin neurones in the lateral hypothalamus (Clasadonte et al., 2017). 
Although not specifically investigated in the study, a role of astrocytic hemichannels 
in mediating LL release to the extracellular space was not excluded.  
Although gap junctions can be assembled from different hemichannel types 
(heterotypic channel) and connect distinct groups of cells (heterocellular gap 
junctions), evidence from freeze–fracture replica immunogold labelling and light 
microscopic immunocytochemistry experiments has not demonstrated the existence 
of functional coupling between astrocytes and neurones via gap junctions (Nagy, 
Dudek, & Rash, 2004; Rash, Yasumura, Dudek, & Nagy, 2001). Indeed, as shown by 
dye-coupling experiments, the majority of brain cells coupled to astrocytes via gap 
junctions are astrocytes, which implies that signalling molecules or metabolites 
mediating astrocyte-to-neurone communication are mainly released to the 
extracellular space (Giaume, Koulakoff, Roux, Holcman, & Rouach, 2010). However, 
the possibility of gap junctions linking astrocytes to neurones, even if rare, should not 
be excluded. 
 
6.1.3 L-lactate transport through astrocytic hemichannels 
Experimental evidence has shown that connexin hemichannels in astrocytes play a 
crucial role in the modulation of brain activity in vivo (Karagiannis et al., 2015; 
Stehberg et al., 2012). Microinjection into the basolateral amygdala of TAT-Cx43L2 






gap junctional interactions, affected fear memory consolidation (Stehberg et al., 
2012). On the other hand, when a mixture of gliotransmitters that included LL among 
others was co-infused with the blocking peptide, the learning capacity was rescued 
(Stehberg et al., 2012). Evidence that specifically LL is released via functional 
connexin hemichannels was recently confirmed by a study that used LL biosensors 
to monitor in real time the fluctuations in LL concentration in different regions of the 
brain (Karagiannis et al., 2015). Reduction of extracellular Ca2+ in order to enhance 
open probability of hemichannels resulted in increased LL release from brainstem, 
hippocampus, and cortex acute slices from adult rats. This response was reduced by 
pharmacological manipulations that inhibit connexin hemichannels, while blockade of 
MCTs had no impact on the tonic release of LL (Karagiannis et al., 2015). 
Interestingly, this mechanism of LL release was also recruited during hypoxic 
conditions in vitro as well as in periods of intense neuronal activity in vivo (Karagiannis 
et al., 2015).  
Considering astrocytes as a LL reservoir cell and taking into account that LL can be 
released through connexin hemichannels, the challenge will be now to define the 
precise mechanisms regulating their open probability to LL. Connexin hemichannels 
are known to release molecules under well-defined circumstances and are generally 
found in their closed/inactive state under physiological resting conditions (Giaume, 
Leybaert, Naus, & Sáez, 2013). Several experimental conditions have been described 
to activate connexin hemichannels in astrocytes, including reduction of extracellular 
Ca2+ concentration, robust depolarisation, metabolic inhibition, and pro-inflammatory 
treatments (Contreras et al., 2002; Hofer & Dermietzel, 1998; Karagiannis et al., 2015; 
Retamal et al., 2007) 
  
Therefore, in an attempt to better comprehend the role played by connexin 
hemichannels in the astrocytic release of LL, we have designed and constructed a 









6.2 RNAi as a strategy for knock-down of specific proteins in specific cell types 
RNAi is a phylogenetically conserved mechanism to decrease expression of a specific 
gene which works via small RNAs that exhibit sequence complementarity to the target 
mRNA. The underlying molecular pathway behind this gene silencing phenomenon 
has become clear following a study from Fire and Mello labs using the nematode C. 
elegans, in which injection of dsRNA reduced expression of the corresponding gene 
(Fire et al., 1998). Similar RNA suppression pathways have been subsequently 
described in distinct genetic systems such as protozoa, plants, fungi, and animals 
(Leung & Whittaker, 2005; Tijsterman, Ketting, & Plasterk, 2002). Since dsRNA can 
be introduced by replicating viruses or integrated transposons, RNAi is thought to be 
part of an endogenous defence scheme, which may explain its highly evolutionary 
conserved nature (Tijsterman et al., 2002). Importantly, dsRNA can also originate 
from transcription of specific genome sequences that encode the so-called 
microRNAs (miRNAs), which contribute to cellular regulation of gene expression.  
The cellular mechanisms underpinning RNAi triggered by endogenous miRNA involve 
several steps (Figure 6.2) (Bartel, 2009; Gebert & MacRae, 2019; Ying, Chang, & Lin, 
2008). Firstly, primary precursor miRNA (pri-miRNA) is transcribed from the genome 
mainly through the activity of RNA polymerase type II (Pol-II), forming a hairpin-
containing transcript (Gebert & MacRae, 2019; Ha & Kim, 2014). Pri-miRNA is then 
cleaved by the Microprocessor complex, formed by the RNase III enzyme Drosha and 
the DGCR8 protein, which results in a ~60-70 nucleotide (nt)-long precursor miRNA 
(pre-miRNA). Pre-miRNA is then carried from the nucleus to the cytoplasm by Ran-
GTP and the receptor Exportin-5, where it is further cleaved by another RNase III 
enzyme known as Dicer. This process yields the mature miRNA, which consists of an 
RNA duplex composed of 18-25 nt in a hairpin structure with 2-nt overhang at the 3’ 
end and a 5’ phosphate (Bartel, 2004; Gebert & MacRae, 2019; Ying et al., 2008). 
Finally, one strand of the miRNA (guide strand) is incorporated into the protein 
Argonaute, forming the RNA-induced silencing complex, whereas the other strand 
(passenger strand) is discarded and degraded. miRNA drives Argonaute to the target 
sites generally located in the 3’ untranslated region (UTR) of target mRNAs, where 
the complex binds, leading to repression of translation and degradation of targeted 






Figure 6.2. Schematics of the miRNA biogenesis and RNAi mechanisms. The 
multistep process of miRNA biogenesis starts in the nucleus with transcription to pri-
miRNA, which is further processed in the nucleus as well as in the cytoplasm to yield 
the mature miRNA comprised of approximately 22 nt. The guide strand of the miRNA 
is then loaded into Argonaute, which guides the miRNA-Argonaute silencing complex 
to bind to the target mRNA, resulting in gene silencing. Figure adapted from Gebert 
and MacRae (2019). 
 
6.2.1 Knock-down of Cx43 using miRNA  
In order to knock-down Cx43 expression in astrocytes, we designed a vector that 
drives the expression of engineered miRNAs targeting Cx43 gene under RNA Pol II 
promoter. Cloning of the expression cassette was performed using BLOCK-iT™ Pol 
II miR RNAi Expression Vector Kit with EmGFP (Invitrogen, K493600). This system 
leads to the construction of an expression clone encoding one or more pre-miRNA 






Due to murine mir-155-derived regions flanking the pre-miRNA sequences, these are 
subsequently cleaved by the cytoplasmic enzyme Dicer, yielding the mature miRNA. 
Design of the guide RNA sequences was carried out according to the optimisation 
algorithm provided by Invitrogen (see below). In order to enhance the degree of gene 
knock-down, three guide sequences targeting different parts of the Cx43 mRNA were 
linked together. This approach resembles the natural organisation of miRNA 
templates which can be found in clusters in the genome and are transcribed as a 
single and long primary transcript (Ambros, 2004; Gebert & MacRae, 2019; Ha & Kim, 
2014). 
 
6.2.1.1 Design of pre-miRNA sequence 
Design of pre-miRNAs is a critical step in gene silencing by RNAi. Using BLOCK-iT™ 
RNAi Designer online tool, complementary ssDNA oligonucleotides were designed 
and later annealed in order to generate a dsDNA. For proper assembly of the pre-
miRNA structure, the top strand of the oligonucleotide carried from 5’ to 3’ end the 
following features: 
• TGCT nt derived from miR-155, which supplies 5’ overhang compatible for 
ligation with the vector.  
• 5’G followed by 21-nt antisense sequence of the target gene, which will form 
the mature miRNA sequence. Once transcribed, the mature miRNA will target 
the gene of interest and, therefore, it must be antisense to the target mRNA. 
• 19 nt derived from miR-155, which will compose the terminal loop of the pre-
miRNA.  
• Nucleotides 1-8 and 11-21 of the sense sequence of the target gene. Removal 
of nucleotides 9 and 10 was designed in order to increase knock-down efficacy 
by creating a short internal loop in the structure of the mature miRNA.  
• CAGG derived from miR-155, which is also compatible with the vector and it 






The bottom oligonucleotide strand comprised of the reverse sequence of the top 
strand, except for the 5’ TGCT, which was swapped to CCTG to create a 5’ overhang.  
Submitting the nucleotide sequence of Cx43 (Gap junction alpha-1 protein – Gja1) 
from rattus norvegicus to the BLOCK-iT™ RNAi Designer online tool generated a 
range of miRNAs ranked according to their knock-down probability. We selected 3 
sequences exhibiting the greatest likelihood of knock-down success, which were 
rearranged to include the required features detailed below (Table 6.1). 
 
 Table 6.1. Sequence of the oligonucleotides encoding the pre-miRNA targeting 
Cx43 mRNA. The table depicts the location of the target sequence in the Cx43 mRNA 
as well as the sequence of the top and bottom strands from 5’ to 3’ end. Nucleotides 
comprising the linker are in purple, the mature miRNA sequence is in green, the 
sequence forming the external loop is shown in blue and the 1-8 and 11-21 
nucleotides of the 21-mer target is in red. 
 
6.2.1.2 Construction of Cx43 knock-down expression vectors  
First, complementary top and bottom strand oligonucleotides were annealed in order 
to generate ds oligos. Each ds oligo was then cloned into the linearized pcDNA™6.2-
GW/EmGFPmiR, which is the backbone vector provided by the supplier (Invitrogen). 
pcDNA™6.2-GW/EmGFPmiR is driven by a CMV promoter and contains a sequence 
coding Emerald Green Fluorescent Protein (EmGFP) for tracking of vector 































overhangs derived from miR-155 sequences, which are compatible for directional 
ligation with the ds oligo inserts. By ligation of the linearized vector with each ds oligo, 
3 recombinant plasmids were generated: pcDN6.2-GW/EmGFP-miR155-Gja1-273, 
pcDN6.2-GW/EmGFP-miR155-Gja1-559, and pcDN6.2-GW/EmGFP-miR155-Gja1-
707. Assessment of the plasmid sequence through diagnostic restriction digestions 
with the enzymes SalI & XhoI confirmed a correct outcome. The samples were also 
sequenced (Eurofins MWG) using EmGFP forward primer 
(GGCATGGACGAGCTGTACAA) and miRNA reverse primer 
(TCTAGATCAACCACTTTGT), which exhibited the expected outcome following in 
silico alignment using Vector NTI.  
 
6.2.1.2.1 pcDN6.2-GW/EmGFP-miR155-Gja1-RNAi 
In order to target co-cistronic expression of the 3 pre-miRNAs for simultaneous 
transcription in one single structure, pre-miRNAs sequences derived from the novel 
recombinant plasmids were linked together in one construct. Firstly, pcDN6.2-
GW/EmGFP-miR155-Gja1-273 was double-digested with the endonucleases BglII & 
XhoI, producing a vector backbone of 5.7kb. Pre-miRNA 559 was then isolated from 
the recombinant plasmid pcDN6.2-GW/EmGFP-miR155-Gja1-559 through restriction 
digestion with the enzymes BamHI & XhoI, generating an insert fragment of  
approximately 150bp. Vector and insert were then ligated together to form pcDN6.2-
GW/EmGFP-miR155-Gja1-273-559 (Figure 6.3, step 1). Of note, BglII and BamHI 
restriction endonucleases produce compatible overhangs, enabling ligation between 
2 DNA fragments. The novel recombinant plasmid containing 2 pre-miRNA 
sequences (273 and 559) underwent diagnostic restriction digestion with SalI & XhoI, 
which yielded the expected bands. Sequencing using EmGFP forward primer 
(GGCATGGACGAGCTGTACAA) and subsequent alignment with the vector map 
confirmed the construct to be correct.  
Since the pattern of restriction sites in the expression cassette is regenerated after 
addition of a pre-miRNA sequence (Figure 6.3), linking of the third pre-miRNA 
followed the same cloning strategy as described above. Accordingly, pre-miRNA 707 
was extracted from pcDN6.2-GW/EmGFP-miR155-Gja1-707 by BamHI & XhoI digest, 






containing the pre-miRNAs 273 and 559 – pcDN6.2-GW/EmGFP-miR155-Gja1-273-
559 – was double-digested with the enzymes BglII & XhoI, resulting in a 6.0kb vector 
fragment. Ligation of both vector and insert created the recombinant plasmid 
pcDN6.2-GW/EmGFP-miR155-Gja1-RNAi (Figure 6.3, step 2), which contained 
sequence encoding three pre-miRNAs (273, 559, and 707). Successful cloning was 
confirmed by diagnostic restriction digestion with the enzymes SalI & XhoI and 
sequencing using specific primers to EmGFP (forward: 
GGCATGGACGAGCTGTACAA) and miRNA (reverse: 
TCTAGATCAACCACTTTGT).  
 
Figure 6.3. Construction of an expression cassette for co-cistronic expression 
of three miRNAs targeting different regions of mRNA transcribed from the Cx43 
gene (Gja1). Other constituents of the expression cassette such as CMV promoter, 
EmGFP and miR155 flanking regions were only depicted in the last construct of the 
figure to simplify the schematic representation. Linking of multiple pre-miRNAs in one 






compatible cohesive ends and are lost or regenerated, respectively, following vector 
and insert ligation. 
 
6.2.1.2.2 pXCX-sGFAP-EmGFP-miR-Gja1-RNAi  
In order to create a recombinant plasmid that drives the expression of Cx43-targeting 
miRNAs specifically into astrocytes, the sequence encoding EmGFP followed by the 
three pre-miRNAs from pcDN6.2-GW/EmGFP-miR155-Gja1-RNAi was transferred to 
a pXCX-shuttle backbone under the control of a sGFAP promoter. For this purpose, 
pXCX-sGFAP-tdTomato was double-digested with the restriction endonucleases 
AgeI & NotI, which resulted in the removal of tdTomato sequence and formation of a 
10.0kb vector backbone. EmGFP and pre-miRNAs sequences were then amplified by 
PCR using pcDN6.2-GW/EmGFP-miR155-Gja1-RNAi as a template and forward 
Gja1 AgeI primer (CATACCGGTGCTAACTAGAGAACCCACTG), adding an AgeI 
restriction site, and the reverse Gja1 NotI primer 
(TTGCGGCCGCGTACAAGAAAGCTGGGTC), adding a NotI restriction site to the 
amplicon of  1.3kb, EmGFP-miR155-Gja1-RNAi. The PCR product was then ligated 
with the vector fragment, generating the recombinant plasmid pXCX-sGFAP-EmGFP-
miR-Gja1-RNAi (Figure 6.4A). Diagnostic restriction digestions were carried out using 
the enzymes SalI and BglII, which confirmed an accurate outcome. Sequencing by 
Eurofins MWG with specific primers for the pXCX backbone (reverse, 
ACCTTCCAGGGTCAAGGAAG) and a primer for the GFAP promoter (forward, 




BLOCK-iT™ Pol II miR RNAi Expression Vector kit (Invitrogen, K493600) also 
provides a plasmid carrying an insert able to form a hairpin structure that is further 
processed into mature miRNA. However, the miRNA formed does not target any 
known vertebrate gene, acting as a control for RNAi analysis. The control miRNA 
plasmid was transferred to a pXCX-shuttle backbone using similar strategy as 






of pXCX-sGFAP-tdTomato with AgeI & NotI was ligated together with a 1.1kb 
amplicon, which had been generated through PCR of pcDNA™6.2-GW/miR-control 
using the primers Gja1 AgeI and Gja1 NotI 
(CATACCGGTGCTAACTAGAGAACCCACTG and 
TTGCGGCCGCGTACAAGAAAGCTGGGTC, respectively) (Figure 6.4B). The novel 
recombinant plasmid pXCX-sGFAP-EmGFP-miR-control was submitted to diagnostic 
restriction digestions with SalI and BglII, which yielded the expected bands. 
Sequencing with reverse pXCX backbone and forward GFAP promoter primers 
(ACCTTCCAGGGTCAAGGAAG and ATGGGTGAGGGGAGAGCT, respectively) 
also confirmed a correct outcome. 
 
Figure 6.4. Construction of pXCX-sGFAP-EmGFP-miR-Gja1-RNAi and pXCX-
sGFAP-EmGFP-miR-control. (A) Vector map of the recombinant plasmid carrying 
the expression of three pre-miRNAs targeting Cx43 gene under the control of a 
sGFAP promoter. (B) Vector map of the recombinant plasmid carrying the expression 
of a pre-miRNA that produces a non-functional miRNA under the control of a sGFAP 
promoter. 
 
6.3 In vitro evaluation of knock-down efficacy of miRNA targeting Cx43 in 
astrocytes 
The recombinant plasmid driving the expression of miRNAs targeting Cx43 knock-
down selectively in astrocytes was directed to the production of AVV, which was 








































































astrocytes in organotypic brain slices. Successful expression of the reporter gene 
EmGFP was confirmed by fluorescence imaging (Figure 6.5).  
 
Figure 6.5. Astrocytes transduced with AVV-sGFAP-EmGFP-miR-Gja1-RNAi 
express the reporter gene EmGFP. Domain structure of the cassette for co-cistronic 
expression of three different pre-miRNAs targeting Cx43 gene in astrocytes. Below: 
Fluorescent images of dissociated astrocytes (A, scale bar 100µm) and astrocytes in 
organotypic slice culture (B and C, scales bar 100µm and 15µm, respectively) 
expressing the construct. 
 
The ability of AVV-sGFAP-EmGFP-miR-Gja1-RNAi to knock-down Cx43 expression 
in astrocytes was quantitatively evaluated at the protein level with western blot, which 
was performed by Dr. Iliana Barrera using anti-Cx43 (Abcam, ab11370, 1:5000 
dilution) and anti-actin (Sigma, C6198, 1:5000 dilution) antibodies and equal amount 
of protein loading (10µg/ml). 
Non-transduced (No-AVV) primary cultured astrocytes as well as astrocytes 
transduced with either AVV-sGFAP-EmGFP-miR-control (Control miR) or AVV-
sGFAP-EmGFP-miR-Gja1-RNAi (Cx43 miR) at MOI 100 were harvested 3 days after 
plating and transduction. Cx43 immunopositive bands were detected at approximately 
43kDa, which is the molecular mass predicted for the protein. Western blot analysis 
suggested that 3 days of AVV transduction did not change the level of Cx43 
expression in Cx43 miR primary astrocytes (Figure 6.6). Preliminary results on 
astrocytes with increased time of incubation with the AVVs driving the expression of 
GAL4p65 mCMV GfaABC1D EmGFP WPRE AVV 
Pre-miRNAs 






the constructs suggested a slight increase in the knock-down rate of Cx43 expression 
(Figure 6.6). 
 
Figure 6.6. Effect of RNAi-mediated Cx43 knock-down strategy in the 
expression of Cx43 in primary cultured astrocytes. (A) Western blot analysis of 
Cx43 immunoreactivity in non-transduced primary cultured astrocytes (No-AVV, 
1.25±0.36, n=3) and astrocytes transduced with AVV-sGFAP-EmGFP-miR-control 
(Control miR, 1.06±0.11, n=3) or AVV-sGFAP-EmGFP-miR-Gja1-RNAi (Cx43 miR, 
1.06±0.34, n=3) following 3 days of AVV incubation. Error bars represent SEM. (B) 
Western blots of astrocytes following 5 and 9 days of AVV transduction. 
 
6.4 Discussion of the knock-down of Cx43 in astrocytes 
The role of connexin hemichannels in the release of LL in the brain has just recently 
been demonstrated (Karagiannis et al., 2015). In order to further investigate the 
specificities of this transport mechanism, we developed a molecular tool based on 
RNAi to selectively decrease Cx43 expression in astrocytes. 
RNAi is a post-transcriptional gene silencing tool that has been widely used for the 






time-consuming process of creation of knockout animals. RNAi-mediated gene knock-
down allows the generation of loss-of-function phenotypes without removal of the 
target gene, preventing, for example, developmental tissue malformations (Iacobas, 
Iacobas, Urban-Maldonado, Scemes, & Spray, 2008). Cx43 knockout mice die shortly 
after birth, which has been associated with abnormal heart function (Reaume et al., 
2006). Moreover, widespread transcriptomic modification of the target gene in 
knockout mice may trigger genetic compensation, masking the effects of the missing 
gene (El-Brolosy & Stainier, 2017). Nonetheless, although the simplicity and cost- 
effectiveness of RNAi, a major disadvantage of this gene knock-down technique is 
that the degree of disruption in the expression of the target gene may not be high 
enough to evoke loss-of-function phenotype. Iacobas and colleagues observed 
inconsistency in the level of Cx43 knock-down amongst their biological replicas using 
RNAi (Iacobas et al., 2008). 
In this study, analysis of Cx43 expression in primary cultured astrocytes transduced 
with Cx43-targeting miRNAs showed no effect three days following transduction, 
which is the incubation time employed in the majority of the AVV-mediated transgene 
expression carried out during my PhD project. Although one apparent reason for this 
unsuccessful knock-down rate may be the lack of efficacy of the selected miRNAs, at 
least one out of the three miRNAs expressed in astrocytes would be expected to 
contribute to gene silencing. As previously detailed in this chapter, the three miRNAs 
were selected based in the highest probability of Cx43 knock-down success according 
to the optimisation algorithm provided by the manufacturer. Our group previously used 
similar RNAi approach to knock-down the expression of GPR37 and GPR37L in 
astrocytes (Liu et al., 2018). Employment of three miRNAs to target different regions 
of the target mRNA successfully decreased the expression of both GPR37 and 
GPR37L to non-detectable protein levels (Liu et al., 2018). Besides the fact that 
different proteins were targeted, our previous and current work also differed regarding 
the promoters used. Since in Liu et al. (2018) the miRNAs were meant to be used in 
a homogenous astrocytic cell culture, the CMV promoter was not swapped to sGFAP. 
In this investigation, however, a sGFAP promoter was employed so that we could use 
this tool in a more complex in vitro preparation or in vivo application. Even though a 






of Cx43 knock-down because analysis of the expression of the reporter gene 
suggested an adequate transcriptional rate driven by sGFAP (Figure 6.5).   
In order to assure full establishment of miRNAs expression, we increased the 
incubation time and harvested the cells 5 and 9 days following AVV transduction. 
Preliminary results indicated that the knock-down rate of Cx43 proportionally 
increased over time, reaching approximately 50% at 9 days of AVV incubation. 
Intriguingly, Cx43 half-life, which is the time required for turnover of half the amount 
of the protein at steady-state levels, is relatively short. Reports of Cx43 expression in 
various cellular cultures suggested that the protein turnover ranges from 1 to 5 hours 
(Berthoud, Minogue, Laing, & Beyer, 2004; Falk, Bell, Kells Andrews, & Murray, 
2016). 
In conclusion, we do not know at this point the reasons for which the engineered pre-
miRNAs targeting Cx43 mRNA did not result in protein knock-down. Since the level 
of Cx43 expression in astrocytes did not change substantially, we have not proceeded 




















7.1 Limitations in the study of astrocyte-derived L-lactate roles in the brain 
It is now well accepted that astrocytes are active elements in the processing of 
information by the brain (Allen & Lyons, 2018). By perceiving neuronal activity and 
environmental conditions, astrocytes are able to respond to them through the release 
of neuroactive substances (Bazargani & Attwell, 2016). At the same time, astrocytes 
are the major regulators of brain metabolic homeostasis. These cells are endowed 
with the machinery to metabolise, store and dynamically shuttle energy substrates 
throughout the astrocytic network and to the extracellular space (Giaume et al., 2010).  
LL, in particular, has gained increasing attention due to its dual function as a metabolic 
and signalling compound in the brain (Magistretti & Allaman, 2018). This molecule is 
mainly produced by astrocytes through the metabolism of glucose or glycogen and 
may be released to adjacent neurones in case of high energy demand (Magistretti & 
Allaman, 2015; Pellerin & Magistretti, 2012). Moreover, LL can selectively activate 
neuronal receptors and modulate the function of neurones, including excitability 
(Mosienko et al., 2018). By activating a Gs-coupled LL receptor in noradrenergic 
neurones, astrocyte-derived LL increases neuronal activity and NA release, resulting 
in enhanced sympathoexcitation and arterial blood pressure in rats in vivo (Marina et 
al., 2015; Tang et al., 2014). 
Although astrocytes are reported to possess various elements that favour the 
glycolytic processing of glucose to produce pyruvate and LL, the actual role of 
astrocyte-derived LL in the brain is very controversial. Whilst some researchers have 
suggested that LL is shuttled from astrocytes to neurones in order to sustain the 
energetic requirements of neuronal function (Bélanger et al., 2011; Pellerin & 
Magistretti, 1994; Pellerin & Magistretti, 2012), others have consistently contested this 
hypothesis and even challenged whether the source of the increased LL levels that 
follow neuronal activation is in fact astrocytic (Díaz-García & Yellen, 2019; Dienel, 
2012, 2017; Dıaz-Garcıa et al., 2017). Therefore, the main challenge in the 
investigation of the metabolic role of LL in the brain is to provide evidence of the cell 
type accountable for stimulation-induced LL release. 
On the other hand, although the role of LL as a signalling molecule is not under dispute 






through acute application of high doses of LL. Decreased neuronal activity mediated 
by LL-induced activation of GPR81, for example, has been described following 
addition of supraphysiological levels of LL (Bozzo et al., 2013), In contrast, 
investigation of the effect of LL in memory formation has been contested partially 
because the amount of LL applied in the hippocampus is likely to be sustained only 
for a short duration due to the rapid metabolism of LL, making it less probably that it 
may influence memory consolidation (Dienel, 2012; Suzuki et al., 2011). 
In fact, much of the research carried out on both metabolic and signalling effects of 
LL in the brain has used acute approaches to change aspects of LL production and 
release at short-term. These approaches include glucose deprivation and 
pharmacological interventions that inhibit glycogenolysis, astrocytic metabolism, LDH 
activity, transport of glucose or LL, as well as genetic manipulations to reduce 
expression of LL transporters and components of the glycolytic pathway  (Clasadonte 
et al., 2017; Herrero-Mendez et al., 2009; Newman, Korol, & Gold, 2011; Parsons & 
Hirasawa, 2010; Sotelo-Hitschfeld et al., 2015; Suzuki et al., 2011; Walls, 
Heimbürger, Bouman, Schousboe, & Waagepetersen, 2009). Overall, although 
pharmacological compounds are of great use for manipulation of selective enzymes 
or transporters, they do not offer specificity towards the cell type to be targeted – 
unless the pharmacological targets are indisputably expressed in a single cell type – 
and their effects are transitory. Genetic manipulations, on the other hand, can offer 
improved cell specificity and lasting effects. Nonetheless, in some applications, such 
as the decrease of MCT expression used to study LL-mediated memory formation 
(Suzuki et al., 2011), the level of knock-down may not be enough to overcome the 
high capacity of the transporters, and other mechanisms of LL release, not well 
described yet, may be utilised (Dienel, 2017; Karagiannis et al., 2015; Sotelo-
Hitschfeld et al., 2015). 
 
7.2 Novel molecular tools to limit astrocytic L-lactate release and action 
The advanced study of LL actions requires selective tools able to chronically modulate 
LL production and release specifically from astrocytes as well as to interfere with the 






developed during my PhD project work a range of viral vector-based molecular 
actuators that aim to target different aspects of astrocyte-derived LL action in the 
brain, which includes decreasing the intracellular LL pool in astrocytes, interfering with 
astrocyte-to-neurone LL signalling, and partial reduction of LL release.  
For the design of these tools, we innovatively selected enzymes that are natively 
found in bacteria and made them specifically expressible in astrocytes. Accordingly, 
in order to create tools that reduce the astrocytic LL pool, we used the enzymes LOX 
and LMO, which irreversibly convert LL into pyruvate and hydrogen peroxide or 
acetate, water and CO2, respectively. For the design of a tool to interfere with LL 
signalling, we selected the bacterial enzyme DLDH. This enzyme reduces pyruvate 
to DL, which has been described to antagonize the excitatory effect of LL in 
noradrenergic neurones in the brainstem (Tang et al., 2014). In addition, in an attempt 
to further investigate the mechanisms of astrocytic LL release and add to the tool kit 
for blocking it, we constructed a RNAi-based tool to drive the expression of miRNAs 
targeting Cx43 gene silencing specifically to astrocytes.  
The ORF sequence of the LL catabolic enzymes LOX and LMO from Aerococcus 
viridans and Mycobacterium smegmatis, respectively, as well as the DL-producing 
enzyme DLDH from Lactobacillus bulgaricus were adapted to the mammalian codon 
usage and cloned under the control of a transcriptionally-enhanced astrocytic 
promoter.  An expression vector that drives the expression of three engineered 
miRNAs targeting Cx43 gene under the control of the astrocyte-selective promoter 
was also constructed. Viral vectors were employed in order to deliver the expression 
of these enzymes to primary dissociated cultured astrocytes and to astrocytes in 
organotypic brainstem slices. Approaches that combine FRET-based sensors with 
real-time imaging techniques were adopted in order to analyse the functional effects 
of transgene expression in the intracellular glycolytic state of individual astrocytes. 
Moreover, enzyme-based LL biosensor and amperometric recordings were adopted 
to investigate the effects of the expression of the novel molecular tools in extracellular 
LL dynamics in the brain tissue. A cell-based NA sensor was also applied in order to 
evaluate how the expression of these enzymes influences LL-induced NA release 






7.2.1 Summary of the functional in vitro validation of the novel molecular tools  
Investigation of the tonic LL or DL release from astrocytes expressing the novel 
molecular tools confirmed that the enzymes of bacterial origin are enzymatically active 
in mammalian cells. Primary cultured astrocytes expressing LOX or LMO decreased 
the constitutive release of LL, while expression of DLDH induced significant increase 
in the tonic release of DL to the extracellular space. Although DLDH-mediated 
production of DL utilizes the same substrate and coenzymes as the enzymatic 
reaction that leads to the generation of LL, the levels of LL were not altered by DLDH 
expression. A similar scenario was found in organotypic brainstem slices, in which 
expression of DLDH in astrocytes did not interfere with the LL tone of the slice. 
Astrocytic expression of LOX or LMO, on the other hand, consistently decreased the 
tonic release of LL from brainstem organotypic slices.  
The effects of the expression of the novel enzyme-based molecular tools were also 
investigated on the LL release upon acute stimulation. Using a trans-acceleration 
protocol to force maximal LL extrusion, which involves the application of high doses 
of pyruvate, astrocytes showed decreased LL release when expressing LOX, LMO, 
or DLDH. On the other hand, in organotypic brainstem slices, only astrocytic 
expression of LOX resulted in significant reduction of LL release upon acute 
stimulation.  
We further examined the effects of the expression of the genetically-encoded 
enzymatic tools on astrocytic metabolism. Since LL release is one of the factors that 
affect LDH-mediated LL production, we inhibited it in order to gain insight into LL and 
pyruvate handling by astrocytes expressing the novel molecular tools. Inhibition of LL 
release was performed by application of AR-C155858, which specifically blocks 
MCT1 in astrocytes. Importantly, AR-C155858 does not affect mitochondrial pyruvate 
uptake, in contrast to the broadly employed MCT inhibitor α-cyano-4-hydroxycinnamic 
(4-CIN) (Compan et al., 2015; Ovens et al., 2010). Blockade of pyruvate uptake by 
the mitochondria could potentially lead to increased glycolysis since oxidative 
phosphorylation of glucose would be impaired (Dienel, 2012; McKenna, Hopkins, & 
Carey, 2001). Although there is evidence for additional routes for LL extrusion from 
astrocytes (Karagiannis et al., 2015; Sotelo-Hitschfeld et al., 2015), MCTs are 






steady-state conditions. In line with this, application of the MCT1 blocker AR-C155858 
consistently increased intra-astrocytic LL concentration. Nonetheless, further 
increase in intracellular LL levels upon concomitant application of the MCT1 blocker 
with LL indicated that other LL transport pathways are present in astrocytes. 
Accumulation of LL in the astrocytic cytosol applies back-pressure on the LDH 
reaction until a new thermodynamic equilibrium is reached (Díaz-García & Yellen, 
2019; Dienel, 2012).  
Analysis of the rate of LL build-up showed no change in astrocytes expressing LOX 
or LMO, suggesting that the LDH reaction remains highly active when the enzymatic 
tools are expressed. However, surprisingly, the rate of pyruvate accumulation was 
decreased to the same extent in LOX- and LMO-expressing astrocytes, even though 
only LOX activity leads to additional pyruvate formation. This scenario led to 
speculation that there may be an increased drive towards LL formation in LOX or LMO 
expressing astrocytes which, in turn, slows down the rate of pyruvate accumulation. 
Such an increased LL production drive may be consistent with an alteration in LDH 
composition/activity due to compensation for the chronic LL sink imposed by LOX or 
LMO expression. In DLDH-expressing astrocytes, one factor that may contribute to 
the decreased rate of pyruvate build-up is the consumption of pyruvate by the DLDH 
enzymatic reaction. More experiments will be required to test these hypotheses, 
including the blockade of other specific metabolic processes, such LHD reaction, as 
well as detection of real-time fluctuations of cellular components that are closely 
involved in LL handling, such as NADH and NAD+. 
An additional strategy to limit LL actions in the brain refers to the partial inhibition of 
LL release from astrocytes. Since it has been shown that astrocytes release LL via 
connexin hemichannels (Karagiannis et al., 2015), we hypothesised that astrocyte-
selective knock-down of Cx43, the major connexin type expressed by astrocytes, may 
contribute to the reduction of astrocytic LL release. A vector that drives the expression 
of three miRNAs that target different regions of Cx43 mRNA specifically in astrocytes 
was designed and constructed. However, when transduced in primary dissociated 
cultured astrocytes, the efficiency of Cx43 knock-down analysed at the protein level 
was minor. Preliminary results indicate that the Cx43 expression reduces 
proportionally to the time in which astrocytes were incubated with the Cx43 miRNA-






exhibiting a quick turnover rate (Falk et al., 2016). Since the level of Cx43 expression 
did not considerably changed, no further characterization experiments were carried 
out using this tool. 
 
7.2.1.1 Application of the novel molecular tools to inhibit L-lactate induced 
noradrenaline release 
In order to investigate if the decreased intra-astrocytic LL pool or the release of DL by 
astrocytes expressing the novel molecular tools affect NA release, we employed a 
cell-based sensor for NA detection in LC organotypic slices (Muller et al., 2014). The 
same NA detection system, which translates noradrenergic volume transmission into 
fluorescence signals, has been previously used by our group and confirmed the prior 
finding obtained by fast-scan cyclic voltammetry, which is that LL evokes NA release 
from LC neurones (Mosienko et al., 2018). However, the challenge in the current 
project was to trigger selective release of LL or DL from the intra-astrocytic reservoir 
and assess if endogenous LL-driven NA release is different from the NA released 
following exogenous application of LL. Acute stimulation of LL release from the slice 
was triggered by the application of high doses of pyruvate (trans-acceleration). In 
slices whose astrocytes were expressing LOX, NA release triggered by pyruvate-
driven LL extrusion was decreased as compared to the NA released following 
application of exogenous LL. On the other hand, neither LMO nor DLDH expression 
changed the amount of NA released by LC neurones.  
 
7.2.2 Methodological considerations  
In order to assess the functionality of the enzyme-based constructs, it was essential 
to induce intracellular LL depletion in cells. Since this is not possible using any known 
physiological stimulus, LL depletion has been achieved using the trans-acceleration 
protocol. One important caveat of the application of high doses of pyruvate to evoke 
LL release from astrocytes is the extreme nature of this stimulus, which does not 
directly reflect physiological LL efflux. Moreover, although application of high doses 






intracellular accumulation of pyruvate, which is directly involved in the pathways we 
are targeting with the expression of the enzyme-based tools. Accordingly, intracellular 
pyruvate can be converted to LL (and DL in the case of DLDH), which is broken down 
at different rates by LOX and LMO. In order to restrict LL formation following pyruvate 
application, glucose concentration in the superfusion buffer was reduced so that the 
generation of NADH through glycolysis was limited. Another issue with the trans-
acceleration protocol in more complex brain tissue preparations such as organotypic 
brainstem slices is the non-selective nature of this stimulus. Many cells in the brain 
that are not targeted by the bacterial enzymes, such neurones and microglia, express 
MCTs, which would also contribute to the pyruvate-induced LL release. This may be 
the reason why in some experiments forced LL release was significantly decreased 
in dissociated astrocytes expressing the molecular tools but unchanged when 
measured in organotypic brainstem slices. 
Moreover, trans-acceleration may not be the ideal approach to evoke DL release from 
astrocytes expressing DLDH in the assessment of LL-induced NA release in 
organotypic brainstem slices. Since DL affinity to MCTs is low, it seems likely that DL 
was not released from DLDH-expressing astrocytes in sufficient amounts, even with 
pyruvate-forced extrusion. 
The validation experiments also required assessment of the glycolytic state of cells 
expressing the bacterial enzymes. However, it is highly complex to measure the 
dynamics of a variable that is in constant flux. LL is being constantly produced, 
released and catabolised. To make matters worse, blockade of one pathway can 
dynamically change other pathways. Blockade of MCT-mediated extrusion of LL, for 
example, drives by mass action LDH reaction towards pyruvate generation, which in 
turn impairs glycolysis (Dienel, 2018). LL formation, on the other hand, decreases 
pyruvate availability, which is an essential substrate of enzymatic reactions that 
ultimately lead to de novo synthesis of glutamate and GABA in astrocytes (Dienel, 
2018). In the current study, we blocked MCTs in order to investigate the rate of 
intracellular LL and pyruvate accumulation. Nonetheless, we do not discard the 
possibility that other mechanisms related to LL flux may be changed due to the 






In vitro validation of the DLDH construct was hampered by the lack of technical means 
to directly measure DL dynamics in biological tissues. In fact, most of the results 
presented in my thesis report indirect effects of DLDH expression in astrocytes. 
Moreover, even though we successfully reported production and release of DL from 
astrocytes expressing DLDH, we proposed that improving astrocytic expression levels 
of DLDH would affect mechanisms in the brain that are sensitive to higher 
concentrations of DL as discussed below. 
 
7.2.3 Future projections  
Since LOX is the molecular tool that showed the most prominent results towards the 
decrease of LL release and action in the brain, this tool has been applied by our 
collaborators in vivo in the hippocampus and amygdala of mice in order to interrogate 
astrocyte-derived LL effects on behaviour patterns. Analysis of the morphology of 
cells expressing the reporter gene of the LVV driving LOX expression indicated 
predominant expression of the construct in astrocytes 4 weeks following LVV 
injections, indicating selective and long-lasting expression of the construct. Moreover, 
preliminary results showed that in vivo expression of LOX in astrocytes in the 
amygdala of mice enhanced anxiety-like behaviour. Therefore, LOX has potential to 
be employed in vivo in the study of the roles of astrocytic LL in the brain.  
In order to enhance DLDH expression in astrocytes, our group is developing an AAV 
containing a ubiquitous promoter that drives the expression of a DLDH sequence 
flanked by Lox sites. This AAV will be used in a transgenic mouse in which Cre 
recombinase is regulated by the astrocyte-selective promoter Aldh1l1, resulting in 
selective expression of DLDH in astrocytes. Apart from antagonizing LL actions in 
noradrenergic neurones, DL has been suggested to act on other signalling pathways. 
Accordingly, DL was shown to decrease neuronal excitability through GPR81 
activation with an EC50 value of approximately 3mM (Bozzo et al., 2013). Moreover, 
application of 4mM of DL has also been suggested to produce neuroprotective effects 
in ischemic models in vitro and in vivo (Castillo et al., 2015). Some researchers have 
also expressed interest in the utilization of an AAV for expression of LOX enzyme in 






Overall, the genetically encoded LL-processing or DL-producing molecular tools show 
promise for future studies of the roles of astrocytic LL in the brain. LL-limiting tools 
represent a distinguishable approach to address many aspects of LL function in 
various physiological contexts. The viral vector-based molecular actuators, in 
particular LOX, decrease intra-astrocytic LL content and, consequently, LL release 
specifically from astrocytes. The selective nature of these tools is an essential 
requirement in the study of the metabolic compartmentalization of astrocytes and 
neurones. Moreover, these tools can be chronically expressed in the brain, changing 
LL dynamics at long-term, which has significant potential for the study of astrocyte-
derived LL signalling. 
Further arrangements in the vectors such as swapping of promoters can make these 
bacteria-derived enzymatic tools valuable in understanding the role of LL in other 
contexts such as in cancer cells, which have been extensively shown to favour LL 
formation (Ippolito, Morandi, Giannoni, & Chiarugi, 2019; Koppenol, Bounds, & Dang, 
2011; Vander Heiden & DeBerardinis, 2017). To note, LMO may not be an ideal 
approach to be employed in this situation because the product of the reaction, acetate, 
is widely reported to be oxidized by cancer cells to be used as an additional energy 
substrate (Lin et al., 2018; Liu et al., 2018; Qiu et al., 2019). 
 
7.3 Conclusion  
In this thesis, I have described the development and functional validation of novel 
molecular tools to limit astrocyte-derived LL release and actions in the brain. As the 
ultimate goal, genetically encoded LL-processing or DL-producing microbial enzymes 
delivered selectively to astrocytes were designed to allow a better comprehension of 
the astrocytic function and its role in the regulation of neuronal activity. Application in 
different physiological contexts confirmed that these genetic tools, once expressed in 
mammalian cell lines, rat primary cultured astrocytes or cultured brainstem slices, are 
enzymatically active and change LL dynamics in vitro. Moreover, LL-limiting tools 
show potential for in vivo application in the study of LL roles in the metabolic and 
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